Melatonin, sleep and circadian rhythms in critical care patients. by Bourne, Richard Stanley
Melatonin, sleep and circadian 
rhythms in critical care patients 
Richard Stanley Bourne 
Submitted in total fulfilment of the requirements of 
the degree of Doctor of Philosophy 
Academic Unit of Clinical Pharmacology 
University of Sheffield 
August 2008 
Volume 1 
Abstract 
Critical care patients commonly experience sleep fragmentation, in which sleep 
quality is poor and distributed throughout the 24 hour cycle. This irregular sleep 
wake pattern is a form of circadian rhythm sleep disorder. The causes of sleep 
disturbances are multifactorial and contribute to patient morbidity. Conventional 
hypnotic treatment is often ineffective and, indeed, may cause delirium and reduced 
sleep quality. 
Administration of exogenous melatonin has been shown to re-enforce circadian 
rhythm disorders and improve sleep in other patient groups. 
An open evaluation of 5 mg oral melatonin was undertaken in a group of 12 critical 
care patients exhibiting sleep disturbances resistant to conventional hypnotics. 
Melatonin significantly increased observed sleep quantity by night 3, compared to 
baseline. 
An oral solution of melatonin was formulated to allow administration by enteral 
feeding tubes. It was shown to have a 1 year shelf life when refrigerated and 
protected from light. 
A randomised controlled trial was undertaken in 24 critical care patients weaning 
from mechanical ventilation. Melatonin 10 mg orally increased nocturnal bispectral 
index sleep quantity over nights 3 and 4 compared to placebo. Agreement of the 
other sleep measurement techniques with the bispectral index was poor. Actigraphy 
was not a useful measure of sleep in critical care patients and nurse observation 
overestimated sleep quantity. 
The clearance of melatonin appeared to be decreased in critical care patients 
compared to that in healthy subjects. Doses of 1-2 mg should be used in future 
critical care studies. 
11 
Acute administration of melatonin did not have a significant effect over placebo on 
rest-activity rhythms, which remained delayed, fragmented and reduced. Similar 
disturbances were present in plasma melatonin and cortisol rhythms, which were no 
longer phase locked. 
Melatonin therapy may prove beneficial in the treatment of sleep and circadian 
rhythms in critical care patients, and further larger studies should be pursued. 
III 
Acknowledgements 
I have been fortunate to have had the support and assistance of a number of people 
during the course of this thesis, to whom I wish to acknowledge my gratitude. 
Firstly, to Professor David Edbrooke for taking me to the European Society of 
Intensive Care Medicine annual conference in 1999, and challenging me to undertake 
research into the care of the critically ill patient. I am very grateful to my research 
supervisors for their continuous support, advice and guidance over the whole 
research period. Dr Gary Mills and Professor Edbrooke who provided almost 
constant advice on my research development in our day to day working. Professor 
Geoff Tucker, who made significant contributions to my understanding of 
pharmacokinetics and helped mould this thesis into a more coherent work. He 
continued to provide prompt and constructive advice even after his retirement from 
the University of Sheffield. 
Special thanks to Dr Cosetta Minelli who provided valuable statistical advice which 
greatly improved the presentation of the results. Her drive and enthusiasm for this 
work, most of which was conducted over the phone and bye-mail, provided great 
encouragement. 
To my colleagues in Sheffield Teaching Hospitals who supported me throughout my 
research, including the time needed to undertake this work. Specifically to Mr John 
McLaughlin, for his high performance liquid chromatography expertise and the 
conduction of the melatonin oral solution stability assays. Mr Roger Brookes, for 
providing moral support, the facilities of the pharmacy manufacturing unit, and 
assistance in securing funding from the Pharmacy Department which allowed further 
thesis development. I am also grateful to Mrs Perm Wilson and her colleagues in 
Clinical Chemistry for allowing me to conduct the melatonin RIA within their 
IV 
Department, and patiently answering my many questions. To Mr Neil Smith 
(Department of Clinical Chemistry), for undertaking the plasma cortisol assays. The 
critical care nursing staff who completed the nurse sleep assessments; in particular to 
those individuals who actively supported the research studies. 
I appreciate the efficient and professional assistance provided throughout the 
development of this thesis by the University of Sheffield Health Services Librarians. 
I acknowledge the graphic design skills of Professor Milagros Figueroa-Ramos 
(University of California), which assisted with the presentation of sleep mechanisms, 
and her continued interest in the areas of sleep and delirium in critical care patients. 
To my parents for their unrelenting support and encouragement in everything I have 
done. 
Most importantly to my wife Karen, without whose love and support I would not 
have been able to complete this work - thank you. To our children, Alexander and 
Jennifer, who have patiently put up with daddy's "home work". Hopefully we will 
now be able to spend a lot more time together. 
v 
Presentations and publications 
Invited presentations 
Thames Valley Critical Care Network "Weaning Event". Oxford, England. June 
2005. 
Sedation monitoring techniques affecting weaning from mechanical ventilation. 
British Association of Critical Care Nurses, 21 5t Annual Conference. Newcastle upon 
Tyne, England, September 2006. 
Detection, prevention and treatment of delirium in critically ill patients. 
Mid and South Trent Intensive Care Society "State of the Art" Meeting. Nottingham, 
England, September 2006. 
The use of melatonin for night sedation on ICU. 
Society of Critical Care Medicine, 36th Critical Care Congress. Orlando, Florida, 
USA, February 2007. 
Drug therapy for sleep disruption in the critically ill. 
Association of Teaching Hospital Chief Pharmacists. Sheffield, England, May 2007. 
Research into melatonin in the critically ill. 
Alzheimer's Society and NHS South Central, "The Delirium Dilemma" meeting. 
Oxford, England, August 2007. 
How do we prevent delirium? 
Manchester Critical Care Network and Association of North West Intensive Care 
Units, "Delirium and Cognitive Impairment in Critical Care" meeting, Manchester, 
England, August 2007. 
Guidelines on the detection, prevention and treatment of delirium. 
European Delirium Association, 2nd Scientific Meeting, Limerick, Ireland, 
November, 2007. 
Drug treatment of delirium - the evidence base. 
Conference poster presentations 
2th International Symposium on Intensive Care and Emergency Medicine. Brussels, 
Belgium. March 2007. 
Bourne RS. Assessment of melatonin, cortisol and rest-activity rhythms in critically 
ill patients weaning from mechanical ventilation. 
Critical Care 2007; 11 (Supplement 2): S71. 
28th International Symposium on Intensive Care and Emergency Medicine. Brussels, 
Belgium. March 2008. 
Bourne RS. Pharmacokinetics of oral melatonin in patients recovering from critical 
illness. 
Critical Care 2008; 12 (Supplement 2): S200. 
VI 
Conference oral presentations 
European Society of Intensive Care Medicine, 14th Annual Congress. Geneva, 
Switzerland. October 2001. 
Bourne RS. Preliminary evaluation of melatonin therapy to aid sleep in intensive 
care patients. 
Intensive Care Medicine 2001; 27 (Supplement 2): S293 
European Society of Intensive Care Medicine, 19th Annual Congress. Barcelona, 
Spain. September 2006. 
Bourne RS, Mills GH. Melatonin increases depth of sleep in intensive care patients 
weaning from mechanical ventilation. 
Intensive Care Medicine 2006; 32 (Supplement 1): S 114 
Journal publications 
Bourne RS, Mills GH. Sleep disruption in critically ill patients - Pharmacological 
considerations. Anaesthesia 2004; 59: 374-84. 
Bourne RS, McLaughlin JP, Simpson Cc. Benefits on patients' sleep patterns can be 
studied using a stable oral liquid melatonin formulation. Pharmacy in Practice 2005; 
15: 246-9. 
Bourne RS, Mills, GH. Melatonin: Possible implications for the postoperative and 
critically ill patient. Intensive Care Medicine 2006; 32: 371-9. 
Bourne RS, Borthwick M. Guidelines on the detection, prevention and treatment of 
delirium in the critically ill patient. Journal of the Intensive Care Society 2007; 8: 76-
78. 
Bourne RS, Minelli C, Mills GH, Kandler R. Sleep measurement in critical care 
patients: research and clinical implications. Critical Care 2007; 11: 226. 
Bourne RS, Mills GH, Minelli C. Melatonin therapy to improve nocturnal sleep in 
critically ill patients: encouraging results from a small randomised controlled trial. 
Critical Care 2008; 12: R52. 
Bourne RS. Delirium and use of sedation agents in intensive care. Nursing in 
Critical Care 2008; 13: 195-202. 
Bourne RS, Tahir T A, Borthwick M, Sampson EL. Drug treatment of delirium: Past, 
present and future. Journal of Psychosomatic Research (In press). 
Book chapters 
Borthwick M, Bourne RS. Agitation and confusion. In Oxford Desk Reference-
Critical Care. Eds Walterman K, Soni, N & Rhodes, A. Oxford University Press, 
Oxford UK. (In press). 
VII 
6-SMT 
dBA 
ABW 
APACHE II 
ARDS 
ACTH 
ASPS 
ALT 
AUC 
AUC(O-24) 
AUC(O-Infinity) 
AAS 
ASB 
ADHD 
F 
BIPAP 
BIS 
BMI 
CNS 
Cl 
MIO Onset 
L5 Onset 
CAM-ICU 
CPAP 
CIR 
CRH 
CYPIA2 
DSPS 
DLMO 
D 
EEG 
EMG 
EOG 
GABA 
GC-MS 
GM-CSF 
G-CSF 
Abbreviations 
6-sulfatoxymelatonin 
A-weighted decibels 
Actual body weight 
Acute physiology and chronic health 
evaluation II 
Acute respiratory distress syndrome 
Adrenocortrophic hormone 
Advanced sleep phase syndrome 
Alanine Transaminase 
Area under the curve 
Area under the plasma concentration-
time curve between 0 and 24 hours 
Area under the plasma concentration-
time curve between 0 and Infinity 
Ascending arousal system 
Assisted spontaneous breathing 
Attention deficit hyperactive disorder 
Bioavailability 
Biphasic positive airway pressure 
Bispectral index 
Body mass index 
Central nervous system 
Clearance 
Commencement of 10 hour period of 
most activity 
Commencement of 5 hour period of least 
activity 
Confusion Assessment Method for the 
Intensive Care Unit 
Continuous positive airway pressure 
Controlled release 
Corticotrophin releasing hormone 
Cytochrome P450 1 A2 
Delayed sleep phase syndrome 
Dim light melatonin onset 
Dose 
Electroencephalogram 
Electromyogram 
Electro-oculogram 
Gamma amino butyric acid 
Gas chromatography-mass spectroscopy 
Granuloctye macrophage-colony 
stimulating factor 
Granulocyte-colony stimulating factor 
Vlll 
HPLC-F 
6-SMT 
HPLC-MS 
HAD 
IBW 
ICU 
IL 
Cmax 
MRT 
Mesor 
M/R 
NAT 
NREM 
NNH 
PVN 
%CV 
C(08) 
tl/2 
PTSD 
RIA 
REM 
RHT 
RCSQ 
SAS 
SSRIs 
SQI 
SAHS 
SE 
SEI 
SL 
SWS 
SCN 
SIR 
SIRS 
TST 
TNFa 
VLPO 
VSH 
VAS 
Vss 
IX 
High performance liquid 
chromatography - fluorescence 
6-sulfatoxymelatonin 
High performance liquid 
chromatography-mass spectroscopy 
Hospital anxiety and depression scale 
Ideal body weight 
Intensive care unit 
Interleukin 
Maximum plasma concentration 
Mean residence time 
Midline estimating statistic of rhythm 
Modified release 
N -acety ltransferase 
Non-rapid eye movement 
Number needed to harm 
Paraventricular nucleus 
Percent coefficient of variation 
Plasma concentration at 0800 hours 
Plasma half-life 
Post traumatic stress disorder 
Radioimmunoassay 
Rapid eye movement 
Retinohypothalmic tract 
Richards-Campbell sleep questionnaire 
Sedation agitation scale 
Selective serotonin reuptake inhibitors 
Signal quality index 
Sleep apnoea! hypopnoea syndrome 
Sleep efficiency 
Sleep efficiency index 
Sleep latency 
Slow wave sleep 
Suprachiasmatic nucleus 
Sustained release 
Systemic inflammatory response 
syndrome 
Time to maximum plasma! serum 
concentration 
Total sleep time 
Tumour necrosis factor alfa 
Ventrolateral preoptic nucleus 
Verranl Synder-Halpern Sleep Scale 
Visual analogue scale 
Volume of distribution at steady state 
Table of Contents 
ABSTRACT 
ACKNOWLEDGEMENTS 
PRESENTATIONS AND PUBLICATIONS 
INVITED PRESENTATIONS 
CONFERENCE POSTER PRESENT A T10NS 
CONFERENCE ORAL PRESENT A TIONS 
JOURNAL PUBLICA T10NS 
BOOK CHAPTERS 
ABBREVIATIONS 
1 INTRODUCTION 
INTRODUCTION 
BACKGROUND 
RESEARCH AIMS 
KEY RESEARCH QUESTIONS 
THESIS STRUCTURE 
~ BACKGROUND LITERATURE 
NORMAL SLEEP 
NORMAL SLEEP ARCHITECTURE 
NEUROPHYSIOLOGY OF SLEEP AND WAKEFULNESS 
PHARMACOLOGY OF SLEEP AND WAKEFULNESS 
THE SLEEP-WAKE CYCLE 
SLEEP DISORDERS 
MEASUREMENT OF SLEEP 
Polysomnography 
Actigraphy 
Nurse assessment 
Subjective assessment 
Bispectral index 
SLEEP IN THE CRITICALLY ILL 
SLEEP ARCHITECTURE IN CRITICALLY ILL PATIENTS 
CONSEQUENCES OF DISRUPTED SLEEP IN THE CRITICALLY ILL 
Respiratory effects 
Cardiovascular effects 
Neurological effects 
Immunological effects 
Long-term effects 
CAUSES OF SLEEP DISRUPTION 
Environment 
Noise 
Light 
Care activities 
Acute illness 
Respiratory considerations 
Drugs used in intensive care 
Sedative agents 
Non-opioid analgesics 
x 
II 
IV 
VI 
VI 
VI 
VII 
VII 
VII 
VIII 
1 
2 
3 
3 
4 
5 
6 
7 
7 
10 
12 
15 
16 
18 
18 
19 
20 
20 
21 
22 
22 
23 
23 
25 
25 
27 
28 
29 
29 
29 
31 
32 
33 
33 
36 
37 
38 
Cardiovascular Drugs 
Gastric protectors and antiemetic agents 
Anti-asthma therapy 
Antimicrobial agents 
Antidepressants 
Anticonvulsants 
Miscellaneous Drugs 
Drug Withdrawal Reactions 
TREATMENT OF SLEEP DISORDERS IN CRITICALLV ILL PATIENTS 
SLEEP VERSUS SEDATION 
NON-PHARMACOLOGICAL TREATMENT 
PHARMACOLOGICAL TREATMENT 
Benzodiazepines 
Non-benzodiazepine GABAA agonists 
Propofol 
Antidepressants 
Tricyclics 
Miscellaneous antidepressants 
Chloral hydrate 
Alcohol 
Antipsychotics 
Alpha-2 agonists 
Antihistamines 
Melatonin 
MELATONIN 
CIRCADIAN RHVTHM 
PHARMACOLOGV 
INFLUENCE OF LIGHT ON MELATONIN SECRETION 
THE PHARMACOKINETICS OF EXOGENOUS MELATONIN 
MELA TONIN THERAPV FOR SLEEP DISORDERS 
Jet lag 
Night Shift 
Insomnia 
Other circadian rhythm disorders 
THE POTENTIAL EFFECTS OF ACUTE ILLNESS ON MELATONIN 
Intra and post-operative disturbances in melatonin turnover 
Melatonin and sleep disruption in the critically ill patient 
Melatonin in septic patients 
Melatonin and delirium 
ADVERSE EFFECTS 
PRECAUTIONS 
DRUG INTERACTIONS 
DOSAGE AND ADMINISTRA TION 
CONCLUSIONS 
38 
40 
40 
41 
42 
42 
43 
44 
49 
49 
49 
50 
53 
54 
55 
55 
55 
56 
57 
57 
58 
59 
59 
60 
61 
61 
62 
65 
69 
70 
71 
72 
73 
75 
77 
77 
81 
82 
84 
86 
87 
88 
91 
93 
J. PRELIMINARY EVALUATION OF MELATONIN THERAPY IN INTENSIVE 
CARE PATIENTS REFRACTORY TO CONVENTIONAL HYPNOTIC THERAPY 
94 
INTRODUCTION 
MATERIALS AND METHODS 
PATIENTS 
STATISTICAL ANALYSIS 
RESULTS 
Xl 
95 
99 
100 
101 
102 
DISCUSSION 
CONCLUSIONS 
1. FORMULATION OF AN ORAL MELATONIN SOLUTION 
INTRODUCTION 
MATERIALS AND METHODS 
MATERIALS 
METHODS 
Chemical stability 
Statistical analysis 
RESULTS 
pH STABILITY 
CHEMICAL STABILITY 
DISCUSSION 
CONCLUSIONS 
~ METHODS 
METHODOLOGICAL DEVELOPMENT 
STUDY DESIGN 
PATIENT SELECTION 
STUDY ENDPOINTS 
STUDY SIZE 
MELATONIN DOSE 
MEASUREMENT OF PLASMA MELATONIN 
Melatonin RIA procedure 
PHARMACOKINETIC ANALYSIS 
CIRCADIAN RHYTHM ANALYSIS 
Cortisol assay procedure 
NEUROMUSCULAR STRENGTH ASSESSMENT 
ENVIRONMENTAL CONTROL 
PEER SUPPORT 
FUNDING 
ETHICS COMMITTEE ApPROVAL 
FINAL STUDY PROTOCOL 
SCHEMA 
STUDY OBJECTIVES 
Primary end point 
Secondary end points 
PATIENT ELIGIBILITY CRITERIA 
PA TIENT RANDOMISATION 
TREATMENT SCHEDULE 
SLEEP MEASUREMENT 
PLASMA SAMPLES 
STATISTICAL ANALYSIS 
Sleep and Circadian Rhythm analysis 
Agreement 
Xll 
107 
114 
115 
116 
119 
119 
120 
122 
122 
123 
123 
123 
126 
130 
131 
132 
132 
132 
132 
135 
135 
136 
137 
137 
138 
139 
139 
139 
140 
141 
141 
143 
143 
144 
144 
144 
144 
145 
145 
145 
146 
146 
146 
147 
~ MELATONIN THERAPY TO IMPROVE NOCTURNAL SLEEP IN 
CRITICALLY ILL PATIENTS 149 
INTRODUCTION 150 
METHODS 152 
RESULTS 153 
DISCUSSION 158 
CONCLUSIONS 167 
Z KINETICS OF ORAL MELATONIN IN CRITICAL CARE PATIENTS 168 
INTRODUCTION 169 
METHODS 180 
RESULTS 180 
DISCUSSION 184 
CONCLUSIONS 190 
R. SLEEP MEASUREMENT IN CRITICAL CARE PATIENTS. RESEARCH AND 
CLINICAL IMPLICATIONS 191 
INTRODUCTION 192 
MITOO~ 1~ 
LITERATURE REVIEW 193 
RESULTS 194 
LITERATURE REVIEW 194 
AGREEMENT BETWEEN SLEEP MEASUREMENT TECHNIQUES IN THE MELATONIN 
INTERVENTION STUDY 194 
OBJECTIVE MEASUREMENTS OF SLEEP 211 
POLYSOMNOGRAPHY 211 
BISPECTRAL INDEX 215 
ACTIGRAPHY 217 
SUBJECTIVE MEASUREMENTS OF SLEEP 219 
Patient assessment 220 
Verran/Synder-Halpem Sleep Scale 220 
Richards-Campbell Sleep Questionnaire 220 
Nurse assessment 222 
METHODOLOGICAL PROBLEMS OF REVIEWED STUDIES 224 
CONCLUSIONS 227 
.2 MELATONIN, CORTISOL AND REST-ACTIVITY RHYTHMS IN 
CRITICALLY ILL PATIENTS 228 
INTRODUCTION 229 
METHODS 231 
RESULTS 232 
CORTICOSTEROID EXPOSURE 232 
EFFECT OF MELATONIN ON REST-ACTIVITY RHYTHMS 234 
PLASMA MELATONIN RHYTHM ANALYSIS 237 
PLASMA CORTISOL RHYTHM ANALYSIS 242 
EFFECT OF MELATONIN ON PLASMA CORTISOL LEVELS 249 
Xlll 
RELATIONSHIP BETWEEN PLASMA MELATONIN AND CORTISOL LEVELS 250 
RELATIONSHIP BETWEEN PLASMA MELATONIN AND CORTISOL RHYTHMS AND REST-
ACTIVITY RHYTHMS 251 
DISCUSSION 252 
CONCLUSIONS 262 
10 CONCLUSIONS AND SUGGESTIONS FOR FURTHER RESEARCH 263 
REFERENCES 271 
ApPENDICES 305 
ApPENDIX 1 GUIDELINES ON MELATONIN USE IN INTENSIVE CARE 305 
ApPENDIX 2 PRELIMINARY MELATONIN THERAPY EV ALUA TlON FORM 307 
ApPENDIX 3 ENVIRONMENTAL DISTURBANCES LOG 308 
XIV 
Tables 
TABLE 2-1 ELECTROENCEPHALOGRAM CHARACTERISTICS OF NON-RApID EYE 
MOVEMENT AND RApID EYE MOVEMENT SLEEP PHASES 9 
TABLE 2-2 NEUROTRANSMITTER EFFECTS ON SLEEP AND WAKEFULNESS 13 
TABLE 2-3 DRUGS COMMONLY USED IN ICU AND THEIR EFFECTS ON SLEEP 
ARCHITECTURE 48 
TABLE 2-4 DRUGS WITH POTENTIAL TO AFFECT MELATONIN METABOLISM BY 
INHIBITION OR INDUCTION OF CYTOCHROME P450 lA2 89 
TABLE 2-5 DRUGS KNOWN TO AFFECT MELATONIN SECRETION OR EXCRETION 90 
TABLE 3-1 INTENSIVE CARE SOCIETY SEDATION SCORE 100 
TABLE 3-2 PATIENT HYPNOTIC ADMINISTRATION PRIOR TO MELATONIN 
ADMINISTRA TION 102 
TABLE 3-3 NURSE OBSERVATION OF NOCTURNAL TOTAL SLEEP TIME AT BASELINE AND 
AFTER MELATONIN ADMINISTRATION 103 
TABLE 3-4 DIFFERENCES IN OBSERVED TOTAL SLEEP TIME MEANS COMPARED TO 
BASELINE 
TABLE 3-5 SUBJECTIVE NURSE ASSESSMENT OF BENEFIT NIGHT 1 COMPARED TO 
SUBSEQUENT NIGHTS 
103 
105 
TABLE 3-6 NOCTURNAL INTENSIVE CARE SOCIETY SEDATION SCORE OVER THE STUDY 
PERIOD 105 
TABLE 4-1 ROYAL HALLAMSHIRE HOSPITAL PHARMACY PRODUCTION WORKSHEET 
FOR A 0.5 MGt ML ORAL MELATONIN SOLUTION 121 
TABLE 4-2 pH OF 0.5 MGtML ORAL MELATONIN SOLUTION OVER TIME 123 
TABLE 4-3 STABILITY OF MELATONIN IN THE 0.5 MGt ML SOLUTIONS 124 
TABLE 6-1 BASELINE PATIENT CHARACTERISTICS 156 
TABLE 6-2 EFFECT OF MELATONIN ON NOCTURNAL SLEEP EFFICIENCY ON NIGHTS 3 & 4, 
DETERMINED USING DIFFERENT OUTCOME MEASURES 157 
TABLE 7-1 SUMMARY OF STUDIES REPORTING BLOOD MELATONIN CONCENTRATIONS 
AFTER ORAL DOSAGE (STUDIES IN ADULTS AND PUBLISHED IN ENGLISH) 179 
TABLE 7-2 SUMMARY OF MELATONIN PHARMACOKINETIC DATA AFTER A 10 MG ORAL 
DOSE IN CRITICAL CARE PATIENTS (MEAN (SD» 181 
TABLE 7-3 ASSOCIATIONS BETWEEN POTENTIAL CO-VARIATES AND MELATONIN 
EXPOSURE 
xv 
182 
TABLE 7-4 CORRELATIONS BETWEEN MARKERS OF MELATONIN EXPOSURE AND BIS 
MEASURES OF SLEEP 
TABLE 7-5 ASSOCIATIONS BETWEEN MELATONIN ORAL CLEARANCE AND 
ADMINISTRA TlON OF DRUGS AFFECTING CYPIA2 ACTIVITY 
183 
183 
TABLE 8-1 SUMMARY OF METHODS USED IN CRITICAL CARE FOR SLEEP MEASUREMENT 
199 
TABLE 8-2 POLYSOMNOGRAPHY STUDIES OF SLEEP IN CRITICAL CARE PATIENTS 204 
TABLE 8-3 ACTIGRAPHY AND BIS STUDIES OF SLEEP IN CRITICAL CARE PATIENTS 205 
TABLE 8-4 SUBJECTIVE STUDIES OF SLEEP IN CRITICAL CARE PATIENTS 207 
TABLE 8-5 SUMMARY OF MISSING DATA FROM THE MELATONIN INTERVENTION STUDY 
208 
TABLE 9-1 PATIENT CORTICOSTEROID EXPOSURE 233 
TABLE 9-2 REST-ACTIVITY ANALYSIS BY TREATMENT ALLOCATION 234 
TABLE 9-3 REST-ACTIVITY ANALYSIS FOR ALL CRITICAL CARE PATIENTS 235 
TABLE 9-4 COSINOR ANALYSIS OF PLASMA MELATONIN LEVELS 240 
TABLE 9-5 COSINOR ANALYSIS OF INDIVIDUAL PATIENT PLASMA CORTISOL LEVELS 247 
TABLE 9-6 COSINOR ANALYSIS OF PLASMA CORTISOL LEVELS 248 
TABLE 9-7 EFFECT OF MELATONIN ON PLASMA CORTISOL AREA UNDER THE 
CONCENTRATION TIME CURVE FOR A 24 HOUR PERIOD 249 
TABLE 9-8 COMPARISON OF MELATONIN AND CORTISOL ACROPHASES IN PLACEBO 
PATIENTS 250 
XVI 
Figures 
FIGURE 2-1 HISTOGRAM REPRESENTING NOCTURNAL SLEEP STAGES IN A HEALTHY 
YOUNG ADULT 8 
FIGURE 2-2 ASCENDING AROUSAL SYSTEM MAINTAINING WAKEFULNESS 11 
FIGURE 2-3 VENTROLATERAL PREOPTIC·NUCLEUS MAINTAINING SLEEP 12 
FIGURE 2-4 Two PROCESS MODEL OF SLEEP REGULATION 15 
FIGURE 2-5 PROPOSED APPROACH TO THE DRUG TREATMENT OF SLEEP DISORDERS IN 
CRITICALLY ILL PATIENTS 52 
FIGURE 2-6 EFFECT OF AGE ON PLASMA MELATONIN VERSUS TIME 61 
FIGURE 2-7 SYNTHESIS OF MELATONIN IN THE PINEAL GLAND 64 
FIGURE 2-8 REGULATION OF MELATONIN SECRETION BY LIGHT 65 
FIGURE 2-9 LIGHT PHASE RESPONSE CURVE 67 
FIGURE 2-10 MELATONIN PHASE RESPONSE CURVE 71 
FIGURE 3-1 PROPORTION OF NIGHTS IN WHICH NURSE PERCEPTION OF OBSERVED SLEEP 
QUALITY DURING MELATONIN ADMINISTRATION WAS RANKED AS "BETTER" THAN 
BASELINE HYPNOTIC TREATMENT 104 
FIGURE 4-1 CHROMATOGRAM SHOWING THE SEPARATION OF MELATONIN FROM ACID 
DECOMPOSITION PRODUCTS AFTER AUTOCLAVING AT 121-124°C FOR 15 MIN IN O.IM 
HYDROCHLORIC ACID 124 
FIGURE 4-2 CHROMATOGRAM OF THE 0.05% wlV MELATONIN SOLUTION AFTER 
STORAGE AT 25°C FOR 450 DAYS 125 
FIGURE 5-1 FINAL STUDY PROTOCOL 143 
FIGURE 6-1 PATIENTS RECRUITMENT ANALYSIS 155 
FIGURE 7-1 PLASMA MELATONIN CONCENTRATIONS (MEAN ± SD) AFTER ORAL 
ADMINISTRATION OF A 10 MG DOSE IN SOLUTION AT 2100 HOURS TO CRITICAL CARE 
PATIENTS 
FIGURE 8-1 SCATTER PLOTS COMPARING THE RESULTS FROM FOUR DIFFERENT 
TECHNIQUES USED TO MEASURE NOCTURNAL SLEEP EFFICIENCY IN THE MELATONIN 
181 
INTERVENTION STUDY 209 
FIGURE 8-2 BLAND-ALTMAN PLOTS FOR THE FOUR DIFFERENT TECHNIQUES USED TO 
MEASURE NOCTURNAL SLEEP EFFICIENCY IN THE MELATONIN INTERVENTION STUDY 210 
FIGURE 9-1 EXAMPLES OF REST-ACTIVITY ACTOGRAMS IN (A) HEALTHY VOLUNTEER 
AND CRITICAL CARE PATIENTS DEMONSTRATING A MODERATE (B) AND LIMITED (C) 
CIRCADIAN RHYTHM ACTIVITY V ARIA TION 236 
XVll 
FIGURE 9-2 FITs OF THE SINGLE COSINOR MODEL PLASMA MELATONIN 
CONCENTRATIONS IN INDIVIDUAL PATIENTS RECEIVING PLACEBO 
FIGURE 9-3 FIT OF THE SINGLE COSINOR MODEL TO PLASMA MELATONIN 
CONCENTRATIONS IN ALL PATIENTS RECEIVING PLACEBO 
FIGURE 9-4 PLASMA MELATONIN AREA UNDER THE CURVE FOR A 24 HOUR PERIOD IN 
239 
239 
ELDERLY CONTROLS 1387) AND CRITICAL CARE PATIENTS 241 
FIGURE 9-5 FITS OF THE SINGLE COSINOR MODEL TO PLASMA CORTISOL LEVELS IN 
INDIVIDUAL PATIENTS 245 
FIGURE 9-6 FITs OF THE SINGLE COSINOR MODEL TO PLASMA CORTISOL LEVELS IN (A) 
PLACEBO PATIENTS, (B) MELATONIN PATIENTS AND (C) ALL PATIENTS 246 
FIGURE 9-7 PLASMA CORTISOL AREA UNDER THE CURVE FOR A 24 HOUR PERIOD IN THE 
MELATONIN AND PLACEBO GROUPS 249 
XVlll 
Melatonin, sleep and circadian rhythms in critical care patients Chapter J Introduction 
1 INTRODUCTION 
1 
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Introduction 
The use of sedatives in critical care is an every day occurrence. Medical, nursing and 
pharmacy staff of all grades working in this unique environment are experienced in 
the common indications, clinical and adverse effects of these agents. Almost as 
common are the remarks of nursing staff highlighting yet another patient who has not 
slept well last night. The general response to this plea is the prescription of a night-
time sedative drug. In the case of an unsatisfactory response, then a larger dose or 
another sedative agent is added. This approach seems to work in some patients (i. e. 
they appear to be asleep for more of the night shift), but clearly does not help in all 
cases and, indeed, may complicate matters. In late 1999, whilst discussing one such 
patient I was asked about the potential value of melatonin supplementation in this 
scenario by one of the medical consultants. Dr David Edbrooke, a seasoned traveller 
who had recently supplemented his pre-flight whisky with melatonin to then discover 
that he arrived at his destination in a "blink of an eye". Like any self respecting 
phannacist, my initial reaction was to express my views that this area was the subject 
of over zealous reporting by the lay press, that there would be difficulties obtaining a 
pharmaceutical product and recommended that we just try some nocturnal 
amitriptyline instead. The patient received their additional sedative agent that night 
but, on reflection, the discussion prompted me to undertake an unexpected journey 
that was to dominate much of my subsequent waking life and which has resulted in 
this thesis. 
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Background 
The primary role of intensive care is to provide organ support to acutely ill patients 
while attempts to diagnose and then treat the underlying condition(s) are undertaken. 
Assuming the patient is successfully resuscitated, stabilised and appropriate 
treatment commenced, organ support is eventually weaned, and survivors are 
subsequently discharged to a ward or intermediate care facility. However, this 
process underestimates important aspects of recovery. In recent years there has been 
a greater appreciation of the long term implications for survivors of critical illness 
requiring intensive care [1-3]. The consequences for patient morbidity, including 
quality of life and functional status, has even led to a plan by the National Institute of 
Clinical Excellence to guide specialised follow up services to meet the needs of 
patients. How we identify sub-groups of patients to receive this care and, indeed, 
how we actually reduce the actual requirement, remains poorly understood. Sleep 
during recovery from a critical illness is an example of an issue that may be regarded 
as of minor significance in the overall care of an intensive care patient. However, 
sleep disturbances and treatments may ultimately have affects on medium and longer 
term outcomes [4]. 
Research Aims 
This research aims to review: 
1. The current literature on normal sleep mechanisms. 
2. How critical illness and intensive care therapy affects patients sleep. 
3. The efficacy and safety of drug therapy routinely used to treat sleep disorders in 
intensive care patients. 
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4. The basis of relevant circadian rhythms, the role of melatonin, and the theoretical 
basis for melatonin therapy in critical care patients. 
On this basis, studies are described that: 
I. Investigate the efficacy of melatonin on nocturnal sleep quantity in patients 
recovering from critical illness. 
II. Make recommendations for future oral melatonin dosing strategies in critical care 
patients. 
III. Investigate the degree of circadian rhythm disturbances in intensive care patients 
as well as the acute effects of melatonin administration. 
IV. Make recommendations for future research including guidance on alternative 
sleep measurement techniques for clinical and research use. 
Key Research Questions 
1. What is the theoretical basis for melatonin therapy in patients recovering from 
critical illness? 
2. What oral melatonin product can be used to dose intensive care patients? 
3. Does melatonin improve sleep quantity and quality in intensive care patients? 
4. How does critical illness affect the kinetics of melatonin and what dose should be 
recommended in future studies? 
5. How should sleep be measured in intensive care patients, both in clinical practice 
and research studies? 
6. Do patients recovering from critical illness demonstrate disturbed circadian 
rhythms, and does acute melatonin therapy improve rhythms? 
7. Do plasma melatonin and cortisol maintain their phase relationship in critical 
illness? 
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Thesis Structure 
Chapter 2 describes the background literature on the problem of sleep disturbances in 
critical care patients, mechanisms, potential interventions and adverse effects 
including the relationship with delirium. It also introduces the basis of circadian 
rhythm disturbances, the importance of melatonin and the application of melatonin 
therapy. In Chapter 3 a description is given of a service evaluation designed to 
examine if there was any merit in the use of oral melatonin to aid sleep in intensive 
care patients. The development and stability of a melatonin oral solution is described 
in Chapter 4. Chapter 5 develops what was learnt in the preliminary evaluation and 
background literature review to describe the methods used in a randomised control 
trial of melatonin in patients recovering from critical illness. Chapter 6 evaluates the 
results of melatonin therapy on nocturnal sleep quantity and Chapter 7 describes the 
kinetics of melatonin in the study subjects. Chapter 8 comments on the degree of 
agreement between some of the measures of nocturnal sleep, and makes 
recommendations for clinical application and research studies. Chapter 9 discusses 
the circadian rhythm disturbances found in critical care patients, including the 
relationship between melatonin and cortisol. Chapter 10 presents the final 
conclusions, explores the limitations of the research, the challenges of studying sleep 
in critical care patients and makes recommendations for further research. 
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2 BACKGROUND LITERATURE 
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Normal Sleep 
"Sleep is a reversible behavioural state of perception disengagement from and 
unresponsiveness to the environment" [5]. Early concepts of sleep regarded it as a 
passive process (i.e. a cessation of wakefulness), whilst modem sleep research has 
shown that sleep is a dynamic process that requires the activity of elaborate 
mechanisms involving numerous areas of the brain. To date, the complete 
mechanism of sleep regulation and its importance to human health has not been fully 
deciphered. However, the intensity of sleep after waking is proportional to the 
duration of wakefulness, which emphasises the necessity of recovery during sleep. 
The proposed functions of sleep are biochemical (metabolic rate slows during sleep); 
physiological (positive effects on the immune system); neurological 
(neurodevelopment, memory), psychological (memory consolidation, creative mental 
activity, problem solving capabilities, emotions) and social. 
N onnal sleep architecture 
Sleep occurs in two distinct phases, involving rapid eye movement (REM) and non-
rapid eye movement (NREM). NREM sleep comprises four subdivisions (1-4) with 
increasing sleep depth. The more restful sleep of stages 3 and 4 represents slow wave 
sleep (SWS). REM is also a restful period of sleep but has a lower threshold for 
awakening than SWS. Dreaming normally occurs during periods of REM sleep. 
Normal sleep architecture is described by a continuous cycle during the night 
between NREM and REM sleep; the cycle lasts approximately 90 minutes (Figure 2-
I). REM periods of the sleep cycle become more prolonged the further into the total 
sleep episode. 
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o 1 2 3 4 5 6 7 
TIme (Hours) 
Figure 2-1 Histogram representing nocturnal sleep stages in a 
healthy young adult 
REM: Rapid Eye Movement 
The NREM sleep stage is characterised by the frequency and amplitude of the 
electroencephalogram (EEG), the presence of sleep spindles and K-complexes in 
combination with electro-oculogram (EOG) and electromyogram (EMG) patterns. In 
REM sleep desynchronised EEG frequencies with loss of EMG and characteristic 
rapid eye movements emphasise the intense cerebral cortical activity that occurs 
during this sleep phase (Table 2-1). 
8 
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Characteristics 
EEG 
%TST 
Wave 
Stage 1 
2-5% 
Low 
voltage. 
Mixed 
frequency 
activity. 
Alpha 
waves. 
NREM 
Stage 2 SWS 
45- 55% 10-15% 
Gradual High voltage slow 
high waves. 
voltage of Delta waves. 
slow wave Delta activjty: 
activity. 20-50% (Stage 3); 
Intermittent >50% (Stage 4). 
"sleep 
spindles" 
and 
"K-
complexes". 
REM 
20-25% 
Low-
voltage 
amplitude. 
High 
frequency. 
Sawtooth 
wave. 
Slow alpha 
activity. 
Table 2-1 Electroencephalogram characteristics of Non-Rapid Eye 
Movement and Rapid Eye Movement Sleep Phases 
EEG: Electroencephalogram; TST: Total Sleep Time; NREM : Non-Rapid Eye Movement Sleep; 
SWS: Slow Wave Sleep; REM : Rapid Eye Movement Sleep 
(Adapted from MI Figueroa-Ramos with permission) 
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Neurophysiology of sleep and wakefulness 
Within a 24 hour period, a healthy individual cycles wakefulness, NREM sleep and 
REM sleep. Recent work has consolidated our understanding of the sleep and 
wakefulness process. Regions of the brain involved in wakefulness are the forebrain, 
reticular formation, thalamus and hypothalamus [6]. The ascending arousal system 
(AAS) originates from the upper brain stem and projects to the basal forebrain and 
thalamus [7]. Cortical arousal results from two pathways, namely a dorsal route 
through the thalamus and a ventral route through the hypothalamus and basal 
forebrain. This interaction between the ventrolateral preoptic nucleus (VLPO) and 
components of the arousal systems has been demonstrated to be mutually inhibitory, 
and has been compared to an electronic "flip-flop" switch [7] (Figure 2-2). State 
dissociation may become more prominent if one side of the switch becomes 
weakened and, therefore, less able to resist the dominance of the other [7]. 
The hypothalamus and brain stem are closely involved with the regulation of sleep 
[5]. Within the hypothalamus the suprachiasmatic nucleus, lateral hypothalamus, 
VLPO, tuberomamillary nucleus and pineal gland help to orchestrate sleep. The 
VLPO neurons are primarily active during sleep [7] (Figure 2-3). 
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VLPO 
"Off" 
/' Cortex 
/ Thalamus 
~\~;:'-t~---Hypothalamus 
Basal forebrain 
Pons 
Figure 2-2 Ascending arousal system maintaining wakefulness 
VLPO: Ventrolateral Preoptic Nucleus; PPT: Pedunculopontine; LOT: Laterodorsal Tegmental ; LC: 
Locus Coeruleus ; TM: Tuberomammillary Nucleus; vPAG: ventrolateral periaqueductal grey; 
Inhibition: ---- ; Activation: -
(Adapted from MI Figueroa-Ramos w ith permi ss ion) 
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Homeostatic 
process 
I / ircadian r pcoce" 
.......... 
..... ~ 
GABA 
----------,----------~ 
-----_ ..... 
" 
Figure 2-3 Ventrolateral preoptic nucleus maintaining sleep 
VLPO: Ventrolateral Preoptic Nucleus; LC: Locus Coeruleus; TM: Tuberomammillary Nucleus; 
Raphe: Dorsal Raphe Nucleus; PPT: Pedunculopontine; LOT: Laterodorsal Tegmental ; cVLP: VLPO 
cluster ; eVLP: VLPO extended; vPAG : ventrolateral periaqueductal grey; REM : Rapid Eye 
Movement; NREM : Non-Rapid Eye Movement; Inhibition: ----; Activation: -
(Adapted from MI Figueroa-Ramos with permission) 
Pharmacology of sleep and wakefulness 
The sleep-wake cycle and sleep stages are regulated by a complex interplay of 
neurotransmitters including noradrenaline, serotonin, acetylcholine, dopamine, 
histamine and gamma aminobutyric acid [8] (Table 2-2). The activity of 
neurotransmitters themselves is affected by cotransmitters which may alter the 
sensitivity of the receptor and, via neuromodulation, also affect transmitter synthesis 
and release. Other sleep factors such as hypnotoxins, somnogens and sleep regulatory 
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substances also interact with intrinsic neurotransmitter control of the sleep-wake 
cycle. 
Promotes 
Noradrenaline Wakefulness 
Wakefulness 
Acetylcholine 
REM 
Serotonin Wakefulness 
Dopamine 
Histamine Wakefulness 
GADA NREM 
Inhibits 
REM 
REM 
REM 
REM 
Other 
Influences mood 
and behaviour 
Motor inhibition in 
REM 
Influences mood, 
behaviour and 
motor control 
Influences 
thoughts, emotions, 
behaviour and 
motor control 
Table 2-2 Neurotransmitter effects on sleep and wakefulness 
REM: Rapid Eye Movement; GABA: Gamma Aminobutyric Acid; NREM: Non-Rapid Eye 
Movement Sleep 
(Adapted from Shneerson [9]) 
Noradrenaline is involved in controlling wakefulness and in the inhibition of REM 
sleep. The cholinergic system is also involved in the generation of REM sleep and 
sleep-wake regulation. The role of serotonin is complex but overall it appears to 
promote wakefulness [9]. 5HT IA and 5HT2A have the most impact on sleep and 
inhibition of the latter receptors promotes REM sleep. The effects of dopamine (02) 
agonists and antagonists on sleep and wakefulness are affected by neuromodulation 
[9]. Dopamine promotes alertness and disturbances in dopamine activity induce 
diurnal sleep. Histamine has a role in the control of wakefulness and limitation of 
REM sleep. Gamma aminobutyric acid (GABA) is an important inhibitory 
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neurotransmitter; its release within the VLPO inhibits aminergic induced 
wakefulness [9]. 
Many other amino acids, hormones, cytokines and prostaglandins are also involved 
in the regulation of sleep and wakefulness. Adenosine is probably an important sleep 
regulatory substance, and accumulation of this purine nucleoside accounts for some 
of the homeostatic sleep drive. Pituitary hormones may be of functional significance 
in the maintenance and quality of sleep [8]. The neurohormone melatonin is also 
important in regulating the sleep-wake cycle in humans [10]. Prostaglandin D2 
(PGD2) induces NREM and REM sleep while PGE2 promotes wakefulness. 
Cytokines may also act as sleep factors. Interleukin-l (lL-l) promotes NREM sleep 
and Tumour Necrosis Factor alfa (TN Fa) increases SWS sleep while reducing REM 
sleep [11, 12]. Raised IL-6 plasma concentrations are associated with reduced sleep 
quality [13]. Abrupt changes in the levels of these cytokines during a systemic 
inflammatory response syndrome (SIRS) or sepsis will, therefore, have adverse 
effects on sleep regulation [14]. Orexins (hypocretins) are important in maintaining 
wakefulness and disturbances in their secretion occur in some disorders such as the 
obstructive sleep apnoea syndrome [15]. 
Clearly, as long as they penetrate the blood brain barrier, drugs that have an effect on 
neurotransmitters and hormones may influence normal sleep architecture. Sleep stage 
classification and spectrum analysis using polysomnography (continuous polygraph 
of multiple physiological variables during sleep) can provide detailed information on 
the adverse effects of drugs on sleep [16]. However, few data are available, 
especially in relation to critically ill patients. 
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The sleep-wake cycle 
The sleep-wake cycle is governed by two di stinct types of process - homeostatic 
("sleep dri ve") and circadian [17]. During wakefulness accumulation of sleep factors 
(e.g. adenosine) increases the propensity fo r sleep while the circadian process 
counteracts thi s drive (preventing sleep intrusion) until a threshold when the "sleep 
gate" is opened. The latter probably follows the surge in plasma melatonin 
concentration. The homeostatic drive during sleep is eventuall y depleted as the 
circadian dri ve for wakefulness returns (low plasma melatonin levels) and awakening 
occurs. 
Increased SWA 
7 23 7 23 7 23 10 
time of day 
Figure 2-4 Two process model of sleep regulation 
Sleep drive is a function of homeostatic and circadian processes. The second 24 hour period represents 
a period of sleep deprivation (due to nocturnal work) with subsequent accumulation of sleep drive 
wh ich eventually results in increased recovery sleep [17]. 
Process S: Homeostati c process; Process C: Circadian process; SWA: Slow wave acti vity; TST: Total 
sleep time 
The sleep-wake cycle is the most visible human circadian rhythm. The biological 
clock is entrained to a 24-hour rhythmicity by retinal transmission of the effect of 
environmental light. Light is the most important ze itgeber (time cue) in the 
entrainment of the biological clock. 
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Disorders of the sleep-wake cycle occur in the form of advanced sleep phase 
syndrome (ASPS), delayed sleep phase syndrome (DSPS) and irregular sleep-wake 
rhythm. International travel Get lag) and the demands of shift work also affect the 
sleep-wake cycle. 
Drugs have the potential to affect the timing of the biological clock by stimulation or 
inhibition of the neural pathway of the suprachiasmatic nucleus (SCN). Thus, those 
that are capable of crossing the blood brain barrier have the potential to phase 
advance or delay the biological clock depending on the individual receptor type they 
interact with and whether they are agonists or antagonists. Clearly, critically ill 
patients will have acute changes in endogenous neurotransmitters and are exposed to 
many drugs under stressful conditions. Also, changes in environmental light cues as 
a consequence of institutionalisation in the critical care area will have an influence. 
A detailed description of the role and regulation of the endogenous zeitgeber 
melatonin with regard to the sleep-wake cycle is given later in this chapter. 
Sleep disorders 
The International Classification of Sleep Disorders (2005) groups sleep disturbances 
into four categories [18]. These are dyssomnias, parasomnias, sleep disorders 
associated with mental, neurologic or other medical disorders and proposed sleep 
disorders. Dyssomnias are disorders that affect the initiation or, maintenance of 
sleep, and include insomnia, which is one of the most common symptoms of a sleep 
disorder encountered in general practice. Insomnia is characterised by difficulty in 
falling asleep (increased sleep latency) and! or difficulty in maintaining sleep and! or 
early awakening. Although insomnia is often an acute problem associated with a 
trigger such as stress, it may become chronic. Insomniacs frequently experience 
increased autonomic activity either at night, in anticipation of problematic sleep, or 
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during sleep itself. This autonomic activity is responsible for increases in blood 
pressure and heart rate, muscle tension and peripheral vasoconstriction. 
The parasomnias are disorders that intrude into the sleep process and are not 
disorders of sleep and wakefulness, as such. They are disorders of arousal (or partial 
arousal) or sleep transition disturbances that occur during sleep. Parasomnias usually 
associated with REM sleep include nightmares and REM Sleep Behavioural 
Disorders. Patients recovering from critical illness are particularly susceptible to 
REM rebound when potent REM suppressing drugs such as opioids are discontinued 
acutely. REM rebound is characterised by hypertension, tachycardia, hypoxia, 
hypoventilation, hypopnea and nightmares. 
Sleep disorders associated with mental, neurologic and other medical disorders are 
those where intercurrent illness disrupts the sleep-wake cycle. In critically ill 
patients, sleep disturbances are routinely listed as a precipitating factor for 
developing delirium. However, it may well be that in many patients, these sleep 
disturbances are actually an early symptom of delirium itself [19]. In particular, some 
patients may develop state dissociation disorders manifesting as hallucinations and, 
in the most extreme form, as REM Sleep Behavioural Disorders [20]. 
Of the proposed sleep disorders, terrifying hypnagogic hallucinations may pose the 
greatest problem to critical care patients. Hallucinations can also occur in the 
transition from wakefulness into NREM sleep (hypnagogic) and from NREM sleep 
to wakefulness (hypnopompic). Critical care patients may be particularly vulnerable 
to hypnagogic and hypnopompic hallucinations, [20] which present a form of state 
dissociation [21, 22]. Sleep disorders in the critically ill patient may therefore share 
some of the symptoms of delirium. 
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Excessive daytime sleepiness occurs in the fonn of narcolepsy, hypersomnia and 
sleep apnoea. In critically ill patients sleep apnoea is common. This is because many 
postoperative patients with sleep apnoea secondary to opioid-induced apnoea and 
hypoxia are referred to critical care areas. Additionally, critically ill patients with 
congestive heart failure or chronic obstructive pulmonary disease may develop 
Cheyne-Stokes respiration and sleep apnoeas during weaning from mechanical 
ventilation. Patients with sleep apnoeas may require prolonged continuous positive 
airway pressure ventilatory support. 
Measurement of sleep 
Sleep quantity has been measured by a variety of techniques, of which 
polysomnography is regarded as the gold standard. 
Polysomnograpby 
Polysomnography is the only method of sleep measurement that is capable of 
identifying individual sleep stages (sleep quality). It involves electroencephalogram 
(EEG), electro-ocularogram (EOG) and electromyogram (EMG) recordings that are 
especially difficult to make in the critical care environment. 
Because critically ill patients often become delirious, removal of one or more of the 
electrodes during recording is a significant risk. This and other issues relating to the 
cost of investing in the necessary equipment and skilled staff has lead to the 
adaptation of other methods of assessing sleep in critical care. In a review of critical 
care sleep studies, only 25% used polysomnography continuously for 24 hours or 
more [23]. 
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Actigraphy 
An actigraph is a small wristwatch device that is capable of both sensing and storing 
information on movement. An accelerometer detects movement in two or three axes, 
translating this into digital counts during pre-defined epoch periods. The epoch 
length is the period of time over which the actigraphy data are averaged. The 
actigraph is capable of collecting data over extended periods before data is 
downloaded into a personal computer. Computer software based on validated 
algorithms translates the movement data into sleep-wake cycles, which can then be 
analysed further. 
Actigraphy has advantages over polysomnography in the critical care setting relating 
to robustness, capability of monitoring continuously over extended periods and 
automated analysis. It has been shown to be very sensitive for the recording of Total 
Sleep Time (TST), Sleep Latency «SL), time to fall asleep) and Sleep Efficiency 
«SE) (total nocturnal sleep time expressed as a ratio/ percentage of time available for 
sleep), but tends to overestimate these parameters compared to polysomnography 
[24]. As actigraphy technology and algorithms have improved it has gained a greater 
acceptance. These improvements were reviewed [25] and led the American Academy 
of Sleep Medicine to outline practice parameters for the use of actigraphy [26]. In 
summary, the recommendation was that, while actigraphy should not be used 
routinely to evaluate sleep disorders, it may be used in the 'assessment of sleep 
variability, measurement of treatment effects, and detection of sleep phase alterations 
in insomnia secondary to circadian rhythm disturbance' [26]. 
However, in critical care patients, who are especially prone to neuromuscular 
problems, a measurement technique that relies on movement to interpret sleep-wake 
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patterns may be compromised. Indeed, actigraphy has never been validated against 
polysomnography in these patients. 
Nurse assessment 
It is usually the nursing staff from the night shift who identify patients who have not 
appeared to sleep. In local critical care practice they record whether the patient was 
asleep or awake on an hourly basis. Hypnotic therapy is often commenced on the 
basis of the sleep assessment record and the nursing staff recommendation. The 
accuracy of this form of sleep quantity assessment is questionable and it seems that 
TST is overestimated when compared to the findings ofpolysomnography [27]. On 
the other hand, according to Edwards, [28] nurses were able to assess a patient's 
sleep or wake state correctly 80% of the time compared to polysomnography . 
Over the course of a night shift, the nurse probably collects an impression of the 
patient's overall sleep during the period, which is not appropriate as a research 
method of sleep quantity, but is useful clinically. 
Subjective assessment 
The use of sleep diaries in critically ill patients is obviously limited by the mental 
and physical ability of the patient to record their experience, and their use in this 
context has never been widely developed. 
The Richards-Campbell Sleep Questionnaire (RCSQ) comprises 5 visual analogue 
scales (VAS) covering the sleep domains of depth, latency, awakenings, percent time 
awake and quality of sleep [29]. A moderate correlation has been shown between the 
polysomnography sleep efficiency index (5 hours each night) in 70 critically ill men 
and the RCSQ. 
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The RCSQ has been used by nurses to assess the sleep of critically ill patients unable 
to report their own subjective sleep efficiency [30]. However, only about half of the 
patients studied were able to complete the questionnaire. 
Bispectral index 
The BIS is a processed EEG technique which digitises raw EEG data and rejects 
artefacts before translating it into a numerical range (0-100) based on a complex 
algorithm. A BIS score of zero reflects an isolectric EEG and one of 100 a fully 
awake individual. BIS has been compared to polysomnography in 10 patients being 
investigated for sleep apnoea! hypopnoea syndrome (SAHS) [31]. BIS scores fell 
during periods of sleep although there was considerable overlap between BIS values 
recorded for the various sleep stages. The BIS value increased during periods of 
patient arousal. 
BIS has been used successfully to detect the loss of consciousness occurring at the 
onset of natural sleep in healthy volunteers [32]. None of the subjects were awake 
when BIS values were less than eighty and all were conscious at values greater than 
92. 
The ease of application of the BIS sensor and the simple scoring output are 
advantages that should be weighed against limitations in identifying sleep stages and 
a lack of validation against polysomnography in critical care patients. 
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Sleep in the critically ill 
Sleep disturbances are common in critical care patients. The importance of this 
should not be underestimated as patients report sleep disturbance as one of the most 
stressful components of an intensive care admission [33]. 
Sleep architecture in critically ill patients 
Recent reviews, [23,34] have identified numerous studies of the effect of critical 
illness on sleep architecture. Of these studies, only seven used continuous 
polysomnography for more than 24 hours. There is conflicting evidence as to 
whether the patients suffer from sleep deprivation. Some studies show a reduced 
TST, [27,35] while others found normal TST over the 24 hours. [36,37] However, 
more than half of the TST may occur during the day [35, 36]. Therefore, patients 
have frequent sleep episodes throughout the 24 hour period that, at least according to 
some studies, accumulate to being equivalent to the normal nocturnal sleep TST. 
This constitutes an irregular sleep-wake rhythm sleep disorder [18]. In fact, the 
patients suffer from sleep fragmentation, in which they have frequent arousals and 
awakenings, [35,36,38] comparable to that observed in sleep apnoea patients [23]. It 
is, therefore, not unexpected that critically ill patients will experience a disrupted 
sleep-wake cycle as a direct result of the frequent arousals and awakenings. TST 
itself may be less important than the ability of the patient to achieve continuous, 
deeper and more restorative periods of sleep. 
Critically ill patients demonstrate greatly reduced SWS and REM sleep percentages 
compared to healthy individuals [27, 35, 36]. The percentage of REM sleep has been 
reported to be approximately 5% of TST in critically ill patients compared to the 
normal 25% [23]. Importantly, patients with suppressed REM sleep are at risk of 
developing REM rebound at some stage during their recovery. There is an increase in 
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NREM Stage 1 sleep, although this is of no value in tenns of restorative capability 
[27, 35, 36]. 
Both homeostatic and circadian processes of sleep regulation are required for 
optimum sleep to occur. Attempts to improve the sleep continuity of critically ill 
patients must also consider the effects on the sleep-wake cycle, which it is important 
to try to restore [39]. 
Consequences of disrupted sleep in the critically ill 
Sleep disruption has adverse consequences that are especially important in critically 
ill patients. It is still debatable whether these patients actually suffer from sleep 
deprivation, as opposed to sleep fragmentation. Much more is known about the 
adverse effects of sleep deprivation. It remains unknown whether sleep continuity, or 
sleep quantity is more important with regard to the recuperative function of sleep 
[40]. 
Respiratory effects 
Sleep fragmentation, similar to that exhibited by critically ill patients, has been 
shown to cause sleep related breathing abnonnalities [41, 42]. Sleep fragmentation 
more than sleep deprivation produced upper airway collapse associated with a 
significant increase in the apnoea-hypopnoea index. This suggests that critically ill 
patients without a diagnosis of sleep-apnoea may show an increased tendency for 
apnoea as a direct result of sleep fragmentation. Obese patients or those known to be 
snorers, may be particularly at risk of the effects of sleep fragmentation when 
recovering from critical illness. 
Human volunteers who were deprived of specific SWS or REM sleep stages showed 
a rebound increase in REM sleep on the subsequent night [43]. Average ventilation 
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was not altered during wakefulness in either group. However, the increased REM 
periods were associated with reduced ventilatory responses to both hypoxia and 
hypercapnia and an increase in the frequency of long episodes of decremented 
breaths. The latter may be particularly important in a high-risk group of known 
snorers and! or obese critically ill patients who subsequently may develop apnoeas. 
REM sleep rebound may be caused by a variety of drugs and procedures, including 
anaesthesia [44]. Efforts to minimise REM sleep disruption and, therefore, to reduce 
the risk of REM rebound will minimise the risk of respiratory malfunction. 
Further studies have reported that sleep deprivation reduces the ventilatory response 
to hypoxia and hypercapnia as a consequence of reduced chemoreceptor function 
[45-48]. Males appear to demonstrate a greater reduction in ventilatory response to 
hypercapnia during sleep stages than females [48]. However, a recent study found 
that sleep deprivation did not decrease the ventilatory response to hypercapnia [49]. 
Futhermore, all studies tested the response to sleep deprivation in healthy volunteers, 
[43, 45-49] and therefore, the effects of acute illness on ventilatory response remain 
unknown. Ultimately the type of sleep fragmentation, duration of deprivation and 
individual patient risk factors may determine the importance of sleep fragmentation 
in terms of hypercapnic response. This is an important issue, as critically ill patients 
who demonstrate a reduced chemoreceptor response are less capable of coping with 
withdrawal of mechanical ventilation [50]. 
Critical care patients discharged to the ward are still at risk of sleep related breathing 
disturbances. Patients who had received prolonged mechanical ventilation on an 
intensive care unit (lCU) were subsequently found to have significant nocturnal 
sleep-related breathing disorders on the ward [51]. Thirteen of the 15 patients studied 
had oxygen desaturation (Sa02 < 90% for> 2 hours) and 11 had a raised apnoea-
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hypopnoea index. The effect of sleep fragmentation on respiratory function may not 
only delay weaning from mechanical ventilation and hence length of ICU stay, it 
may also affect morbidity on discharge and increase the risk of readmission to ICU. 
This has important resource and cost implications with regard to the provision of 
leu facilities. 
Cardiovascular effects 
Evidence that sleep disruption during critical illness is a direct cause of 
cardiovascular morbidity or mortality is lacking. The respiratory effects described 
above, are expected to increase demands on the cardiovascular system. Certainly 
critically ill patients who are aroused or awakened from sleep often have 
hypertensive episodes as a consequence of transiently increased sympathetic activity. 
Patients who have had suppression of their REM sleep may experience REM 
rebound as their acute illness resolves and! or REM suppressing medication such as 
opioids are discontinued [52]. REM rebound augments the cardiovascular response 
that normally occurs during the REM sleep phase. This has the potential to cause 
tachycardia and hypertension in vulnerable patients. REM rebound also causes 
apnoeas and hypoxia, the cardio-respiratory consequences are important in this 
vulnerable patient group. 
Neurological effects 
Sleep disturbance is often considered to be a risk factor for 'ICU psychosis'. 'ICU 
psychosis' is one of the many misnomers for the acute confusional state that occurs 
in critically ill patients, and is more appropriately described as delirium [53]. The 
evidence that sleep disturbances are a cause of delirium in the intensive care unit is 
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limited and has recently been questioned [53]. Delirium itself is associated with a 
circadian rhythm abnormality which translates into an irregular sleep-wake rhythm. 
Delirium has many confirmed risk and precipitating factors such as high exposure to 
anti muscarinic drugs [54]. Tricyclic antidepressants and antihistamines, with 
significant antimuscarinic activity, are often used in critical care patients to aid sleep. 
Disruption of the sleep-wake cycle itself may be particularly important in the 
development! pathophysiology of delirium. Nuttall et aI, [55] reviewed the charts of 
intensive care patients to examine the relationship between the lack of circadian 
rhythm and the incidence of delirium. The nadirs of urine output and temperature 
were used as markers of circadian rhythm. However, no relationship was found 
between disrupted circadian rhythm and delirium. Some aspects of this study were 
questioned in an accompanying editorial [56]. In critically ill patients, urine output 
and temperature may be affected by numerous variables and may not be the most 
appropriate markers of circadian rhythm in this patient group. As discussed later, 
melatonin may be a more appropriate marker of the sleep-wake cycle, offering more 
information on the relationship with delirium. Also, in the study of Nut all et ai, [55] 
the evaluation of delirium was based on clinical diagnosis alone and not on any of 
the recognised ICU screening tools. This may explain the low incidence of delirium 
(12% compared to 70% - 80% in other studies [57, 58]). 
Outside of critical care, reinforcement ofthe sleep-wake rhythm has been shown to 
ameliorate behavioural disorders, including delirium, in elderly institutionalised 
patients [59]. 
The importance of delirium with regard to patient morbidity, length of stay and 
mortality, [58] is only now being realised. Factors predisposing to delirium need to 
be identified and methods to prevent them implemented [57, 58]. Also, delirium 
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should be taken into account when choosing pharmacological interventions to aid 
sleep. The treatment of underlying delirium with appropriate antipsychotic 
medication may improve sleep, whereas sedative hypnotics may aggravate delirium 
and hence sleep disturbance. 
Immunological effects 
On admission, critically ill patients often have disruption in their immune function as 
a consequence of disease, drug treatment or nutritional factors, compounded by SIRS 
or sepsis [60]. This may be further compromised by sleep deprivation [61,62]. 
Sleep deprivation for 48 hours was shown to decrease cell-mediated immune 
reactions, as measured by lymphocyte production and adhesiveness in healthy 
subjects [63]. Return to baseline values after sleep deprivation was discontinued took 
5 days. When immunised against influenza virus, mice allowed normal sleep 
achieved total viral clearance, whereas sleep deprivation ablated any effect of 
immunisation [64]. 
In volunteers deprived of sleep for 40 hours, IL-l and IL-2 levels were increased 
[65]. Natural killer cell activity continued to decline even when normal sleep was re-
established. Leucocytosis and increased natural killer cell activity have been reported 
in another group of volunteers deprived of sleep [61, 65]. The effect of sleep 
deprivation combined with intense physical activity on immune function has also 
been studied [66]. Overall there is a mixed picture~ some elements of immune 
function are increased, such as neutrophil and monocyte activity, while eosinophil, 
lymphocyte and natural killer cell activity were decreased [66]. 
It appears that even relatively short periods of sleep disruption can impair immune 
function. In subjects deprived of sleep for only 5 hours during the first part of the 
night, natural killer cell and lymphokine killer cell activities were reduced, but 
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returned to baseline after one nights sleep [67]. Stimulated IL-2 levels were also 
reduced after sleep deprivation, but did not return to baseline after a recovery sleep 
[67]. 
The circadian rhythm of cortisol secretion does not appear to be adversely affected 
by short-term sleep deprivation [61, 65]. However, the effects of long term sleep 
disturbances on cortisol secretion remain unknown. 
Recently, the effect on immune function of restricted sleep (6 hours sleep per night) 
over a prolonged period (1 week) was studied [68]. Pro-inflammatory cytokine 
secretion of IL-6 and tumour necrosis alfa (TNFa) (men only) was increased 
significantly. Prolonged sleep deprivation also reduced cortisol secretion [68]. The 
results of the study by V gontzas et ai, [68] may better represent the adverse immune 
effects of sleep disturbances in critical care patients compared to studies of short-
term sleep restriction. 
Long-term effects 
The impact of a period of critical care on the long-term quality of life of patients is 
only now beginning to be appreciated [1]. Patients with acute respiratory distress 
syndrome (ARDS) receive prolonged mechanical ventilation necessitating sedation 
and sometimes paralysis. Sedated patients may appear to be sleeping, but do not 
achieve the restorative benefits of sleep [23]. Long term follow up (up to 41 months) 
of patients treated for ARDS has identified depression and post traumatic stress 
disorder (PTSD) associated with sedative and neuromuscular blocking drug use [69]. 
Although the incidence of psychological morbidity (anxiety and depression) is low 
three months after hospital discharge, [1] some patients may suffer significant 
problems related to their intensive care stay. Memory is adversely affected after 
intensive care admission, with one third of patients having no recall of their stay at 6 
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months post discharge [70]. Deep sedation increases the risk of memory loss and 
prolonged stay in intensive care increases the risks of delusional memory and 
hallucinations [71]. Delusional memories predispose to acute PTSD and preservation 
of factual, even unpleasant memories protects from later development of the 
symptoms of PTSD [72]. Attempts to recreate patient "memories" using diaries of 
patients intensive care stay have been suggested and are used by some intensive care 
units. However, preservation of memory by reducing the severity of illness, 
minimising depth of sedation, reducing the incidence and duration of delirium and 
reinforcing sleep-wake cycles are likely to be more beneficial in improving the 
memories of critical care patients. 
Causes of sleep disruption 
The causes of sleep disturbances in critically ill patients are multifactorial. This is 
important to understand as it emphasises that a single intervention (such as a 
medication) is unlikely to improve sleep quality and quantity. 
Environment 
Noise 
Noise has long been acknowledged as a problem in intensive care [73-75]. 
"Standards for Intensive Care" acknowledges the problem and makes 
recommendations on how noise may it be reduced [76]. Investigations into noise 
levels in hospitals have shown that it is common to exceed 70 A-weighted decibels 
(dBA) during both day and night in the ICU [73]. Accordingly, the use of 
headphones has been studied in critical care staff, and found they improved 
subjective noise assessment [77]. The sources of high noise levels in intensive care 
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include monitor alanns, patient care activities, ventilators. audio-visual equipment, 
construction engineering and staff interaction. 
Noise pollution in a coronary care unit was associated with cardiac arrhythmias and 
ischaemia [78]. Excessive noise has also been identified as a physical stress by 
intensive care patients [79] and noise levels are often regarded as one ofthe principal 
detenninants of disrupted sleep in patients. 
Early evidence for excessive noise as a cause of sleep disruption in critical care 
patients was based on sleep laboratory simulations. A correlation between reduced 
REM sleep and noise levels was observed in volunteers subjected to audiotapes of 
critical care unit night time sounds [80]. These subjects also reported a worsening of 
sleep quality compared to those in a quiet setting [81]. Sleep latency. total sleep time, 
number of awakenings but not dreams were reported to be worse. A small study of 
critical care patients monitored overnight, found a correlation between the number of 
arousals and the level of noise [82]. 
The results of a questionnaire given to over two hundred patients on the day of their 
discharge from a critical care environment indicated that they regarded noise as a 
cause of sleep disruption [83]. However, they also indicated that the monitoring of 
vital signs and phlebotomy was more disruptive to their sleep than noise [83]. 
Polysomnography recording of mechanically ventilated ICU patients suggested that 
environmental noise was responsible for 11.5% of sleep arousals and 17% of 
awakenings [37]. In mechanically ventilated patients noise was found to be 
responsible for 20.9% of total arousals and awakenings [35]. Only 35% of peak noise 
levels> 75 dBA resulted in an arousal of awakening. Recently, Cabello et al [84] 
reported that only 14% of the polysomnographic sleep fragmentation recorded in 
mechanically ventilated ICU patients was associated with an acute increase in noise. 
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It is clear from these studies that environmental noise is a cause of sleep disruption in 
critically ill patients. However, noise is only one factor and does not explain the 
majority of patient arousals and aWakenings. It appears that talking amongst critical 
care staff is the single most disruptive source of noise [35, 73, 78, 85-88]. Therefore, 
it should be possible to reduce the magnitude of environmental noise and hence 
lessen its impact of on patients sleep [85, 87, 89-91], for example by the imposition 
of nurse led "quiet times" [87]. Similarly, attempts at promoting sleep at 
inappropriate times of the day should be discouraged in order not to diminish 
nocturnal sleep drive. Prolonged naps, particular late in the evening, reduce the 
homeostatic sleep drive and aggravate rather than reinforce the monophasic sleep-
wake rhythm. 
Light 
Noctumallight in the leu is often regarded as a cause of sleep disruption. The 
timing and intensity of the environmental light-dark zeitgeber entrains animals and 
humans to a 24-hour sleep-wake cycle via the circadian pacemaker. Inappropriate 
light in the leu has the potential to disrupt circadian rhythms, including the sleep-
wake cycle. Factors specifically determining the disruptive effect of light on 
melatonin secretion are discussed later. 
Walder et ai, [90] found baseline nocturnal mean illuminance levels in an leu to be 
4.6 lux. These low levels would not be expected to disrupt melatonin secretion and 
should support maintenance of a normal sleep-wake cycle. However, attempts to 
control nocturnal light whilst reducing mean illuminance further to 1.6 lux, increased 
variability and maximum light intensities to a mean of 22.8 lux. Some patients would 
then have experienced illuminance levels sufficient to disrupt melatonin secretion. 
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Clearly, any attempts to switch lights off during the day could have confusing effects 
on the circadian sleep-wake cycle. Many ICU patients do not suffer from lack of total 
sleep throughout the 24-hour period, but demonstrate an irregular sleep-wake cycle. 
Attempts to promote nocturnal sleep are necessary as opposed to those that would 
encourage daytime napping. In fact, bright light during the daytime will help 
reinforce the light-dark zeitgeber and improve nocturnal sleep [92]. 
The United Kingdom ICU standards recommend that "The general lights should dim 
without flicker. There should be an independent control of light over each bed, with 
individual patient lighting independent of general background lighting. Good 
spotlighting and low level to illuminate drains and seals are needed at each bed" [76]. 
These recommendations acknowledge the potential for light disruption at night and 
attempt to minimise disruption to patients whilst maintaining their safe care. 
Unfortunately, these recommendations are not universally applied, especially in units 
built prior to their publication. Also, the standards do not stress the importance of a 
light-dark cycle sufficiently. Even units that do adopt these standards allow 
individual illuminance intensity and timing ultimately to be at the discretion of the 
staff. 
Care activities 
Patient care activities in a critical care unit occur throughout the 24-hour period. 
Unlike ward level 0 or 1 areas, level 2 and 3 areas are, by definition, more likely to 
undertake nursing activities at night including drug administration, blood sampling, 
turning of patients and recording of vital signs. A large study of patients from a 
mixture of medical, surgical and cardiac ICUs found that the taking of vital signs and 
blood samples were perceived to be the most sleep disruptive, while the 
administration of medication was less of a problem [83]. 
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Another study of nocturnal nursing care reported that patients experienced hourly 
interruptions in 94% of 147 ICU patient nights studied [93]. The majority of patient 
baths were given during the night [93]. 
Acute illness 
Cytokines have a role in the normal regulation of nocturnal sleep. During SIRS and 
sepsis, pro- and anti-inflammatory cytokines are released that may contribute to the 
sleep disturbance that occurs in acute illness [37]. Pro-inflammatory cytokines also 
augment blood brain barrier permeability, [94] which may potentiate sleep-wake 
regulation disturbances mediated through both endogenous and exogenous 
substances. 
Injection of endotoxin in humans increases levels ofTNFa. and IL-6 followed by a 
reduction in REM sleep and increases in stage 2 NREM sleep [95, 96]. Direct 
injection ofIL-6 in humans has the same effect, [14]. In rabbits, IL-4 has been shown 
to decrease REM sleep [97]. 
Clearly, complex changes in cytokine production during SIRS/ sepsis will have a 
disruptive effect on sleep, compounded by intensive drug therapy, environmental 
conditions and nursing interventions. 
Respiratory considerations 
One of the commonest reasons for admission to a critical care area is for advanced 
respiratory support, requiring either invasive or non-invasive mechanical ventilation. 
Mechanically ventilated patients experience sleep disruption, which is not primarily 
explained by noise and patient care activities [35]. 
Non-invasive positive pressure ventilation in patients with chronic obstructive 
pulmonary disease [98] and continuous positive airway pressure [99] or non-invasive 
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positive pressure ventilation [100] in Cheyne-Stokes respiration patients, can 
improve sleep quality acutely. Non-invasive mechanical ventilation maintains these 
sleep improvements when continued long term [101]. Air leakage through the mouth 
associated with nasal-continuous positive airway pressure ventilation causes sleep 
fragmentation due to patient arousal [102]. 
In the acutely ill patient, non-invasive mechanical ventilation is not always tolerated, 
due to fatigue, anxiety, delirium or discomfort (particularly with the masks). If 
clinically appropriate and the patient is in agreement, invasive ventilation is 
instigated. The mode of mechanical ventilation employed may be important with 
respect to sleep quality. Pressure support ventilation has been shown to increase 
sleep fragmentation compared to assisted control ventilation [38]. The most 
important cause of apnoea leading to arousal was similarity of the resting breath 
PC02 to the apnoea threshold. The addition of a dead space, thereby increasing 
resting PC02 above the apnoea threshold, reduced patient arousal and significantly 
increased sleep efficiency. The effect of dead space addition was only studied for 2-3 
hours, [38] and so it us unkno\\TI how long it takes for the apnoea threshold to reset 
itself with the potential for central apnoeas to recur. Five of the six patients who 
developed apnoeas during pressure support had signs of cardiac failure [38]. This 
emphasises the fact that significant numbers of ICU patients may develop Cheyne-
Stokes respiration as a consequence of their acute illness [103]. Differences between 
controlled and assist controlled mechanical ventilation have also been studied during 
NREM sleep in healthy volunteers [104]. Controlled mechanical ventilation reduced 
respiratory motor output when the frequency was increased even 1 breath per minute 
above eupnoea after mechanical ventilation. Increasing the tidal volume by 65% or 
more from baseline. in addition to increasing the frequency, totally blocked 
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respiratory motor output after mechanical ventilation. Assist controlled ventilation at 
tidal volumes of 165% of baseline or more prolonged expiratory time after 
mechanical ventilation. Controlled mechanical ventilation was associated with a 
significantly greater incidence of central apnoeas compared with assist-controlled 
ventilation. The duration of the apnoeas with controlled mechanical ventilation was 
proportional to the tidal volume. The authors proposed that the mechanism 
underlying the reduced respiratory function was diaphragmatic weakness. 
Recently, two further studies of the effects of mechanical ventilation have 
emphasised the importance of patient-ventilator concordance on sleep quality. 
Bosma randomised 13 patients to receive either pressure support or proportional 
assist ventilation in a cross over study conducted over two nights [105]. 
Polysomnographic recording of nocturnal sleep showed improvements in sleep 
quality (increased SWS and REM sleep) but not quantity during proportional assist 
ventilation. It was concluded that proportional assist ventilation reduces patient-
ventilator discordance as a cause of sleep disruption. In 11 mechanically ventilated 
patients with good patient-ventilator synchrony during pressure support ventilation. 
there was no improvement in sleep quality when changed over to proportional assist 
ventilation [106]. 
Fluctuations in blood gases as a consequence of alteration in respiratory function 
may also affect sleep quality. Increased PC02 prior to airway occlusion potentiates 
the inspiratory effort response and provokes sleep arousal earlier than occlusion 
alone [107]. 
Sleep arousal may be caused by not only hypercapnia, but also hypoxia and resistive 
load [108]. Sleep arousal due to all three stimuli may have a common mechanism of 
arousal. In healthy volunteers during NREM sleep, hypercapnia, hypoxia and 
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restrictive load all caused sleep arousal at similar peak-negative oesophageal 
pressure [108]. The authors concluded that, irrespective of the stimulus, increasing 
ventilatory effort (as measured by peak-negative oesophageal pressure) precipitated 
sleep arousal. The importance of a common alteration in respiratory 
mechanoreception as the unifying cause of sleep arousal has been questioned [109]. 
Hypercapnia induced sleep arousal in tetraplegic patients (spinal cord injury above 
C3 level) predicted to lack mechanoreceptor activity. Irrespective of the chemo or 
mechano-receptor mechanism(s) that ultimately causes sleep arousal, it is clear that 
respiratory causes of sleep disturbances occur in intensive care patients with or 
without mechanical ventilation. 
Sleep deprivation reduces inspiratory muscle endurance in healthy volunteers [110]. 
Reduced inspiratory endurance may become clinically important in acutely ill 
patients weaning from mechanical ventilation who routinely have a chronic 
respiratory condition with minimal respiratory reserve [111]. However, ICU patients 
do not suffer sleep deprivation per se, but display sleep fragmentation [36]. It is 
unknown whether the effect of sleep deprivation on respiratory function can be 
extrapolated to patients suffering sleep fragmentation. 
The timing of airway occlusion in the sleep cycle has an affect on the arousal 
response of the patient. Total nasal occlusion during REM sleep caused a quicker 
arousal response than during NREM sleep [112]. This has led some authors to 
speculate that the reduced REM sleep displayed in intensive care patients [36], is an 
adaptive response to reduce susceptibility to breathing abnormalities [23]. 
Drugs used in intensive care 
Drugs frequently used in ICUs and their adverse effects on sleep architecture are 
listed in Table 2-3. 
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Sedative agents 
The combination of a benzodiazepine and an opioid is often used to facilitate 
mechanical ventilation in patients requiring respiratory support. Benzodiazepines 
alter the normal sleep pattern by prolonging stage 2 sleep initially, with an increased 
TST but decreased duration ofSWS and REM sleep [113, 114]. Tolerance to the 
stage 2 sleep effects occurs within days requiring dose escalation to maintain 
sedation. However, occasionally benzodiazepines can also have paradoxical effects 
including delirium manifesting as insomnia, hallucinations and nightmares. 
Propofol probably induces sedation by GABAA activation [115, 116]. It has been 
postulated that the difference between GABA activation of endogenous sleep, and 
propofol induced sedation, is a result of different GABAA beta subunit activity. 
[117]. Propofol has been considered to have similar disruptive effects on normal 
sleep architecture [118]. Short-term (12 hour) sedation with propofol in rats only 
reduced SWS and REM sleep during the first 4 hours compared to baseline [119]. 
Another study found that after 24 hours of sleep deprivation, rats subjected to a 
further 6 hours anaesthesia with propofol did not demonstrate a markedly different 
rebound in sleep characteristics compared to rats allowed to sleep ad libitum [120]. 
This study suggested that during propofol anaesthesia, some sleep homeostasis can 
occur and, therefore, it may be incorrect to classify all GABA-minergic drugs as 
having the same sleep disturbing potential. It is unknown whether this sleep 
restoration occurs in humans under prolonged sedation, and certainly patients report 
no differences between midazolam and propofol exposure with regard to sleep 
quality [121]. 
Opioids have been shown to decrease both REM and SWS phases in the 
postoperative period [122]. The sedation caused by the a2 adrenoceptor agonist 
37 
Melatonin, sleep and circadian rhythms in critical care patients Chapter 2 Background Literature 
clonidine has been reported to be associated with decreased REM sleep [123, 124]. A 
high affinity for U2 receptors suggests that interruption of the normal sleep cycle may 
also occur with the new sedative agent dexmedetomidine. Whilst, there are no 
reports of dexmedetomidine affecting sleep characteristics in ICU patients, a study in 
rats found increased NREM and decreased REM sleep, and discontinuation led to a 
rebound increase in the latter [125]. Despite some theoretical advantages of 
dexmedetomidine as a sedative agent in critical care patients, one study found that 
patients rated dexmedetomidine worse than propofol in terms of sleep satisfaction 
[126]. 
Non-opioid analgesics 
The use of non-steroidal anti-inflammatory drugs is often limited in critical care 
patients, but they may be useful as analgesics in appropriate patients who have 
sufficiently recovered from their acute illness. Non-steroidal anti-inflammatory drugs 
increase awakenings and decrease sleep efficiency, probably due to inhibition of 
prostaglandin synthesis [127], or possibly decreased melatonin secretion [127]. 
Additional sleep disturbance can be caused by direct gastric irritation. 
Cardiovascular Drugs 
Commonly used inotropic agents could affect sleep quality through their effects on 
adrenergic receptors. Normally, noradrenaline, adrenaline and dopamine do not 
appear to cross the blood brain barrier to a significant degree [128]. However, in 
ewes anaesthetised with propofol or isoflurane, dopamine, noradrenaline and 
adrenaline crossed the blood brain barrier sufficiently to increase cerebral blood flow 
[129]. Additionally, dopamine had a cerebrovascular effect in awake sheep and also 
increased cerebral vascular resistance and intracranial pressure in the anaesthetised 
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animals. Anaesthetic doses of propofol appear to increase blood brain barrier 
permeability [130]. However, it is not known whether this occurs in patients 
receiving sedative doses in the ICU. Nevertheless, the administration of adrenaline to 
patients sedated with propofol increased their sedation score and bispectral index 
values [131]. In rats, blood brain barrier permeability is increased by TNFa and IL-6, 
released as part of the sepsis cascade [94]. However, cytokines/ inflammatory 
mediators are not the only factors increasing blood brain permeability. There is 
increased permeability in the elderly and in association with hyperglycaemia and 
hypertension. It is possible that sedated, critically ill patients experience sleep 
disorders induced by sympathomimetic agents used for cardiovascular support which 
penetrate the blood brain barrier. In this patient group dopamine, via D2 agonism, has 
the potential to decrease SWS and REM, whilst adrenaline and noradrenaline may 
decrease REM sleep. 
Acute beta-blocker therapy is infrequently required in some critical care patients in 
response to a myocardial event or rhythm disturbance. This use can be associated 
with insomnia and nightmares (probably due to REM sleep suppression). The 
potential for ~-blockers to cause these sleep disruptions is dependent on their lipid 
solubility [132]. Thus, atenolol and sotalol are less likely to cause sleep disturbances 
than more lipid soluble compounds such as propranolol and labetalol. Lack of 
intrinsic sympathomimetic activity may also reduce the risk of sleep disruption 
[133]. ~-blocker induced sleep disturbances may be partly due to inhibition of 
nocturnal melatonin secretion [134]. In the critical care setting the choice of~­
blocker is limited by the indication, desired duration of action and the route of 
administration. 
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Treatment of atrial fibrillation with amiodarone has been associated with sleep 
disturbances, primarily nightmares [135], probably as a result of covert 
antimuscarinic activity. Insomnia and nightmares can occur in patients with high 
plasma digoxin concentrations [136], possibly reflecting precipitation of delirium 
due to increased plasma antimuscarinic activity. The use of statins in the secondary 
prevention of myocardial infarction or cerebral vascular accident has been reported 
to lead to sleep disturbances and, as with f3-blockers, this may be related to the 
lipophilicity of the individual drug [137]. However, tolerance may develop as 
another study found no difference in the incidence of sleep-related problems in 
patients receiving simvastatin versus placebo after therapy for over a year [138]. 
Gastric protectors and antiemetic agents 
Ranitidine and other H2 receptor antagonists can cause insomnia [139], although 
cimetidine may also increase SWS, [140] as it is the most likely drug in this group to 
cross the blood brain barrier. There have been a few reports of insomnia and 
hallucinations associated with omeprazole [141]. Additionally, dopamine antagonists 
such as domperidone and metoclopramide can cause sleep disturbances [142, 143]. 
Domperidone was associated with a higher incidence of sleep disturbances than 
metoclopramide, even though its central nervous system penetration is relatively low 
[142]. 
Anti-asthma therapy 
Patients ventilated and sedated for status asthmaticus may also be at risk of sleep 
disorders due to the administration of high dose nebulised or intravenous f3-
adrenoceptor agonists. Aggressive corticosteroid therapy is an important adjunct to 
the control of acute exacerbation of asthma, including status asthmaticus. 
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Corticosteroids can cause sleep disturbances by decreasing SWS and REM sleep, 
[144] especially when high dose therapy is used [145]. 
Theophylline increases sleep latency, fragmentation and stage 1 sleep; SE and TST 
are decreased along with REM and SWS phases [146]. Nightmares have also been 
reported with this drug. Janson and co-workers [147] concluded that the sleep 
disrupting effects of theophylline were most pronounced in caffeine sensitive 
individuals. Theophylline and caffeine associated sleep disorders may be due to 
antagonism of central adenosine mediated central nervous system depression. 
However, Janson and colleagues [148] found no sleep advantage with enprofylline 
therapy, which produces little or no adenosine receptor antagonism, in patients who 
experienced sleep disturbances with theophylline. Insomnia is more likely to occur as 
a symptom of mild theophylline toxicity [149]. The use ofketamine in cases of 
intractable status asthmaticus is accompanied by the risk of emergence reactions 
including insomnia and nightmares. Hypnotic coverage with benzodiazepines or 
propofol will reduce this risk. 
Antimicrobial agents 
Multi-organ failure may result in the accumulation of beta-lac tam antibiotics and 
increased concentrations in the central nervous system, causing sleep disturbances 
and agitation. Sleep disturbances often attributed to antimicrobial agents may have 
been due to host defence mechanisms and not the antibiotic [62]. However, 
quinolones, including ciprofloxacin, sparfloxacin, ofloxacin, grepafloxacin and 
levofloxacin have been reported to cause sleep disturbances possibly due to GABAA 
receptor inhibition. In vitro data suggest that benzodiazepines can prevent the 
adverse central nervous system effects of quinolones [150]. If qui no lone induced 
insomnia is suspected and the antibiotic dose has been reviewed, benzodiazepine 
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therapy could be considered. However, if an alternative antimicrobial agent can be 
utilised instead then this is a better option than merely adding another drug with 
delirium inducing potential. Sleep disturbances have rarely been reported with the 
new oxazolidinone antibiotic, linezolid, which weakly and reversibly inhibits type A 
monoamine oxidase [151]. 
Antidepressants 
Because many of the common antidepressants have sedative effects, they may be 
used to treat insomnia. However, they primarily decrease REM sleep with a minimal 
effect on SWS, probably due to serotonergic effects, especially on 5HT1A receptors 
[152]. Amitriptyline and other sedating tricyclic antidepressants decrease sleep 
latency and prolong SWS but also decrease REM sleep. Clomipramine almost 
completely blocks REM sleep [153]. Venlafaxine can cause nightmares due to 
suppression of REM sleep, possibly by indirect stimulation of 5HT2 receptors [154]. 
Selective serotonin reuptake inhibitors increase wakefulness, decrease TST and SE 
and suppress REM sleep [155, 156]. Sleep disruption caused by fluoxetine was 
associated with eye movement during the NREM sleep phase and the occurrence of 
periodic limb movement in almost half the patients studied [157]. The sleep 
disturbing effects of selective serotonin reuptake inhibitors are usually restricted to 
early treatment and resolve over a period of weeks. 
Anticonvulsants 
Epilepsy is associated with sleep disruption, irrespective of seizure activity, and 
anti epileptic drugs may augment this effect. Phenobarbital decreases SL and 
increases SE, primarily by increasing stage 2 sleep at the expense of REM sleep 
[158]. Acute phenytoin and carbamazepine treatment affects sleep architecture, but 
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patients appear to become tolerant with prolonged therapy. Phenytoin therapy 
decreases SL and stage 1 and 2 sleep but increases SWS without affecting REM 
sleep [158]. Carbamazepine also increases both the number of sleep stage shifts and 
sleep fragmentation whilst reducing the percentage of REM [159]. The acute adverse 
effects on sleep induced by carbamazepine do not occur with chronic therapy [159]. 
There are conflicting data regarding the effects of val pro ate on sleep [160, 161]. 
However, it has been shown to reduce nocturnal melatonin blood levels [162]. In 
patients without a history of epilepsy, gabapentin increased the SWS percentage 
from baseline as compared to placebo, without reducing REM sleep [163]. Hence, 
gabapentin may be a better choice for treating neuropathic pain than carbamazepine 
or a tricyclic antidepressant in patients experiencing or at risk of sleep disturbances. 
Miscellaneous Drugs 
Transdermal nicotine has been reported to cause sleep disturbances and nightmares, 
but this is probably due to inadequate replacement leading to nicotine withdrawal 
[164]. ICU Patients with haematological disorders will often receive granulocyte 
colony-stimulating factor (G-CSF) during periods of neutropenia; filgrastim was 
reported to cause insomnia in 14% of patients in one study [165]. 
The immunosuppressants tacrolimus and ciclosporin are associated with 
neurotoxicity that can manifest as insomnia [166, 167]. In patients undergoing 
primary liver transplantation, sleep disorders occurred more frequently with 
tacrolimus (29.2 %) than with ciclosporin (20.2 %) and appeared to be dose 
independent [167]. 
Haloperidol is sometimes used to treat delirium in critical care patients [118]. 
Although it has been reported to cause sleep disturbances in 4% of patients receiving 
antipsychotic therapy, [168] by treating the delirium per se, there may be 
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improvements in patient's sleep-wake cycles. Newer atypical antipsychotics such as 
risperidone appear to increase SWS compared to haloperidol, probably due to 5HT2-
antagonist activity [169]. 
Drug Withdrawal Reactions 
The most common withdrawal reactions occurring in critically ill patients are those 
related to sedative agents used to facilitate mechanical ventilation. A small study by 
Cammarano and colleagues [170] reported that nine out of28 patients mechanically 
ventilated for more than seven days experienced withdrawal reactions including 
insomnia and sleep disturbances. The authors found a relationship between 
withdrawal syndromes and prolonged administration of high dose opioids and 
benzodiazepines. Another small retrospective study of burn patients in ICU observed 
withdrawal symptoms in all eleven of the patients evaluated [171]. The rate of opioid 
and benzodiazepine weaning was associated with duration of withdrawal symptoms. 
It has been recommended that patients at risk of withdrawal reactions should have 
their sedative dosage tapered systematically [118]. An alternative, sometimes used in 
ICUs, is to replace the opioid and benzodiazepine with longer acting agents such as 
methadone and diazepam, the dosage of which is then slowly tapered. However, the 
optimum method for withdrawing sedation remains unclear. Clonidine may be used 
to control the withdrawal symptoms of opioids, although it does not prevent the 
insomnia that occurs [172]. The use of validated sedation scoring systems will 
minimise the risk of excessive doses, [173] and other objective measures systems 
such as bispectral index may be of use in paralysed patients [174]. Kress and co-
workers, [175] also proposed that sedation should be interrupted daily, allowing the 
patient to awake, thereby minimising excessive dosing. Clearly this is an adjunctive 
intervention and good titration of sedation is still required as a background otherwise 
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the potential benefits of daily wake up will not be realised. The same group showed 
that interruption of sedatives daily also tended to reduce PTSD on follow up [176]. 
All of these techniques, ifused appropriately, can minimise the risk of withdrawal 
reactions. The degree of lorazepam exposure is an independent predictor of 
developing delirium in ICU patients [177]. The ultimate aim, therefore, is to balance 
the use of these sedative agents and to minimise the extent of over sedation. 
The short half-life of remifentanil may increase the risk of withdrawal reactions 
when used for longer term sedation in ICU patients compared to longer acting 
agents. It is possible that the higher re-intubation rates found in the remifentanil 
group in a study comparing analgesic based sedation with that produced by 
midazolam, [178] may have been due to intense REM rebound induced by acute 
remifentanil withdrawal. 
There is little evidence that clinically important withdrawal reactions occur with 
propofol in the ICU, although tolerance to propofol has been described [179]. Au and 
colleagues, [180] reported a case of severe grand mal convulsions attributed to 
propofol withdrawal. However, the interpretation of this observation was obscured 
by confounding factors [181, 182]. Valenete and colleagues [183] also described a 
case of propofol tolerance and then withdrawal leading to generalised tonic-clonic 
seizures. Compared to benzodiazepines, the potential for sleep disturbances after 
propofol withdrawal seems reduced, possibly due to subtle differences in GABA-
minergic activity. 
Administration of chronic medication is often discontinued in critical care patients 
during their acute illness. Chronic medication may be omitted intentionally because 
the critical illness makes the patient vulnerable to adverse effects of the medication; 
or unintentionally, when drug histories are unavailable, administration is not possible 
45 
Melatonin, sleep and circadian rhythms in critical care patients Chapter 2 Background Literature 
(e.g. oral drugs), or simply forgotten. However, although continued therapy may not 
always be appropriate, medication histories should be complete, and a daily review 
made to consider recommencing therapy. Withdrawal effects that occur after long 
term treatment with tricyclic antidepressants, selective serotonin reuptake inhibitors 
and monoamine oxidase inhibitors include insomnia, nightmares and excessive 
dreaming related to REM rebound [184]. Drugs with short half-lives are more likely 
to produce acute withdrawal reactions compared to those with longer half-lives or 
active metabolites. For example, paroxetine (t1/2 15 - 22 hours) use is associated with 
a much greater reporting rate of withdrawal reactions per prescription than fluoxetine 
(tl12 4 - 6 days; norfluoxetine tl/2 4 - 16 days) [185]. However, there remains a 
difficulty in establishing whether the patient's delirium symptoms are in fact due to 
withdrawal or toxicity. Detection will depend on identifying high risk drugs, 
anticipating withdrawal problems and recommencing chronic therapy as soon as 
deemed appropriate. For example, drugs known to increase serotonin activity (e.g. 
selective serotonin reuptake inhibitors, tricyclic antidepressants) may be detrimental 
in patients with a SIRS or sepsis when serotonin over activity may contribute to 
delirium. Sometimes it will be necessary to recommence medication and to monitor 
improvement or worsening of symptoms in order to decide whether to continue or 
withdraw the medication. 
Drugs that are known to suppress REM sleep, such as opioids, tricyclic 
antidepressants, monoamine oxidase inhibitors and selective serotonin reuptake 
inhibitors, will cause REM rebound when discontinued abruptly. REM rebound is 
associated with respiratory problems due to reduced accessory muscle function, 
which may adversely affect ventilation. Chronic obstructive pulmonary disease 
patients are particularly prone to hypoxia during REM sleep [186]. Abrupt 
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withdrawal of H2 antagonists, cimetidine and ranitidine can cause neurological 
disorders including irritability, anxiety, headaches and insomnia [187]. 
Withdrawal from recreational drugs may also be a cause of disrupted sleep in the 
critical care unit. Alcohol withdrawal is a common problem encountered in critical 
care patients, requiring benzodiazepine therapy. The cannabis withdrawal syndrome 
is not dissimilar to that of alcohol and opioids and includes insomnia, which may be 
prolonged. Amphetamine withdrawal is characterised by a prolonged period of sleep 
disturbance with rebound REM sleep and nightmares. Rebound REM also occurs 
after abrupt discontinuation of cocaine [188]. Cocaine and amphetamine abusers 
often take other drugs such as opioids, benzodiazepines, alcohol and cannabis. 
Nicotine withdrawal has been reported to cause delirium and insomnia in patients on 
a neurological ICU [189]. 
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Drug Class or Individual Sleep Disorder Induced Possible Mechanism Dru or Re orted 
Benzod iazepines -l- REM, -l- SWS GABAA receptor 
stimulation 
Opioids -l- REM, -l- s WS ~l rece,Etor stimulation 
Clonidine -l-REM 0.2 receptor stimulatiol) 
Non steroidal anti-
-l- TST, -l- SE Prostaglandin synthesis inflammator~ drugs inhibition 
Noradrenaline/ adrenaline Insomnia, -l- REM, -l- SWS 0.1 receptor stimulation 
Dopamine Insomnia, -l- REM, -l- SWS D2 receptor stimulation / 0.1 receEtor stimulation 
Insomnia, -l- REM, Central nervous system p-P-Blockers Nightmares blockade by lipophillic 
agents 
Amiodarone Nightmares Antimuscarinic activity 
Corticosteroids Insomnia, -l- REM, -l- SWS Reduced melatonin 
secretion 
Aminophylline Insomnia,,!, REM, -l- SWS, Adenosine receptor 
-l- TST, -l- SE antagonism 
Quinolones Insomnia GABAA receptor inhibition 
Antimuscarinic activity 
Tricyclic antidepressants -l- REM and 0.1 receptor 
stimulation 
Selective Serotonin 
-l- REM, -l- TST, -l- SE Increased serotonergic Reuptake Inhibitors activity 
Phenytoin t Sleep Fragmentation Inhibition of neuronal 
calcium influx 
Phenobarbital -l-REM Increased GAB A activity 
Adenosine receptor 
Carbamazepine -l-REM stimulation and/ or 
serotonergic activity 
Table 2-3 Drugs commonly used in leu and their effects on sleep 
architecture 
REM: rapid eye movement, SWS: slow wave sleep, TST: total sleep time, SE: sleep efficiency, 
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Treatment of Sleep Disorders in Critically III Patients 
Treatment with drugs in isolation will not resolve or prevent the majority of sleep 
disorders experienced by critical care patients. Sometimes it is not possible or 
appropriate to make changes in drug treatment to minimise sleep related disturbances 
e.g. sympathomimetic agents in septic shock. Both non-pharmacological and 
pharmacological approaches are required. Consideration of the environment, 
ventilator synchrony and patient specific factors is also required. 
Sleep versus Sedation 
The terms sleep and sedation are often used interchangeably in critical care. For 
example, the original description of the Ramsay Sedation Scale refers to 'asleep 
levels'. Pharmacological interventions are commonly referred to as 'night sedation' , 
however, the ultimate aim is to improve the quality and quantity of sleep. It is 
important to acknowledge that sedation and sleep are two distinct states, although 
they share some important features [190]. 
Sleep deprivation potentiates the sedative effects of anaesthetic agents, [191] which 
emphasises the common neurotransmitter pathways involved in both sleep and 
sedation. Also, sleep and sedation share the same behavioural endpoints of hypnosis 
and amnesia. However, unlike sleep, sedation is not entirely reversible upon 
stimulation and lacks a temporal cycle. Furthermore, sedation does not produce the 
same biological functions as sleep. 
Non-pharmacological treatment 
Environmental controls on noise can be successfully implemented [90], and the use 
of ear plugs can reduce REM latency, increase REM and SE [89]. Non-invasive 
positive pressure ventilation in chronic obstructive pulmonary disease patients, [98] 
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and continuous positive airway pressure [99] or non-invasive positive pressure 
ventilation [100] in Cheyne-Stokes respiration patients can improve sleep quality 
acutely. In the ICU attempts to optimise patient-ventilator synchrony during pressure 
support ventilation will reduce arousals and awakenings, hence supporting sleep 
continuity [105, 106]. 
Cognitive behavioural therapy has been shown to be superior to pharmacological 
therapy in the treatment of chronic insomnia [192]. However, its value has not been 
investigated extensively in critical care. One study found that therapeutic massage 
increased sleep duration by approximately one hour compared to placebo [193]. The 
same study found no significant improvement in sleep in patients exposed to relaxing 
music or relaxation exercises [193]. 
Pharmacological treatment 
The pharmacological treatment of sleep disorders in critical care patients should be 
prefaced by a review of all current medication with the aim to discontinue any 
unnecessary drugs. The possibility of withdrawal reactions to social or prescribed 
medication should be considered prior to commencing hypnotic therapy. Allowance 
for renal and hepatic dysfunction when prescribing drugs will minimise side effects, 
including sleep disorders, whilst maintaining effective treatment. Drugs started in 
critical care should be discontinued as soon as appropriate, e.g. H2 antagonists for 
stress ulceration prophylaxis in patients no longer at high risk. Corticosteroid-related 
sleep disturbances may be minimised by using appropriate doses and duration of 
therapy. When possible, corticosteroids should be dosed in the morning, to minimise 
nocturnal cortisol exposure and adrenal suppression [194]. Theophylline related 
insomnia can be minimised by maintaining its plasma concentrations within the 
therapeutic range. Whilst the evidence that theophylline or aminophylline are 
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effective in acute asthma attacks is limited, these drugs may still have a role in 
intractable cases [195]. 
Drug therapy aimed at inducing sleep over a normal night time period has the 
potential to increase the TST but may not improve the quality of sleep. Critically ill 
patients do not suffer from lack of sleep, but have reduced restful sleep. Any drug 
prescription for acute sleep disturbances in the critical care unit should be for only a 
short course of therapy, as long-term prescription is not warranted without re-
evaluation. Hypnotic therapy should be reviewed daily for efficacy and adverse 
effects, particularly cognitive defects in patients prone to delirium. This is 
emphasised by a meta-analysis of sedative use in elderly patients which found that 
the benefits were limited compared to the risk of adverse events [196]. A proposed 
approach to the drug treatment of sleep disorders in critically ill patients is shown in 
Figure 2-5. 
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Review Current Medication 
Consider Withdrawal Reactions 
Targeted 
Pharmacological Therapy 
Pain 
Anxiety 
Delirium 
I 
Review 1-------. Efficacy 
Adverse effects 
Short term use - review prior 
to hospital discharge 
Figure 2-5 Proposed approach to the drug treatment of sleep 
disorders in critically ill patients 
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Benzodiazepines 
Temazepam is often the first line hypnotic agent used in patients recovering from 
critical illness. However, critically ill patients who have been sedated with a 
benzodiazepine or propofol may show tolerance to the hypnotic effects of normal 
doses ofbenzodiazepines such as temazepam. Even if patients have not been sedated, 
tolerance to benzodiazepines appears within days of therapy requiring dose 
escalation. This in tum, often results in escalating doses of benzodiazepines being 
used, which in tum increases the risks of delirium and! or withdrawal reactions when 
attempts are made to discontinue them. Drug treatment begun in critical care and 
continued after transfer to a general ward bears a risk of being continued long term. 
Patients who are not absorbing their feed or have no naso-gastric or jejunal access, 
may receive an intravenous short acting benzodiazepine such as midazolam. 
However, critical care patients often have low serum albumin levels, and hence have 
large volumes of distributions for highly protein bound drugs such as midazolam. 
Therefore, larger intravenous doses of midazolam are required to produce equivalent 
plasma concentrations to a non-critical care patient. Furthermore, any hepatic and/ or 
renal dysfunction predisposes these patients to a greater risk of prolonged sleep 
inertia (reduced arousal and performance after awakening from sleep) the next 
mornmg. 
The sedative effect of benzodiazepines is primarily due to increased stage 2 sleep 
with reduced SWS and REM [113, 114]. The reduced REM activity may be 
advantageous in some patients such as those with Cheyne-Stokes respiration, in 
whom arousal is reduced [197] and COPD patients [186]. However, again these 
patients' sleep and Cheyne-Stokes respiration might worsen upon benzodiazepine 
withdrawal. Temazepam and other short acting benzodiazepines have less potential 
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for producing sleep inertia than longer acting agents such as diazepam or nitrazepam, 
However, even temazepam can produce hangover effects, especially in patients with 
renal failure. 
Temazepam was made a controlled drug (Schedule 3; CD no reg) in the UK in 1998. 
This means that it must be stored in a controlled drugs cupboard; thereby prolonging 
the nursing time required for preparing it for administration. This increased nurse 
workload, albeit minimal, has promoted the use of alternative benzodiazepine and 
non-benzodiazepine hypnotics in some critical care units. 
Non-benzodiazepine GABAA agonists 
Newer non-benzodiazepine hypnotic agents such as zolpidem (imidazopyridine) and 
zopiclone (cyclopyrollone) do not suppress SWS compared to benzodiazepines. 
Zolpidem appears to have less adverse effects on REM sleep than benzodiazepines at 
normal doses; REM sleep is not reduced although REM latency is increased [198]. 
However, patients do not perceive increased sleep quality with these agents 
compared to benzodiazepines, [199] and these drugs are not without their own risks 
of dependence and toxicity (e.g. psychiatric reactions with zopiclone) [200]. 
Zopiclone has also been reported to cause nightmares and sleep disturbances [201, 
202]. It is unknown whether these non-benzodiazepine agents will increase SWS in 
critical care patients and whether this translates into improvement in memory or a 
reduced incidence of PTSD. 
In the National Health Service, the National Institute for Clinical Effectiveness 
(NICE) has published 'Guidance on the use of zaleplon, zolpidem and zopiclone for 
the short-term management of insomnia' [203]. They concluded that there was no 
advantage in using these drugs as alternatives to conventional (shorter acting) 
benzodiazepines, and that the cheapest drug should be used. 
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Propofol 
It has been suggested that propofol should be used to induce nocturnal sleep in 
critically ill patients being weaned from mechanical ventilation [204]. Propofol 
affects sleep by increasing NREM and TST and reduces SL [115. 116]. In short-term 
sleep models in rats, REM sleep did not seem to be adversely affected by propofol 
[115, 116]. Unfortunately, NREM sleep stages were not differentiated and, therefore, 
the effect of propofol in these studies on SWS is unknown. The effect of propofol 
anaesthesia on sleep homeostasis has also been studied in rats [120]. Animals 
deprived of sleep for 24 hours then subjected to 6 hours of propofol anaesthesia did 
not demonstrate significant rebound of SWS and REM when compared to rats 
allowed to sleep ad libitum. This suggests that with short term propofol anaesthesia 
some sleep debt is recovered. Propofol was reported to be effective in producing 
"diurnal" sedation in nine of 15 critically ill patients [205]. However, no attempt was 
made to distinguish sleep from sedation [205]. Propofol did not appear to offer any 
advantage over midazolam with regard to subjective sleep quality in non-intubated 
leu patients [121]. 
Antidepressants 
Tricyclics 
Amitriptyline is the most commonly used sedating antidepressant used to aid sleep in 
intensive care patients. The antidepressant effect of amitriptyline is primarily due to 
inhibition of noradrenaline and serotonin reuptake. Whilst individual tricyclic 
antidepressants differ in the degrees of noradrenaline, serotonin and antimuscarinic 
inhibition, they all reduce REM sleep. Amitriptyline reduces SL and fragmentation 
and increases TST [206]. Amitriptyline significantly reduces REM activity, the 
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number of REM periods and the percentage REM sleep, even though on prolonged 
use there is partial tolerance to some aspects of REM sleep, REM rebound occurs on 
discontinuation [206]. 
Critical care patients recovering from acute illness often have cardiovascular 
instability which cautions against the use of drugs with marked antimuscarinic 
activity. In such cases doxepin is a more appropriate alternative to amitriptyline 
owing to its lower antimuscarinic activity. The total antimuscarinic burden may also 
predict the risk of delirium development in elderly patients and must be taken into 
account when choosing a hypnotic agent in critical care patients. 
Miscellaneous antidepressants 
There may be a strong temptation to commence antidepressant therapy in patients 
who appear depressed during a prolonged critical care stay. However, since it takes a 
few weeks for the full antidepressant effect to occur, there is a real risk of 
unwarranted prolonged therapy after discharge from the acute care unit. The fact that 
patients with hypoactive delirium are often misdiagnosed as depressed accentuates 
the inappropriateness of antidepressant therapy when anti psychotics are indicated. 
Selective serotonin reuptake inhibitors (SSRIs) are often prescribed as they are 
considered as effective as the older tricyclic antidepressants in the treatment of 
depression and have a better safety profile in overdose. However, they have no sleep 
promoting effects and are known to cause sleep disorders. They should be avoided 
unless alternatives are contraindicated. 
Similar to cyproheptadine, nefazodone has 5HT2 antagonist activity, which may be 
important in the treatment of nightmares [207]. Hicks et ai, [156] compared 
nefazodone and paroxetine in the treatment of depression and concluded that 
nefazodone was associated with increased SE, TST and a subjective feeling of sleep 
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improvement after only three days of treatment. Unfortunately, nefazodone has now 
been withdrawn in Europe because of an association with severe liver failure. 
Two other antidepressants share 5HT 2 antagonist activity - trazodone and 
mirtazapine with the added advantage of low antimuscarinic effects. Trazodone has 
been shown to have a minimal effect on REM sleep compared to amitriptyline [208]. 
Mirtazapine is beneficial in the treatment of sleep disturbances in patients with 
depression [209]. However there is no objective evidence of benefit in critical care 
patients. 
Trazodone has been shown to aid sleep in patients experiencing sleep disturbances 
due to stimulant antidepressants (SSRIs) [210]. This activity is particularly relevant 
for critical care patients as the sleep disturbances (and delirium) they experience may 
be partly due to excess serotonin activity. Although case reports suggest that 
trazodone may be of benefit in the treatment of delirium [211], no randomised 
placebo controlled trials have been done. While a review recommended that 
trazodone should not be used as a hypnotic agent in patients without a mood disorder 
[212], the high incidence (up to 80%) of delirium in critical care patients does not 
preclude its use. 
Chloral hydrate 
Chloral hydrate decreases SL and nocturnal awakenings with minimal effect on REM 
sleep. However, it is less effective than benzodiazepines as a hypnotic, [213] and its 
use in high doses is associated with a high incidence of daytime hangover effects. 
Alcohol 
Patients with a prior history of social alcohol intake may benefit from a "nightcap". 
Roehrs et ai, [214] reported that acute ethanol administration in insomniacs increased 
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SWS, but reduced REM sleep. The dose of ethanol is critical as higher doses may 
cause sleep disruption. Ethanol will not be an appropriate choice in those patients 
with significant liver disease or previous excessive alcohol intake. 
Antipsychotics 
Schizophrenic patients have reduced SWS and REM latency compared to non-
schizophrenics and may, therefore, respond differently to medications that affect 
sleep stages. Chlorpromazine increases TST and decreases patient arousal in 
psychiatric patients, although tolerance to this soporific effect develops within days 
[215]. Generally, chlorpromazine increases SWS while low doses increase, and high 
doses decrease REM sleep [216, 217]. However, the profound antimuscarinic activity 
of chlorpromazine and other phenothiazines makes their use in critically ill patients 
undesirable. Also, as a significant proportion of critically ill patients are elderly, the 
use of antimuscarinic drugs would increases both the incidence and severity of 
delirium [218-221]. 
High doses of haloperidol have sedative effects, although information on its effect on 
sleep architecture is inconsistent. Newer atypical antipsychotic agents, such as 
risperidone, antagonise 5HT 2 and D2 receptors at low doses and increase deep sleep 
in rats [222]. A small study of schizophrenic patients found that, compared to 
haloperidol, risperidone improved SWS [169]. 
Antipsychotics are currently the drugs of choice in the treatment of delirium. Sleep 
disturbances that occur in delirious patients resolve as the delirium resolves. In 
critical care patients with sleep disturbances, their delirium status needs to be taken 
into account when selecting pharmacological therapy. In delirium positive patients an 
antipsychotic dosed regularly, with or without weighted nocturnal dosing, would 
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seem appropriate as sedative hypnotic drugs may worsen the sleep disturbances in 
these patients (Figure 2-5). 
Alpha-2 agonists 
The U2 agonists clonidine and dexmedetomidine are sometimes used for their anal go-
sedative effects in critically ill patients. In the USA, dexmedetomidine is licensed for 
short term sedation of intensive care unit patients to facilitate mechanical ventilation. 
Dexmedetomidine is reported to block noradrenaline activity within the locus 
coeruleus and, activate GAB A activity within the VLPO [223]. This mechanism of 
action more closely mimics the normal sleep-promoting pathways and represents a 
novel action of these drugs. However, there is no supporting evidence to date that U2 
agonists produce a more restorative sleep than other sedative agents. Indeed, a study 
designed to evaluate patient perceptions of sleep quality after overnight sedation with 
dexmedetomidine or propofol concluded that those receiving dexmedetomidine 
found it more difficult to sleep [126]. Nevertheless, another advantage of U2 agonists 
may be that they reduce the need for other opioids or sedatives thereby reducing the 
adverse effects of these drugs on sleep and delirium. More evidence supporting the 
role of these agents is required to substantiate their routine application in critical care 
patients. 
Antihistamines 
Promethazine is regarded as an "antihistamine" in adult patients. However, it is a 
phenothiazine and, as such, has a similar effect to chlorpromazine on sleep 
characteristics. Diphenhydramine and promethazine have both been shown to reduce 
REM sleep, possibly due to their antimuscarinic activity [224,225]. Tolerance to the 
sedative effects of diphenhydramine develops after the first dose [226]. 
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Diphenhydramine has also been reported to make volunteers sad and antagonistic 
(probably delirious) [226]. The significant antimuscarinic effect of these drugs does 
not support their routine use as hypnotics in patients recovering from critical illness. 
Melatonin 
Recently, some intensive care units have begun to use melatonin to aid sleep in their 
patients [227]. The rationale, efficacy and potential advantages of melatonin in the 
treatment of sleep disorders in critically ill patients will be discussed in detail in the 
following section. 
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Melatonin 
Circadian rhythm 
The circadian pacemaker within the SCN triggers the pineal gland to produce 
melatonin at night. It is set by the phase-shifting actions of light such that 
physiological plasma melatonin levels during the day are very low but begin to rise 
from around 2200 h, with a peak at approximately 0200 h returning to daytime 
values by 0900 h. Endogenous production of melatonin is approximately 30 
micrograms per day, [228] associated with peak plasma levels of approximately 100 
pg/ml [229]. The ampl itude of plasma melatonin levels is lower in elderly subjects 
and there is phase delay (i.e . delayed peaking) [230]. 
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Figure 2-6 Effect of age on plasma melatonin versus time 
19-25 years of age: - ; 66-75 years of age: ----
Representation adapted from [230] 
The enterochromaffin cells within the gastrointestinal tract also synthesise melatonin. 
Melatonin secretion from the gastrointestinal tract probably accounts for the normal 
low daytime plasma concentrations and is not under the circadian control of the SCN 
(see Bubenik [231] for review). 
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Pharmacology 
Darkness stimulates retinal photoreceptor release of noradrenaline, which activates 
al and PI-adrenergic receptors in the pineal gland, increasing cyclic AMP, which 
then stimulates enzyme-catalysed synthesis of melatonin. The pineal gland converts 
tryptophan to melatonin via 5-hydroxytryptophan with serotonin, and N-
acetyl serotonin as intermediates. Serotonin is converted by N-acetyltransferase 
(NA T) to N-acetylserotonin which is then converted to melatonin by hydroxyindole-
O-methyltransferase. NAT is the rate-limiting step in the pineal synthesis of 
melatonin (Figure 2-7). The precise mechanism of the sleep-promoting effects of 
melatonin is unknown. Possibilities include induced hypothermia, GABA receptor 
stimulation and a direct action on the seN causing phase shifting of the circadian 
pacemaker and/ or inhibition of an seN alerting mechanism [10]. To date three 
melatonin receptor subtypes have been identified (MTI_3); located in both central and 
peripheral sites, the latter including the lung [232]. 
MTI receptors are responsible for modulation of circadian rhythms via activity in the 
seN [233]. Melatonin appears to also entrain circadian rhythms by stimulation of 
MT2 receptors within the seN [234]. Melatonin agonism at MTI and MT2 receptors 
within cardiac blood vessels results in vasoconstriction and vasodilatation, 
respectively [233]. Stimulation ofMT3 receptors appears to have effects on the 
regulation of intra-ocular pressure and can modifying inflammatory effects on the 
microvasculature [233]. The relationship between plasma melatonin level and 
receptor activity is complicated by the variation in receptor expression and function 
regulated by the light-dark cycle; the SeN; melatonin itself and possibly other 
hormones [233]. Developments in our understanding of the pharmacology of 
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melatonin have facilitated attempts to develop MT receptor agonists for therapeutic 
use. 
In recent years synthetic melatonin agonists have been developed for clinical 
applications. Ramelteon and agomelatine are agonists at both MT I and MT 2 
receptors [235,236]. 
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Figure 2-7 Synthesis of melatonin in the pineal gland 
Acety l-CoA: Acetyl Coenzyme A; CoA : Coenzyme A; SAM : S-adenosylmethionine; SAH : S-
adenosylhomocyste ine 
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Influence of light on melatonin secretion 
The sleep-wake cycle is a circadian rhythm, i.e. it is a biological rhythm with a 
duration of approximately one day. Synchronisation of the sleep-wake cycle to a 
period of approximately 24 hours is due to the combined entraining effects of the 
internal (melatonin) and external (light) zeitgebers. The synthesis and release of 
melatonin are inhibited by light and stimulated by darkness (Figure 2-8). In the 
prolonged absence of the entraining effects of I ight, the secretion of melatonin 
becomes "free-running", i. e. out of phase with the light-dark cycle. 
Figure 2-8 Regulation of melatonin secretion by light 
PVN: Paraventricular nucleus; RHT; Retinohypothalmic tract ; seN: Suprachiasmatic nucleus 
Light stimulates photoreceptors within the retina to transmit a response via the 
retinohypothalmic tract (RHT) to the hypothalamic SeN, the human circadian 
pacemaker. Neural signals then pass through the hypothalamic paraventricular 
nucleus (PVN), down the upper thoracic spinal cord and into the superior cervical 
ganglion before reaching the pineal gland [237]. 
Photoreception occurs only in the eyes, as bilateral enucleation results in the loss of 
the acute suppression of melatonin synthesis caused by light [238]. The effect of 
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light on the inhibition of melatonin is dependent on a number of factors including, 
irradiance, wavelength, duration of exposure, time of day and patient age. 
The fact that blind subjects have a sleep wake cycle entrained by the light-dark cycle, 
[238] encouraged research to identify the specific photoreceptor(s) involved in the 
signalling of the SCN. This resulted in the study oflight of various wavelengths on 
the secretion of melatonin in animals and then humans. A number of studies showed 
that light of short wavelength (420 - 520 nm) is potent in suppressing melatonin 
secretion [239-246]. An opsin-based photopigment has been identified as the SCN 
trigger for light induced melatonin suppression [243]. This is a non-rod, non-cone 
photoreceptor present in the human retina. Red fluorescent lamps emit light of 
approximately A 600 nm and have been shown to have minimal effect on both the 
timing and extent of melatonin secretion [240]. 
Light intensity has also been found to be important in the suppression of melatonin 
secretion. Whilst illuminance is routinely measured by photometry in lux, this is 
specific for the photopic system; ideally irradiance should be used to quantify the 
effect of light in studies of melatonin secretion. Nevertheless, some studies have 
demonstrated that illuminance >80 lux reduces and delays melatonin secretion [247]. 
Doses of light greater than 200 lux are sufficient to produce maximal suppression of 
melatonin secretion, whilst delays require greater than 550 lux [247]. As light 
irradiance increases, (irrespective of A) melatonin secretion decreases [241-243]. All 
short wavelength light intensities ~ 5.5J.lW/ cm2 significantly suppress melatonin 
[242]. 
There is a diurnal sensitivity in the response to light on melatonin secretion. This 
may result from either a change in retinal photoreceptor sensitivity and! or alteration 
in the neural handling of the response. Higher light intensity is required in the 
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morning compared to the evening to suppress melatonin secretion [239]. The elderly 
have a thinner corneal lens than younger adults, which may increase their sensitivity 
to the effects of light on melatonin secretion [243]. This may explain why lower 
levels of endogenous melatonin occur in the elderly [248]. 
The acute effects of appropriate light therapy on the circadian rhythm are dependent 
on time of exposure according to a phase response curve (Figure 2-9). Intense light 
administered during the night will have a phase delaying activity, whilst exposure 
during the early morning will phase advance. Acute pulses of nocturnal light of 
appropriate wavelength and intensity will reduce melatonin secretion. It is believed 
that light exposure for more than 30 minutes is required for this acute affect [249]. 
Polarised light does not alter the photo effect on melatonin secretion [250]. 
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The ICU provides an interesting environment for considering the effect of light on 
melatonin secretion. Firstly, a significant percentage of the patients are elderly and, 
hence, particularly light sensitive. Secondly, the control of lighting is outside the 
control of the patient. Acute periods of high light intensity have resulted when 
specific guidelines to reduce overall light intensity in the ICU have been 
implemented [90]. Therefore, further methods to minimise light interruptions are 
required. The duration of normal illuminance is dictated in the morning by the arrival 
of the next nursing shift and at night by the night shift completing their patient care 
and observations. This may result in a delayed and shortened melatonin secretion 
with periods of interruption throughout the night. In the organisation of critical care 
services, lighting should be considered in respect to patient care. The current United 
Kingdom - "Standards for Intensive Care Units" makes no recommendations 
regarding the wavelength of light used on the ICU [76]. Red lighting causes minimal 
disruption to the melatonin circadian rhythm, [240] and its use may be sufficient for 
the majority of direct nursing care activities at night. Furthermore, high intensity 
white light in the morning will assist in the entrainment of the sleep-wake cycle. 
However, it is necessary to regard both the hormonal needs of the patients and those 
of the staff caring for them. The needs of medical and nursing staff should also be 
considered with regard to lighting arrangements. The rhythm and intensity of light 
exposure during shift work affects the sleep-wake cycle of staff [251]. Sleep 
disturbances in shift work staff can affect performance and have potential detrimental 
effects on patients care [252] In the future, lighting should be considered more 
carefully in the design ofICUs. 
It may seem an easier option to apply eye masks to the patients, thereby minimising 
the effect of light during the night. However, as described in Chapter 6, ICU patients 
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are often unwilling to wear such masks, possibly as a result of their anxiety regarding 
their condition and environment. Staff in adult ICUs are becoming increasingly 
aware of the importance of the light-dark cycle and human circadian rhythms [56]. In 
contrast, those in neonatal units have long accepted that a regulated light-dark cycle 
is of benefit to their patients [253]. 
The pharmacokinetics of exogenous melatonin 
Orally administered melatonin is subject to extensive first-pass metabolism involving 
conversion to inactive 6-sulfatoxymelatonin (6-SMT) [254]. A wide variability in the 
oral bioavailability of melatonin is due to the variable expression and activity of 
hepatic cytochrome P450 lA2 (CYPIA2), which is exclusively responsible for the 
metabolism of melatonin [255]. Absolute oral bioavailability is reported to be 
approximately 15% [254, 256]. Plasma melatonin concentrations have been reported 
to be dependent on a number of factors including; dose, time of administration and 
type of oral preparation used [257]. However, concomitant interacting drug 
administration and liver function are obviously also important determinants. 
The conjugated metabolites of melatonin are renally excreted and, in healthy 
subjects, changes in urine 6-SMT levels provide an indication of changes in plasma 
melatonin levels [258]. The elimination of melatonin from the blood is bi-
exponential, with a clearance of approximately 950 mIl min [259]. Melatonin has a 
steady state volume of distribution (Vss) of approximately 35 L [259] and an 
elimination half-life (tll2) of 30 - 45 minutes [259-262]. In patients with cirrhosis, the 
metabolism of melatonin is impaired, and its average t 112 is extended to 
approximately 100 minutes [260]. 
Exogenous oral doses greater than 0.3 mg produce supraphysiological plasma levels 
in humans [263]. 
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Melatonin therapy for sleep disorders 
It is too simplistic (and probably incorrect) to regard exogenous melatonin as simply 
a soporific or hypnotic agent. Melatonin administered at the appropriate time in a 
patient's sleep-wake cycle will have sleep inducing effects. Similar to light, it has a 
phase response curve, although the phase delaying response is relatively weak 
compared to the phase advancing effect. Melatonin administered to healthy 
individuals during the nocturnal period when endogenous melatonin plasma levels 
are raised had no effect on sleep parameters; while administration during the day 
(low endogenous levels) had a soporific effect comparable to temazepam [264]. 
In fact, melatonin has been described as a "chronohypnotic" or "chronobiotic" agent 
i.e. it primarily acts to entrain circadian rhythms and, for this reason, it may have a 
beneficial effect on circadian rhythm sleep disorders [265, 266]. 
70 
Melatonin, sleep and circadian rhythms in critical care patients Chapter 2 Background Literature 
Advance 
• 
•• 
• 
•••• 
o 
Delay 
18:00 
•• 
•• 
Night 
00:00 
•• 
.. .-
........ 
06:00 
Figure 2-10 Melatonin phase response curve 
Day 
.. -.. 
.•. +. 
• • • 
• • 
• 
• 
• • 
.. 
• • 
• 
• • 
12:00 18:00 
Melatonin phase response curve: ----; Light phase response curve: -; Solid bar represent dark night-
time period 
Administration of melatonin or light will Advance or Delay the circadian rhythm 
depending on time of exposure according to the phase response curves. For example, 
appropriate melatonin administration at 1600 h will have a phase advancing effect; 
whereas administration at 0900 h will phase delay. 
Note: Representation only; times will vary according to an individual's own circadian rhythm 
Jet lag 
Jet lag is the term used to describe the malaise experienced by a person who has 
travelled across several time zones. It is not due to a lack of circadian rhythm in the 
internal body clock, but reflects the resistance of the body clock to change in the new 
time zone. The symptoms of jet lag include fatigue, inability to sleep, loss of 
appetite, indigestion, feeling bloated, reduced concentration, reduced motivation, 
increased irritability and headache. The duration and severity of jet lag vary between 
individuals and with the direction of travel and number of time zones crossed. 
Travelling east is associated with worse symptoms than crossing the same number of 
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time zones westwards. Potential treatment of jet lag includes adjustment of meal 
times, physical activity, bright light and exogenous melatonin. Melatonin has been 
shown to reduce fatigue and improve sleep [267, 268]. Whilst, not all trials have 
found melatonin to be of benefit in jet lag, [269] a recent Cochrane Review 
confirmed its value [270]. The timing of melatonin administration is important in 
order to effect entrainment optimally. A dose of 5 mg appears to be most effective 
[270]. 
The melatonin agonist L Y156735 appears to be of some benefit in relieving the 
symptoms of jet lag, [271] although it may not be as effective as melatonin [270]. 
Night Shift 
Night shift work is associated with a malaise that is similar to the symptoms of jet 
lag. The symptoms are again due to the individual's rest-activity being out of 
synchrony with their own internal biological clock. However, the continued presence 
of fixed time cues such as daytime light exposure, confuse the messages to the 
biological clock and therefore make transition to the new rest-activity pattern more 
difficult. Critical care patients are at risk not only due to the morbidity associated 
with the sleep disturbances they experience, but also because of sleep disturbance in 
the attending staff which may increase the likelihood of medical error [252]. It seems 
reasonable to suggest that changes to the working practices of junior doctors may 
have benefits for their patients in this regard. 
Night workers often take a variety of stimulant drugs, such as caffeine or nicotine, to 
promote alertness and then use hypnotics during the day to promote sleep. The 
evidence for the efficacy of melatonin in the treatment of shift worker's malaise is 
limited. Volunteers subjected to a stimulated period of night shift work found that 
melatonin improved day time sleep without any beneficial effect on nocturnal 
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alertness [272]. Similarly, in a study of nurses working night shifts, morning 
administration of melatonin also increased total sleep time, but again did not have a 
significant effect on night-time alertness [273]. An earlier study reported no benefit 
of morning melatonin administration in doctors working night shifts [274]. A recent 
systematic review concluded that there was no evidence that melatonin therapy was 
effective in treating sleep disturbances related to shift work [275]. 
It is not surprising that administration of a single internal zeitgeber, such as 
melatonin, has limited efficacy in counteracting the continuous effects of light and 
other time cues on the biological clock during acute rest-activity rhythm changes. 
such as working night shifts. 
Insomnia 
Evidence for the efficacy of exogenous melatonin in inducing and improving sleep 
quality is conflicting [276, 277]. It is, therefore, important to identify differences in 
the design of reported studies in order to identify patient groups in which, and 
conditions under which the use of exogenous melatonin is most likely to be of 
benefit. Studies reporting a positive effect used a wide range of melatonin doses from 
0.3 mg (physiological) to 75 mg [277]. Studies demonstrating no positive sleep effect 
used doses of 0.5 to 5 mg. Thus, the dose of melatonin required to induce sleep has 
not been defined [10]. However, there is a very obvious plateau effect that occurs at a 
dose of around 5 mg, above which there appears to be no advantage in increasing the 
dose further. Since the potential beneficial effect of exogenous melatonin on sleep 
disturbances is through a chronotherapeutic effect, [265, 266] it is desirable to use a 
dose sufficient to produce the phase advancing effect, but avoiding overdose. 
Excessive doses will risk supraphysiological plasma melatonin concentrations in the 
morning and therefore the potential for a phase delaying effect. 
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Rogers et ai, [277] identified no differences between the results of sleep studies that 
used immediate release and sustained release melatonin products. In theory, a dosing 
regime that ensures raised melatonin levels throughout the night would be more 
effective than a regime that did not. 
Another explanation of the different reported findings is variation in the timing of 
administration of melatonin. Stone and colleagues [264] administered melatonin to 
healthy volunteers at two different times to investigate the effect of melatonin 
administration time on sleep efficiency. When administered at 2330 h there was no 
significant effect on any sleep characteristics, while administration at 1800 h 
increased TST and SE. Melatonin therapy is more likely to be effective in improving 
sleep in those patients with poorer quality sleep associated with a disrupted circadian 
rhythm of melatonin secretion. Healthy volunteers exposed to experimental insomnia 
showed significantly reduced sleep latency, increased TST and SE when given 
melatonin compared to placebo [278]. 
Exogenous melatonin therapy for insomnia does appear to be more effective in 
elderly subjects [248,279-281]. Nocturnal plasma levels of melatonin are lower and 
daytime levels are higher than in young subjects, indicating a disrupted circadian 
rhythm [282]. 
Melatonin should be administered such that raised plasma concentrations coincide 
with the normal melatonin increase in secretion at night (Le. at approximately 2100 
h). The hypnotic effects of exogenous melatonin therapy may not be manifest for 2-3 
nights after start of dosing [279]. It is possible that this is due to a phase advancing 
effect as opposed to a direct hypnotic effect of melatonin. 
One of the potential disadvantages of hypnotic agents for the treatment of insomnia 
is a hangover effect the next day. In elderly patients given long acting agents this has 
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been associated with an increase in falls and hospital admission. A systematic review 
of adverse effects related to hypnotic use in the elderly reported a number needed to 
harm (NNH) of only 6 patients [196]. It is also desirable in hospitalised patients to 
avoid hangover effects that reduce compliance with tasks such as physiotherapy that 
are required to speed their recovery and discharge. High dose melatonin (75 mg at 
night) over 14 days did not produce any subjective adverse effects on daytime 
alertness in 13 chronic insomniacs [279]. The effects of daytime administration of 
melatonin and temazepam on neurobehavioural tasks were compared in healthy 
volunteers [283]. Both drugs induced sleepiness, but melatonin produced a 
significantly reduced deficit in task performance. The effect of melatonin on post 
sleep psychomotor performance was compared to that of zaleplon, temazepam and 
zopiclone in military personnel [284]. All four agents induced sleep, but melatonin 
had the least impact on task performance [284]. 
It would appear from these studies that melatonin is advantageous in terms of 
reduced hangover effects compared to more conventional hypnotics. Additionally, 
unlike the majority of hypnotics, melatonin appears to cause minimal disruption to 
the normal sleep architecture [285]. 
Other circadian rhythm disorders 
Blind persons often suffer from circadian rhythm disorders, due to the loss of 
entrainment by the light zeitgeber. Melatonin was administered, in a double blind 
placebo controlled trial to 5 totally blind individuals with free running (cycle> 24 
hours duration) circadian rhythms [286]. Melatonin (5 mg), administered at 2200 h, 
phase advanced the circadian rhythm of melatonin in all subjects and that of cortisol 
in 3 cases. In another small placebo controlled trial in blind patients with a free 
running circadian rhythm, [287] melatonin (10 mg) administered one hour before 
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normal bedtime for 3 to 9 weeks resulted in entrainment of circadian rhythm to a 24-
hour cycle in 6 of 7 subjects. This effect persisted on continued dosing of 0.5 mg 
over a 3-month period [287]. 
Melatonin may be particularly effective in resetting of circadian rhythms in blind 
individuals due to the absence of light as a more powerful zeitgeber. 
Treatment of DSPS with melatonin was investigated in a small (n=8), placebo 
controlled trial [288]. Patients were administered 5 mg melatonin at 2200 h, 
approximately 5 hours in advance of their normal sleep onset time. Compared to 
placebo, melatonin significantly advanced sleep and wake times. 
Older patients requiring long term institutionalised care for chronic cognitive 
impairment frequently experience sleep disturbances associated with circadian 
rhythm disorders. Mishima et at [289] reviewed the results of clinical studies of 
melatonin and bright light administration in elderly patients with dementia. 
Melatonin and bright light administration corrected some of the circadian rhythm 
disturbances these patients experience [289]. Specific recommendations were made 
for further studies, including the optimal timing and dosage of the combined 
melatonin and bright light intervention [289]. 
The timing of melatonin administration is crucial with regard to its effect on 
circadian rhythms. A phase response curve for the effect of exogenous melatonin on 
the circadian rhythm has been described [290]. In healthy individuals with a normal 
circadian rhythm, melatonin administered at 1600 h for example, phase advances, 
while 0900 h administration phases delays (Figure 2-10). There appears to be some 
crossover of effect around noon and, therefore, dosing should be avoided during this 
period. The phase advancing efficacy of melatonin appears to be much more evident 
than its phase delaying capability [276]. 
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Appropriately timed melatonin administration affects the timing of endogenous 
melatonin secretion without suppressing the quantity secreted. Administration of 
exogenous melatonin (0,5 to 50 mg) did not affect the amplitude of melatonin 
secretion measured pre and post treatment [291]. 
The potential effects of acute illness on melatonin 
Patients exposed to extensive surgery and! or with critical illness are subjected to 
physiological, pharmacological and environmental insults which may adversely 
affect the circadian rhythms of many systems, including the sleep-wake cycle. 
Intra and post-operative disturbances in melatonin turnover 
It is important to emphasise, that even though many of the papers cited refer to 
melatonin secretion, it is actually the plasma level that is measured, which reflects 
the net difference between secretion and elimination. Patient factors, anaesthetic 
factors and! or the surgical procedure itself may have an impact on the balance 
between melatonin secretion and elimination. Therefore, depending on this balance, 
intraoperative plasma melatonin levels may be either increased or decreased in 
comparison to normal daytime physiological levels. 
Patients undergoing laparoscopic gynaecological surgery have been reported to have 
significantly increased plasma melatonin levels during the procedure compared to 
pre-operative values [292]. Similarly, in a study of two groups of patients undergoing 
cardiac or oesophageal surgery, melatonin levels were raised compared to normal 
daytime levels during the surgical procedure [293]. However, plasma melatonin 
levels in the cardiac patient group were significantly higher than those in the 
oesophageal group throughout the peri operative period. Significantly older patients 
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and use of local anaesthetics, [293,294] may explain the lower plasma melatonin 
levels reported in the oesophageal surgery group. Local anaesthetics inhibit protein 
kinase C, and thereby NAT activity, which may explain the reduced melatonin levels 
after local anaesthetic administration compared to placebo [293, 294]. Unlike local 
anaesthetics, opioid analgesics may increase melatonin plasma levels by increasing 
NAT activity and, therefore, melatonin synthesis. In bovine pineal extracts, morphine 
dose dependently increased the activity of NAT [295]. 
In contrast to findings in the cardiac patients in the study of Uchida et ai, [293] 
plasma levels of melatonin were found to be below the sensitivity of the assay (12.1 
pmol! 1; 2.8 pg/ ml) in patients during coronary artery bypass grafting [296]. Reasons 
for this difference may include differences in patient age, ~-blocker administration 
and benzodiazepine premedication. Central nervous system (CNS) ~I blockade 
reduced urinary 6-SMT excretion compared to placebo in studies of healthy 
volunteers [134,297]. Nocturnal plasma melatonin levels are lower during 
benzodiazepine administration compared to placebo in healthy volunteers [298,299]. 
Benzodiazepines have been reported to reduce melatonin synthesis by reducing NAT 
activity in the pineal gland [300]. 
The circadian rhythm of melatonin secretion is not affected by acute periods of 
daytime darkness. Therefore, intraoperative darkness is not a cause of the increases 
in plasma melatonin levels reported [292, 293]. Reuptake of noradrenaline by 
sympathetic nerve endings within the pineal gland prevents stress induced increases 
in melatonin secretion during surgery [301]. 
In the Guo el al study, [296] low postoperative melatonin levels were accompanied 
by raised cortisol concentrations. Corticosteroids decrease the activity of NA T in the 
pineal gland [302] and, hence raised cortisol levels, may negatively influence the 
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synthesis of melatonin. There is normally a reciprocal relationship between plasma 
melatonin and cortisol levels. The hormones are phase locked in that the peak plasma 
levels of melatonin occur as cortisol plasma levels plasma levels are at their nadir. 
Melatonin appears to have a phasic inhibitory influence on the pituitary adrenal axis, 
possibly mediated by inhibition of corticotrophin releasing factor [303]. This activity 
may explain the low plasma melatonin levels and raised cortisol concentrations 
found in some postoperative patients [296]. 
Different anaesthetic agents may have varying effects on melatonin plasma levels 
during surgery. Reber et al [292] compared the effects of propofol and isoflurane on 
plasma melatonin levels during and after laparoscopic gynaecological surgery. 
During surgery, plasma melatonin levels were significantly elevated from baseline in 
patients receiving propofol or isoflurane compared to controls (volunteers in a theatre 
environment who did not receive anaesthesia or surgery). In recovery, the levels 
were significantly higher in the isoflurane group compared to the propofol group. 
There was no significant difference in levels between the propofol group in recovery 
and healthy controls. It was suggested that the difference between the anaesthetic 
groups might be due to differential effects of the two agents on hepatic blood flow. 
Indeed, melatonin has a high extraction ratio, [228] and therefore changes in hepatic 
flow may affect hepatic clearance. Furthermore, it is unknown what effect these 
anaesthetic agents may have on the distribution into the systemic circulation of 
gastrointestinal synthesised melatonin [304]. 
Postoperative patients have been shown to have decreased plasma melatonin levels 
during the first postoperative night [296, 305-310]. However, the majority of patients 
studied demonstrated a normal circadian rhythm of melatonin secretion by the 
second postoperative night [296, 305, 306]. 
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The reduced melatonin plasma levels observed in the initial postoperative period may 
simply reflect the effect of melatonin depletion and clearance after the transient 
increase in levels during the intraoperative period. Other possible causes include 
premedication with intermediate or long acting benzodiazepines which suppress 
melatonin synthesis, [298, 299] although reduced melatonin levels on the first 
postoperative night have been seen even without benzodiazepine premedication [307, 
308]. 
Saliva melatonin levels were found to be lower on the first postoperative night after 
orthopaedic surgery compared to preoperative levels, following both general and 
spinal anaesthesia [307]. However, the study groups were too small to demonstrate 
any significant difference in saliva melatonin levels due to differences in anaesthesia. 
The extent of the surgical procedure does not appear to influence the extent of 
disruption in the circadian rhythm of plasma melatonin, as indicated by studies in 
patients undergoing laparoscopic cholecyctectomy [309] and major abdominal 
surgery [310]. A significant delay in the timing and amplitude of the rhythm of both 
plasma and urinary melatonin was demonstrated after both types of surgical 
procedure [309, 310]. A positive correlation between duration of surgery and the 
delay in time of dim light melatonin onset (DLMO, time of increase in melatonin 
plasma levels during dim light conditions) was found in the patients studied after 
major surgery [310]. 
In healthy volunteers, plasma melatonin levels are an excellent marker of circadian 
rhythm even when studied over extended periods [311]. The effects of surgical stress 
and anaesthesia on the timing of the melatonin rhythm may be more important for 
patient recovery than simply changes in amplitude of melatonin plasma levels. 
Prolonged disruption of the patient's circadian rhythm may have adverse effects on 
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mood, delirium risk, rest-activity and sleep-wake cycles and ultimately affect patient !. 
recovery. However, the implications circadian rhythm disorders have on patient 
recovery have not to date been investigated. 
Melatonin and sleep disruption in the critically ill patient 
High risk or critically ill surgical patients are often admitted to general medical/ 
surgical ICUs for postoperative care. Therefore, it is possible that some of their sleep 
disturbance while in the ICU is a carry-over from the postoperative period. Shilo et 
af [312] assessed melatonin secretion and carried out actigraphic sleep analysis in 
fourteen conscious medical ICU patients. Actigraph results demonstrated the 
characteristic pattern of short, fragmented periods of sleep. Urine levels of 6-SMT 
were shown to be abnormal in all patients, with 12 not displaying the normal 
nocturnal rise. Control patients from general medical wards showed normal urine 6-
SMT profiles and sleep patterns. 
The same investigators also studied the effect of exogenous melatonin on the sleep of 
medical ICU patients [313]. In a double blind, placebo-controlled study eight COPD/ 
pneumonia patients in a respiratory ICU, including four ventilated patients, were 
given 3 mg melatonin or placebo tablets at 2200 h on two consecutive nights. 
Melatonin induced sleep in all of the patients, producing a mean duration of sleep of 
6.3 (1.1) hours that was only slightly less than that experienced by the controls 
(general medical ward patients) (7.4 (2.1) hours). However, the duration of night 
time sleep while on placebo was not stated (only baseline data were provided). 
Melatonin was reported to increase total sleep time and reduce sleep fragmentation 
after a single dose although, without the placebo data, this is difficult to conclude. 
Previously, melatonin has been reported to require two to three days' dosage to 
improve subjective sleep duration in chronic insomniacs [279]. 
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In contrast to the findings of Shilo, [312] Mundigler et al [314] reported a normal 
circadian rhythm of urine 6-SMT in seven non-septic patients. Possible reasons for 
the differences between the results of the two studies [312, 314] are differences in 
illness (COPDI pneumonia versus post-anoxic coma), duration of illness (unknown), 
different medication and environmental influences (such as the wearing of eye masks 
in the latter study). Both studies measured urine 6-SMT levels as a surrogate marker 
of melatonin secretion [312, 314]. 
Melatonin in septic patients 
Urine 6-SMT levels in septic patients were compared to those in outpatients 
undergoing rehabilitation for rheumatological conditions [314]. All 17 septic patients 
were ventilated, received continuous sedation with midazolam and sufentanil and 
required inotropic support with dopamine. Four also received adrenaline and 10 
received noradrenaline. Sixteen patients demonstrated a high urinary excretion of 6-
SMT, without any circadian rhythm during sepsis. A more normal day-night profile 
of urinary 6-SMT was noted in patients recovered from septic shock. Reasons for the 
high urinary excretion of 6-SMT in septic patients include hormone interactions, 
effects of cytokines and drugs, as well as alterations in hepatic enzyme activity. 
The absence of a circadian rhythm in melatonin secretion during sepsis may be 
related to that also seen with respect to cortisol. In primates, physiological doses of 
endogenous melatonin blocked the adrenocortrophic hormone (ACTH) stimulated 
rise in plasma cortisol [315]. It is possible that melatonin may contribute to the 
ACTH resistance that occurs in septic patients [316]. Some studies also support an 
inverse relationship between melatonin and cortisol production [317, 318], but others 
have found no role for melatonin in the regulation of adrenal function [319, 320]. 
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Further work to investigate the relationship between melatonin and adrenocorticol 
function in septic patients is indicated. 
Physiological levels of melatonin increase vasopressin secretion whilst 
pharmacological doses impair it [319]. In critically ill septic patients, vasopressin 
levels are initially high then become inappropriately low [321]. However, it remains 
unknown if the vasopressin secretion pattern seen in septic shock is also associated 
with changes in melatonin secretion. Melatonin and its metabolites have significant 
antioxidant activity, [322] and elevated levels may be of benefit in septic patients 
[323]. However, significant antioxidant activity may require pharmacological doses 
of melatonin. Melatonin has also been reported to stimulate cellular release of 
granuloctye macrophage-colony stimulating factor (GM-CSF) [324]. Therefore, the 
potential immuno-stimmulatory and suppressive actions of melatonin need to be 
considered in terms of current knowledge of the pathophysiology of sepsis [60]. 
During sepsis elevated levels of endogenous adrenaline and noradrenaline are otten 
increased further by exogenous administration of these sympathomimetics for their 
inotropic effects. Increased CNS activity of noradrenaline would be predicted to 
increase melatonin secretion. The pineal gland is not situated within the blood brain 
barrier and, therefore, drugs without CNS activity may affect melatonin secretion. 
All of the septic patients studied by Mundigler et al [314] were ventilated and 
received IV infusions of sufentanil for sedation. It is unlikely that sufentanil 
increased melatonin secretion, because this did not occur in the single non-septic 
sedated patient and postoperative opioid analgesia does not increase melatonin 
levels. Alterations in cytochrome P450 lA2 activity, which is responsible for the 
metabolism of melatonin, would affect melatonin plasma levels. IfCYPIA2 activity 
increased, plasma levels of melatonin would decrease, whilst increasing plasma 6-
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SMT levels. However, in septic mice CYP1A2 activity is reduced [325] and in the 
presence of sepsis, parenteral feeding potentiates this effect [326, 327]. This again 
underlines the important information provided by measurements of the plasma levels 
of both the parent drug, as well as its metabolites. 
The effect of cytokines released during sepsis, such as IL-6, on melatonin secretion is 
unknown. However, it is possible that there is a relationship as IL-6 is capable of 
disrupting sleep [14] and exogenous melatonin has been shown to reduce IL-6 and 
IL-10 levels in mice [328]. 
Melatonin and delirium 
The role of melatonin in psychiatric conditions has been an active area of interest for 
decades [329]. Although delirium and schizophrenia are distinct conditions, 
schizophrenic patients have decreased plasma melatonin levels, particularly in 
association with chronic disease [330]. Delirium predisposes to the development of 
dementia and there have been a number of studies that suggested an association with 
reduced plasma melatonin levels and, indeed, disrupted circadian rhythms and the 
symptoms of dementia [59, 331]. However, a systematic review of interventional 
trials of exogenous melatonin found no evidence of a beneficial effect of melatonin 
on cognitive function, although behavioural and affective symptoms may decrease 
[332]. 
Haloperidol, a commonly used antipsychotic that is recommended for treatment of 
acute delirium in the ICU [118], increases melatonin secretion in rats [333]. In a 
small study of seven post-oesophagogastrectomy leu patients, none experienced 
delirium even though three had disrupted melatonin levels [306]. Disrupted plasma 
melatonin levels have been reported in elderly postoperative patients [334]. In this 
study, patients experiencing delirium were divided into two groups, with or without 
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post-operative complications (pneumonia, haemorrhagic shock and cardiac failure) 
[334]. Patients with delirium, but no complications, had low melatonin levels, whilst 
patients experiencing complications had elevated melatonin levels, as seen in early 
sepsis [314]. 
Postoperative suppression of plasma melatonin levels may contribute to disrupted 
sleep and predispose to delirium. Prolonged surgery and anaesthesia might be 
expected to be associated with more severe decreases in nocturnal plasma melatonin 
levels. Indeed this has recently been demonstrated in patients undergoing major 
abdominal surgery [310]. 
It is anticipated that appropriately timed exogenous melatonin therapy would be most 
beneficial in patients undergoing major surgery. However, the evidence for this is 
limited to a case report, in which melatonin therapy was successful in treating 
postoperative delirium in one patient and preventing delirium in another who had 
previously experienced postoperative delirium [335]. 
There is conflicting evidence to suggest that an abnormal melatonin circadian rhythm 
may predispose to delirium. Recently, patients admitted to intensive care after 
oesophagogastrectomy were monitored for delirium and had serum melatonin levels 
measured [308]. Eleven patients (27%) developed delirium during the four days 
studied on the ICU. Delirium was associated with increased age and absence of a 
melatonin circadian rhythm, but not absolute serum melatonin concentrations. Seven 
of the patients who developed delirium demonstrated an irregular melatonin rhythm, 
the other four all had medical complications. After major surgery, half of the patients 
(18/36) developed delirium in another study [336]. Patients with delirium had 
significantly worse sleep quality, as would be expected [336]. However, there were 
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no significant differences between patients who did and did not develop delirium 
with respect to melatonin exposure or rhythm [336]. 
These studies do not allow any firm conclusions to be drawn regarding associations 
between melatonin and delirium. Delirium itself can be described as a type of 
circadian rhythm disorder, which is most markedly demonstrated by disturbances in 
the sleep-wake cycle. Patients who are slow to recover their circadian rhythm after 
an acute illness may be particularly vulnerable to developing delirium. However, it 
remains to be seen if circadian rhythm disturbances predispose to delirium or prolong 
its course. There is no doubt that multiple precipitating factors cause stress to the 
CNS and are important in the aetiology of delirium in critical care patients [53]. 
Strategies to minimise the acuity of illness will also reduce disruption of melatonin 
secretion postoperatively and in critical care, which, in tum, may be of benefit in 
reducing the occurrence of delirium. Whether specific interventions to reinforce a 
patient's circadian rhythm, such as exogenous melatonin, can also reduce the 
incidence, severity and duration of delirium requires further investigation. 
Adverse effects 
Some critical care units now administer nocturnal melatonin to their entire medium 
to long stay patients. However, no medication intervention is without the potential 
for adverse effects which need to be balanced against potential benefits on an 
individual patient basis. 
Melatonin appears to be well tolerated and few adverse effects have been reported 
[337]. The latter include; sedation, drowsiness and a small decrease in temperature (~ 
O.5°C). Headaches, dizziness, nausea and drowsiness are the most common adverse 
events reported with short term melatonin administration [275]. 
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Melatonin has been reported to increase seizures in paediatric patients with pre-
existing neurological disorders [338]. However, it is also claimed to potentiate the 
anticonvulsant activity of carbamazepine and phenobarbital [322]. Hyperglycaemia, 
headache, pruritis, depression, tachycardia, confusion and dysphoria have also been 
associated with melatonin therapy, as have autoimmune hepatitis [339] and psychosis 
[340] in single cases. 
The safety and toxicity of long term (>28 days) melatonin has not been formally 
investigated. Until further data become available, it is reasonable to restrict 
melatonin use to the lowest effective dose and duration of therapy based on an 
individual patient basis. 
Precautions 
It would seem prudent not to use melatonin in patients with a history of convulsions 
until further information regarding pro or anti-convulsant activity is available. 
Pregnant or lactating women should not be given pharmacological doses of the drug 
without evidence oflack of teratogenicity. Patients with ischaemic heart disease may 
be at risk from melatonin induced coronary artery vasoconstriction [341]. The 
immune stimulating effect of melatonin may contribute to exacerbations of 
autoimmune diseases such as, multiple sclerosis [342] and encephalomyelitis, [343] 
and exogenous administration should be avoided in these patients. There may be an 
association between peak serum melatonin levels and physiological impairment in 
nocturnal asthma [344]. The oral bioavailability of melatonin may be increased and 
its elimination impaired in patients with severe liver failure, requiring dose reduction. 
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Drug interactions 
Any drug having an effect on CYPIA2 activity might affect the pharmacokinetics of 
melatonin (Table 2-4). Fluvoxamine increases its oral bioavailability dramatically as 
a consequence ofCYPlA2 inhibition [345]. Melatonin may reduce calcium channel 
blocker antihypertensive activity [346]. 
Any concomitant medication exerting a central nervous (CNS) depressant effect 
would be expected to potentiate the effects of melatonin. Patients who receive drugs 
that increase serotonin levels, as well as melatonin, may therefore be at risk of 
adverse CNS effects. This is because melatonin levels may be further increased by 
pineal gland conversion of serotonin to melatonin. Fluvoxamine increases serum 
melatonin concentrations by an alternative mechanism. Metabolism is decreased, as a 
consequence ofCYPIA2 inhibition rather than melatonin production being increased 
[347]. In practice, however, therapeutic doses offluoxetine, paroxetine, citalopram, 
imipramine and desipramine have not been shown to increase serum melatonin 
concentrations [348] and acute psychosis has only been reported in a single patient 
receiving melatonin and fluoxetine [340]. 
There are two case reports of withdrawal effects after long-term melatonin therapy 
was abruptly discontinued [349, 350]. Administration of melatonin for 1 month in 
volunteers was not associated with any adverse effects on withdrawal after one week 
[337]. 
Drugs considered interfering with melatonin secretion or excretion are listed in Table 
2-5. 
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Inhibitors 
Amiodarone 
Cimetidine 
Ciprofloxacin 
Clari thromycin 
Enoxacin 
Erythromycin 
Fluvoxarnine 
Isoniazid 
Grepafloxacin 
Norfloxacin 
Oral contraceptives (containing 
oestrogen) 
Ticlopidine 
Inducers 
Carbarnazepine 
Insulin [351] 
Modafanil 
Hydrocarbons in tobacco smoke 
Omeprazole 
Phenytoin 
Phenobarbital 
Rifampicin 
Ritonavir 
Thiopentone 
Table 2-4 Drugs with potential to affect melatonin metabolism by 
inhibition or induction of cytochrome P450 lA2 
Adapted from references [352, 353] 
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Effect on 
Drug Group! Drug Proposed plasma Reference Mechanism melatonin 
level 
Local anaesthetics Inhibition of protein -!- [293 , 294] kinase C 
Beta blockers CNS ~I-receptor [134, 297] blockade 
Benzodiazepines Decreased NAT [298, 300, 320] 
activity 
-!-
Opioids Opioid mediated t [295] increase in NAT 
Corticosteroids Decreased NAT -!- [302] 
activity 
Calcium channel Decreased NAT blockers 
activity [354, 355] (dihydropyridine) 
Non-steroidal Inhibition of 
antiinflammatory drugs prostaglandin -!- [127] 
synthesis 
Clonidine a 2 receptor agonism -!- [356] 
Sodium valproate Increased GABA 
-!- [162] levels 
Table 2-5 Drugs known to affect melatonin secretion or excretion 
NAT: N-acetyltransferase; GABA: Gamma Amino Butyric Acid; CNS: Central Nervous System; t: 
Increased; .J..: Decreased 
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Dosage and administration 
The large number of clinical trials using melatonin for a wide variety of indications 
have utilised a wide range of doses. Endogenous plasma levels similar to those seen 
in young adults are achieved with doses of approximately 0.5 mg at night. Doses 
greater than this are commonly used, and are regarded as producing a 
pharmacological effect. Physiological doses of melatonin reduce sleep latency (time 
to fall asleep), but do not increase total sleep time or adversely affect sleep 
architecture [285]. The sleep promoting effects of melatonin increase with dose, but 
appear to reach a plateau such that very large doses may not produce any additional 
benefit. Doses of 2 to 10 mg have been used successfully to improve sleep quality 
[248] and to reset irregular circadian rhythms [287]. 
Melatonin is available as immediate release or sustained release formulations. It may 
also be given sub-lingually, and attempts have been made to develop a transdermal 
delivery system, [357] which would bypass first-pass metabolism of the compound. 
Indeed a melatonin implant has been developed for animal use - specifically to 
accelerate the fur priming cycle in adult minks! 
The study by Shilo et of [313] in ICU patients used a 3 mg controlled release 
formulation. This dosage form has the advantage of maintaining plasma melatonin 
levels throughout the night, mirroring the effect of normal secretion [358, 359]. 
However, controlled release formulations are not always suitable for ICU patients 
reliant on naso-gastric or jejunal feeding. An alternative approach would be to use a 
higher dose (10 mg), thereby overcoming the constraint on duration of effect 
imposed by the short elimination half-life of melatonin (~40 minutes). The timing of 
administration is important and should be one hour before lights-out in the ICU. This 
is to reinforce both the effects of melatonin and light on the patient's body clock. 
91 
Melatonin, sleep and circadian rhythms in critical care patients Chapler 2 Background Literature 
Patients most likely to respond to pharmacological melatonin are those with sleep 
deprivation and/or impaired melatonin secretion. 
The majority of melatonin products are health foods, which cannot be relied on to 
meet pharmaceutical standards [360]. Pharmaceutical grade melatonin formulations 
are available, but may need to be imported and are unlicensed medicines. Although 
melatonin is normally produced by chemical synthesis, some products may contain 
material derived from animal sources. 
If melatonin is to be used clinically for clearly defined indications, appropriate 
pharmaceutical products need to be available. There have been some pertinent 
developments in this regard over recent years. In April 2007, the European 
Medicines Agency (EMEA) granted Neurim Pharmaceuticals orphan drug status for 
their melatonin product (Circadin), a 2mg prolonged release oral formulation, for the 
treatment of non-24-hour sleep-wake disorders in blind people with no light 
perception. Subsequently, the EMEA licensed Circadian for the treatment of primary 
insomnia in patients 55 years and older. As of November 2007, phase III studies of a 
UK melatonin product are currently underway in the treatment of sleep disorders in 
blind people. Posidorm (Alliance Pharma) is a chemically synthesised 1.5 mg 
controlled release oral tablet formulation. Melatonin agonists have also gained 
licensing approval. Ramelteon (Rozerem) has been licensed by the US Federal Drug 
Administration (FDA) for insomnia characterised by sleep difficulty with sleep 
onset. Agomelatine (Valdoxan; Thymanax) has recently (July 2006) had a license 
application for the treatment of major depressive disorder rejected by the EMEA, 
citing insufficient supporting evidence. 
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Conclusions 
The states of sleep and wakefulness are controlled by a complex cascade of 
neurotransmitters involving numerous regions of the brain. Critical care patients 
commonly experience sleep fragmentation and an irregular sleep-wake rhythm. The 
causes of sleep disturbances in critical care patients are multifactorial, and include 
the effects of the environment, care activities, the acute illness, pain, delirium, 
circadian rhythm disturbances and ventilatory desynchrony. 
Studies of sleep deprivation suggest that critical care patients experiencing sleep 
disturbances are predisposed to respiratory, cardiovascular, neurological and 
immunological morbidity. However, direct evidence of morbidity associated with 
sleep fragmentation in critical care patients including long term effects, are lacking. 
Attempts to treat patient sleep disturbances with hypnotic agents are of limited 
patient benefit, and indeed, may have adverse consequences. Multicomponent 
interventions are likely to be required to treat sleep disturbances in critical care 
patients. The latter include re-enforcing the patient's circadian rhythm, and sleep-
wake cycles. 
Plasma melatonin levels are a robust marker of human circadian rhythm. There is 
evidence that critical care patients experience circadian rhythm disturbances and 
therefore, patients sleep may benefit from administration of exogenous melatonin. 
However, the effect of melatonin on critical care patients sleep quantity and quality 
has not been extensively studied. Furthermore, the kinetics of oral melatonin in 
critical care patients have not been investigated, and therefore dosing guidance are 
not available to optimise therapy. 
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3 PRELIMINARY EVALUATION 
OF MELATONIN THERAPY IN 
INTENSIVE CARE PATIENTS 
REFRACTORY TO 
CONVENTIONAL HYPNOTIC 
THERAPY 
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Introduction 
The general medical-surgical intensive care unit at the Royal Hallamshire Hospital, 
Sheffield caters for patients requiring mechanical ventilation as part of advanced 
respiratory support for acute respiratory failure. In common with similar ICUs with a 
similar patient case mix, some patients require prolonged weaning from mechanical 
ventilation due to the severity of their acute illness and/ or chronic respiratory co-
morbidities. It is relatively common for these patients to develop sleep disturbances 
during this weaning period. 
It is usually the ICU nursing staff that identify patients as having sleep disturbances. 
This assessment is primarily based on a subjective assessment by the nurse caring for 
the patient during the night shift. Sometimes the patient themselves are able to 
communicate to the nursing or medical staff that sleep disturbances are a problem. 
Sedative or hypnotic therapy is frequently commenced based on these reports; ideally 
they are also used to direct therapy both in terms of efficacy (or potentially lack 
thereof) as well as possible adverse effects. 
Historically, the intensive care unit has lacked formal guidance on the indications or 
selection of hypnotic agents. As such it was common for patients to receive multiple 
nocturnal sedative agents, often with limited success. At the time chloral hydrate, 
temazepam and lorazepam (i.e. GABAminergic drugs) were the most commonly 
prescribed hypnotic agents. 
In late 1999 during discussion related to an individual ICU patient, one of the 
consultant medical staff questioned the potential benefit of melatonin administration 
in patients undergoing prolonged weaning from mechanical ventilation with sleep 
disturbances. Although the patient in question received conventional hypnotic 
therapy, a literature search was subsequently undertaken ofMEDLlNE and 
95 
Melatonin, sleep and circadian rhythms in critical care patients Chapter 3 Preliminary evaluation 
EMBASE databases for studies pertaining to melatonin use in critical care or 
intensive care. This initial literature search was able to identify very limited 
supporting evidence for melatonin administration in critical care patients. However, 
it did stimulate the author's interest sufficiently to attempt to understand more about 
the regulation of sleep, pathophysiology of sleep disturbances, circadian rhythm 
disorders and specifically the potential role of exogenous melatonin in critical care 
patients. The most obvious question related to the potential efficacy regarding 
improvements in sleep quantity and quality, although other important questions co-
existed. Which patients should receive melatonin? What dose should be used? What 
adverse effects could be expected? What precautions or contraindications were 
there? 
Although classified as a medicine, no licensed melatonin products were identified in 
the UK. If the decision was to use melatonin in particular subgroups of patients, it 
would be necessary to identify an oral product that was suitable for clinical use. 
Although it would be unlicensed, the aim was to find a "pharmaceutical grade" 
product that was chemically synthesised. After a search of potential products, the 
most suitable oral dose identified was a 5 mg capsule preparation manufactured by 
Penn Pharmaceuticals. This product came supplied with a certificate of analysis 
which provided some reassurance regarding the quality of the dose form. The latter 
was a legitimate concern given the real potential for variation in content and 
contaminants in other melatonin products sold world-wide as health foods. At this 
time this product was used by a number ofNHS hospitals, primarily for sleep 
disorders in paediatric patients with Attention Deficit Hyperactive Disorder 
(ADHD). In the era before Medicines Safety Committees requirement to approve the 
purchase and supply of all unlicensed medications and licensed medications for 
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unlicensed indications, specific criteria still had to be met before we could obtain a 
pharmacy supply. This included the requirement to have the support of the Clinical 
Director for the specialty, some guidance on its administration and an undertaking to 
evaluate an agreed clinical endpoint. Using the previously identified questions, draft 
guidance on the use of melatonin in critical care patients was compiled. In early 
2000, the author formally presented a proposal to the Critical Care Directorate 
Clinical Management Group to consider exogenous melatonin therapy in ICU 
patients with sleep disturbances refractory to traditional hypnotic therapy. The 
Critical Care Directorate discussed the existing evidence base related to the potential 
application of exogenous melatonin therapy to improve sleep characteristics in 
intensive care patients. Evidence at the time suggested that intensive care patients 
lacked a nocturnal peak of urinary 6-SMT levels [312] and that exogenous 
supplementation may improve TST as measured by actigraphy [313]. Furthermore, 
an abstract reported that nocturnal administration of melatonin in mechanically 
ventilated patients decreased sedative requirements with a trend to reduced duration 
of ventilation [361]. The preliminary report by Lewis et al [361] had not appeared as 
a peer reviewed paper (and to date has not), but the Clinical Management Group 
agreed that there was sufficient evidence to consider melatonin in patients deemed 
unresponsive to conventional hypnotic therapy. Use would be on the authorisation of 
consultant medical staff only, to reduce the potential for indiscriminate use outside of 
the agreed criteria. 
In November 2000 recommendations regarding dose, cautions, contraindications, 
drug interactions and prescribing authority were collated into guidance on melatonin 
use on the intensive care unit written (Appendix 1). To meet the pharmacy supply 
requirements for the use of an unlicensed medicine, a simple service evaluation was 
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designed to provide some objective measure of efficacy and safety in critical care 
patients (Appendix 2). Of particular concern was the potential hypothermic effect of 
melatonin and whether this would have consequences for infection surveillance. 
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Materials and Methods 
Unblinded open label service evaluation of the effect of enteral melatonin 
administration on nocturnal sleep quantity in intensive care patients. The evaluation 
examined the use of melatonin therapy as part of the leu procedure for treating 
refractory sleep disturbances. Analysis was based on data already routinely collected 
on the ICU, with the inclusion of a simple questionnaire for nursing staff. It was 
therefore classified as a service evaluation under the research governance procedures 
at the time. Ethics committee approval was not required or pursued. 
The evaluation was undertaken on a single general medical-surgical intensive care 
unit. Melatonin 5 mg (Penn Pharmaceuticals, Gwent, UK) was administered orally or 
via enteral feeding tubes by the nursing staff at 2200 h for four nights. It was at the 
discretion of the medical consultant to increase the dose if they felt that an individual 
patient may benefit. Nocturnal total sleep time was estimated by nurse observation 
according to normal clinical practice. Each hour the nurse judged the patients as 
predominantly asleep or awake. Nocturnal sleep was considered as between 2200 
and 0700 h and therefore there was a potential for 9 hours sleep to be recorded. The 
average sedation score for each night was ranked by the nursing staff using the 
Intensive Care Society definitions (Table 3-1). The lowest routine tympanic 
temperature between 2200 and 0700 h was also recorded during melatonin therapy 
and compared to the lowest previously recorded for each patient. Nursing staff were 
also asked to subjectively rank the quality of sleep of the patient during melatonin 
therapy compared to that when receiving traditional hypnotic medication. Quality of 
sleep was ranked as "worse"; "equivalent"; "better" each night compared to baseline 
sleep during conventional hypnotic therapy. Nursing staff also recorded if medical 
(non-nursing) interventions disturbed the patient during the night. Finally, nursing 
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staff were asked if they perceived sleep quality had benefited from melatonin 
administration compared to baseline hypnotic therapy. 
Sedation Score 
3 
2 
o 
-1 
-2 
-3 
A 
P 
Description 
Agitated and restless 
A wake and uncomfortable 
A wake but calm 
Roused by voice 
Roused by touch 
Roused by painful stimuli 
Unarousable 
Natural sleep 
Paralysed 
Table 3-1 Intensive Care Society Sedation Score 
Baseline and historical data were collated from the intensive care unit clinical 
information system (MetaVision, IMD-Soft, Tel Aviv, Israel). Baseline nocturnal 
sleep time was the sleep duration observed and recorded by nursing staff for the 
patient on the last night of conventional hypnotic therapy immediately prior to the 
administration of melatonin. 
Patients 
Non-sedated intensive care patients that were identified by nursing staff observation 
to have severe sleep disturbances that were resistant to conventional hypnotic 
therapy. Patients with multiple sclerosis, encephalomyelitis and other severe 
autoimmune diseases were excluded. Sleep disturbances were defined as 4 hours or 
less observed sleep between 2200 and 0700 h each night. 
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Statistical Analysis 
Data are described using descriptive statistics quoting mean and 95% confidence 
intervals (95% CI). Parametric analysis of continuous data undertaken with Student's 
t test displayed as mean (SD); non-parametric testing undertaken with Mann-
Whitney Rank Sum Test displayed as median (lQR). Categorical data tested using 
Mann-Whitney Rank Sum Test displayed as median (lQR). Comparison of 
proportions of observations in groups was analysed by Fisher's Exact Test. The 
assessment of the relationship between continuous data lacking a normal distribution 
used Spearman Rank Order Correlation quoting correlation coefficient (r) and a p-
value < 0.05 was regarded as statistically significant. 
The primary endpoint was a difference in nurse observation of total sleep time 
between baseline and Nights 3 and 4 combined. Melatonin has a limited soporific 
effect when administered during the nocturnal period and probably has a 
predominantly chronohypnotic effect that may take up to three nights to demonstrate 
[279]. The secondary endpoint was a comparison between baseline and all four 
nights of melatonin administration. 
Statistical analysis was undertaken using Sigmastat 3.1 (Systat Software Inc. 
California, USA) and SPSS 13.0 (SPSS Inc, Chicago, Illinois, USA). 
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Results 
Fourteen patients received at least one nocturnal dose of melatonin. One patient 
received three courses of melatonin and only the first melatonin episode was 
analysed in this patient. A total of twelve patients received melatonin for at least 
three nights and were included for evaluation. Complete sleep quantity data were 
available for Nights 1-3 ; only seven of the 12 patients received melatonin on Night 4 
for a variety of clinical reasons e.g. transfer out of intensive care unit. No patient 
received melatonin doses in excess of 5 mg during the courses evaluated. 
Five different hypnotic agents were administered to the twelve patients prior to 
melatonin evaluation (Table 3-2). The patients received a median 1.0 (1.00; 1.50) 
hypnotics each, of which temazepam was the most commonly prescribed hypnotic 
agent administered to eight patients prior to melatonin. 
Hypnotic drug Number of patients 
Chloral hydrate 2 
Diazepam 1 
Haloperidol 3 
Lorazepam 2 
Temazepam 8 
Total 16 
Table 3-2 Patient hypnotic administration prior to melatonin 
administration 
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Observed total sleep time at baseline and on subsequent nights after melatonin 
administration are shown in Table 3-3 . 
Nocturnal period Nurse observation Total 95% Confidence Interval Slee 
Baseline 1.6 to 3.6 
Night 1 3.2 1.3 to 5.1 
Night 2 3.5 2.8 to 4.2 
Night 3 5.2 4.4 to 6.0 
Night 4 3.9 0.8 to 7.0 
Table 3-3 Nurse observation of nocturnal total sleep time at baseline 
and after melatonin administration 
Compared to baseline total sleep time, patients demonstrated a statistically 
significant increase in sleep duration on Nights 3&4 after commencing melatonin 
therapy. There was a trend to improved sleep quantity over the whole study period 
but this did not reach statistical significance (Table 3-4). 
Total Sleep Time 95% Confidence p-value Coefficient Interval 
Nights 3&4 2.6 0.6 to 4.5 0.011 
All Nights 1.4 -0.2 to 3.1 0.08 
Table 3-4 Differences in observed Total Sleep Time means compared 
to baseline 
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Figure 3-1 shows the proportion of nights that patient's sleep were ranked 
subjectively by nursing staff as "better" than basel ine conventional hypnotic 
treatment. There was a trend to increased perception of benefi t by nursing staff when 
Nights 1 and 3 were compared, but this did not reach statistical significance (Table 3-
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Figure 3-1 Proportion of nights in which nurse perception of 
observed sleep quality during melatonin administration was ranked 
as "better" than baseline hypnotic treatment 
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Night 1 versus Night 3 
Night 1 versus Night 4 
Night 1 versus Nights 3 & 4 
-value 
0.179 
0.070 
1.000 
0.102 
Table 3-5 SUbjective nurse assessment of benefit Night 1 compared 
to subsequent nights 
Medical interventions (non-nursing) di sturbed pati ents on twenty o f the 43 nights 
studied (47%). There was no significant relationship between nurse observation of 
total sleep time and medical interventions (r = -0.05 (-0.35 to 0.25); P = 0.764). 
A verage sedation score over the nocturnal period was recorded by the nursing staff 
each night. The median sedation score fo r each ni ght is shown (Table 3-6). Sedation 
scores remained relatively constant during the study period, with patients all tending 
to be in the "awake" state. Those patients who were predominantly agitated on Ni ght 
I remained so on the subsequent nights studied. There was no stati stical di fference in 
sedation score when Night 1 was compared to the other study nights (Table 3-7). 
Night Median ICS Sedation IQR Score 
1 1.0 1.0 - 3.0 
2 1.0 1.0 - 2.5 
3 1.0 1.0 - 3.0 
4 1.0 1.0 - 3.0 
Table 3-6 Nocturnal Intensive Care Society sedation score over the 
study period 
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Night 1 versus Night 3 
Night 1 versus Night 4 
Night 1 versus Nights 3 & 4 
-value 
0.931 
0.931 
0.766 
0.931 
Table 3-7 Nocturnal sedation score Night 1 compared with 
subsequent nights 
During the melatonin administration period, tympanic temperatures recorded were 
lower than or equal to the historical lowest temperature record in four of the twelve 
patients. However, the historical temperature nadir was significantly lower that that 
recorded during melatonin therapy. Mean lowest baseline temperature wa 3S.SoC 
(35.4°C to 35.6°C) compared to during melatonin administration 36.3°C (36.1 °C to 
36.S0C) (p = < 0.001). 
Nursing staff assessment of Nights 3 and 4 reported that compared to baseline 
hypnotic therapy melatonin improved sleep in six of the twelve patients. 
Comments were infrequently completed on the evaluation form and very highly 
variable as might be expected and were not analysed further. Examples include: "No 
difference compared to temazepam"; "Slept more near the end of night, not 
immediately after the drug was administered"; "Second dose worked very well but 
for a short time (3 hours)"; "Has not slept at all"; "Takes a long time to work!". 
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Discussion 
The results of the preliminary evaluation demonstrated an increased observed 
nocturnal sleep time with melatonin compared to baseline in a group of intensive 
care patients with severe sleep disturbances refractory to conventional hypnotics, A 
significant benefit of two and a half hours duration was seen after three night's 
therapy and whilst increased sleep was noted over the whole study period, this did 
not reach statistical significance, Similar to another study in elderly insomniacs, 
[279] melatonin did not appear to have an immediate soporific effect, instead 
compared to baseline subjective assessment by nursing staff, nocturnal sleep duration 
was significantly increased when Nights 3 and 4 were combined. There was also a 
trend to suggest nursing staff subjective rated melatonin therapy as better than the 
conventional hypnotic therapy by Night 3. 
Some patients received multiple (range 1-3) hypnotic agents, on occasions at 
particularly large doses e.g. 2g chloral hydrate. This practice of using significant 
doses of multiple hypnotic agents is not uncommon in intensive care units as staff 
attempt to recreate a more normal sleep-wake cycle in patients who have and are 
vulnerable to repeated episodes of critical illness [205]. Previous, often prolonged 
exposure to GABAminergic medication as part of sedation regimes increases the risk 
of tolerance to benzodiazepine hypnotic medicines and predisposes to reduced 
nocturnal sleep efficacy. This probably manifests itself both as insomnia related to 
GABAminergic withdrawal and tachyphylaxis to nocturnal doses of hypnotic 
benzodiazepines. Increasing doses of hypnotic agents increases the potential for 
adverse events, including further disruption of sleep architecture, but also potential 
for respiratory depression and sleep inertia the next day and therefore delayed 
weaning from mechanical ventilation and increased intensive care length of stay. The 
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potential for adverse cognitive effects should not be underestimated. In attempting to 
obtain nocturnal sleep the hypnotics used may precipitate or aggravate delirium and 
result in increased sleep-wake disturbances. 
The preliminary evaluation was initially designed to meet the Pharmacy and Critical 
Care requirements for the initial use of melatonin. The quantitative data provided 
some reassurance that vulnerable intensive care patients were not being subjected to 
an unlicensed medicine without some perception of benefit. 
The evaluation had numerous obvious limitations. The evaluation was by definition 
unblinded and therefore there was potential for bias amongst the nursing staff 
recording sleep duration each night. At the time of the evaluation there had been 
significant local interest concerning the potential merits of melatonin therapy in this 
patient group and as such there was a degree of anticipation regarding actual clinical 
effects. This may have provided both positive and negative effects on the subjective 
evaluation by staff. The causes of sleep disturbances in intensive care patients are 
multifactorial, including the acute illness itself, environmental factors (e.g. noise, 
light), medication, pain, ventilator settings and patient factors (e.g. age, chronic sleep 
problems) [23]. Since the evaluation compared a pharmacological intervention of 
sleep in patients already identified as refractory to hypnotic medication, no attempt 
was made to take account of individual patient factors as they were considered to be 
relatively constant. However, this convenient approach did not acknowledge the 
acuity of illness, interventions or variability in environmental factors that 
characterise intensive care. The evaluation would have benefited from some 
demographic details which may have demonstrated an association with the sleep 
quantity data. Specifically, there was no measure of illness severity e.g. APACHE II 
score, and as such it was impossible to exclude patient recovery as a factor 
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contributing to the improved sleep duration recorded. Nocturnal sleep during 
melatonin was compared to a baseline night, i. e. the last night in which the patient 
received conventional hypnotic therapy prior to commencing melatonin. Sleep 
disturbances demonstrate significant intra and inter-night variability and it is possible 
that the use of the single baseline night that trigged a change in sleep intervention 
may have actually provided an artificially low quantification of sleep in which to 
compare subsequent nights to. Nursing staff were asked to subjectively rank the sleep 
quality during administration of melatonin compared to baseline hypnotic therapy, 
not all nurses experienced both periods for the same patient and therefore some 
nights relied on nursing kardex and discussions with colleagues, with compounded 
effects on subjectivity. There was no wash out period and therefore the results 
obtained on Night 1 are subject to the potential confounding hang over effects from 
the hypnotic administered on the previous night. Environmental factors such as noise 
and light disturbances are known to account for approximately 20% of arousals and 
awakenings in intensive care patients [35]. The only environmental factor recorded 
was medical disturbances. Patient care activities are a factor affecting sleep quality, 
[35]. There was no correlation between medical interventions and subjective 
nocturnal sleep duration; however these data were limited. Non-nursing disturbances 
were common, but there was no quantification of the degree of disturbance or 
frequency. Furthermore, there was no sample size calculation to inform the number 
of patients required to be evaluated and only twel ve patients met the criteria of 3 or 
more nights of melatonin therapy. The small sample size obviously contributes to the 
caution required when drawing conclusions from this evaluation; however it was of a 
consistent sample size to other critical care reports on this subject at the time [313]. 
The evaluation relied entirely on nurse observation of nocturnal sleep duration as a 
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measure of sleep quantity and quality. Nurse observation has been demonstrated to 
correlate well with polysomnography in terms ofa nurse's capability of recognising 
if a patient is asleep or awake [28]. However, in the study by Edwards el ai, [28] 
nurses assessed sleep every 15 minutes, not hourly as was the local clinical practice. 
The validation period was also relatively short, at four hours compared with the four 
nights in the current evaluation. Although nurse observation is obviously a subjective 
measure of sleep, it provided some indication of sleep quality, which appeared to 
improve during the period of melatonin administration. The evaluation would have 
benefited from application of a validated objective measure of sleep quality in the 
intensive care patients studied. Generally patients are the best judges of the sleep 
quality. Patients would normally be anticipated to have insight into their baseline, pre 
illness sleep quality and in theory should be able to provide a useful subjective 
assessment of the impact of any intervention. A numeric rating or visual analogue 
scale used by the patients would also have added useful data; however this was 
inappropriate for a service evaluation. The potential adverse sleep effects of delirium 
were not accounted for. At the time "ICU psychosis" was a term commonly used to 
describe patients who were agitated and confused on the ICU. Beyond views that 
poor sleep was a risk factor, no attempt to screen for delirium was made and 
therefore it is not possible to comment on the possible effect delirium had on the 
sleep results. However, the fact that three patients had previously received 
haloperidol prior to melatonin administration does suggest that a degree of confusion 
or agitation had been previously identified in these individuals at least. Indeed the 
sedation score remained relatively constant during the study period in each patient, 
including those patients predominantly described as "agitated" (sedation score::::: 3). 
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Locally, there was no clinical experience with oral melatonin and therefore there was 
uncertainty regarding the degree of sedation or hypothermia a 5 mg dose of 
melatonin may have in patients recovering from critical illness. The literature at the 
time had studied a very wide range of doses, including those far in excess of 5 mg 
daily [10]. However, it was also unknown what affect critical illness would have on 
the pharmacokinetics [325, 326, 352] or pharmacodynamics of melatonin in these 
patients. For these reasons nurse assessment data for the average nocturnal sedation 
score for each patient night was recorded, to provide an indication of the depth of 
sleep or sedation related to melatonin administration. The median sedation score was 
I ("awake but calm") and there was no significant difference between any of the 
melatonin nights. In fact no patient had a mean sedation score assessed by the 
nursing staff as sedated but "roused by voice" or "roused by touch" (0 to -1). This 
suggests that while melatonin may be sedation sparing, [361] it did not induce 
significant sedation in these patients. However, this is not totally unexpected as these 
patients represented a subgroup of patients recovering from critical illness who also 
appeared to be refractory to traditional hypnotic agents, possibly as a result of 
GABAminergic tachyphylaxis. GABAminergic activity remains a proposed pathway 
for the soporific effects of melatonin [10]. If melatonin had increased the depth of 
sleep as well as duration, it may be anticipated that a reduction of median sedation 
score at Night 3 would be reported. A patient demonstrating good quality sleep 
would be expected to have a median sedation score of zero (roused by voice), an 
overall nocturnal score none of the patients achieved on any of the nights evaluated. 
It remains that the Intensive Care Society sedation score is unvalidated as a 
subjective measure of sedation and certainly was not designed as a measure of depth 
of sleep. 
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Melatonin is known to have a hypothermic effect and indeed this may be one of its 
mechanisms of action in inducing sleep [10]. Although patients with a SIRS are 
normally pyrexial, some patients can be hypothermic « 36°C) and probably some 
degree of pyrexia is required to optimise host defence mechanisms targeting of 
infection. Therefore, routine nocturnal tympanic temperatures were also evaluated 
during melatonin administration and compared it to the lowest tympanic temperature 
the patient recorded during their intensive care stay. Four patients had temperatures 
as low as or lower than the historical data nadir. However, the historical tympanic 
temperature was statistically lower when compared to the lowest temperature 
recorded during melatonin administration. These data suggest that with a mean 
lowest tympanic temperature of36.3°C there should be minimal concern concerned 
regarding the hypothermic effect of melatonin in these patients unless they have a 
severe infection. A continuous measure of temperature, such as provided by a rectal 
or bladder probe, would be needed to accurately determine nocturnal temperature 
variability. This was clearly beyond the remit of a service evaluation. The nocturnal 
temperature changes may simply reflect the normal variability in temperature that 
occurs during physiological sleep. The presence of better sleep continuity may 
therefore affect nocturnal sleep temperature and reflect a patient's circadian rhythm. 
It was not possible to comment on any chronobiotic (entraining) effect melatonin 
may have had on this marker of circadian rhythm. Although it remains that 
temperature is unlikely to be an accurate marker of rhythm in acutely ill patients 
[56]. Potential thermodynamic effects aside, melatonin may have desirable effects 
with regard to a patient's antioxidant capacity, which may ultimately prove to be of 
benefit during a septic insult [322]. 
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The results of the preliminary evaluation of melatonin therapy provided the stimulus 
to undertake a larger, randomised placebo controlled study of the effects of 
melatonin on sleep in intensive care patients. Furthermore, the initial evaluation was 
useful in assisting with the design of a subsequent study, including sample size 
calculations. The duration of the study period had to be a minimum of three nights to 
ensure that the potential chronohypnotic effects of melatonin were evaluated. It was 
necessary to provide a subjective sleep assessment by nursing stafT, patient 
assessment and objective sleep measurements. Ideally, a measure of sleep depth 
should be included to examine if melatonin increased deep stages (SWS and REM) 
of sleep rather than just increase total sleep time. To examine if melatonin's effect on 
the patient's sleep-wake rhythm it would be necessary to include an objective 
measure of sleep throughout the 24 hour period. 
Appropriate baseline patient data would need to include an indicator of historical 
sleep quality, and also exclude patients with chronic sleep problems. A method of 
controlling for the environmental effects of noise, light and patient care activities 
needed to be accounted for. Similarly, potential for adverse effects of medicines and 
mode of ventilation had to be quantified. 
It was also necessary to consider the administration method of oral melatonin via 
feeding tubes, to ensure dosing confidence and effective investigator blinding in the 
study. A pharmacokinetic study would be required to provide guidance on oral 
melatonin dosing in future studies of critical care patients. Finally, the results of the 
preliminary evaluation would also assist with obtaining ethics committee validation 
of both the study protocol and patient information sheets. 
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Conclusions 
The open service evaluation found improved sleep quantity after 3 nights melatonin 
therapy when assessed by nurse observation. There was a trend to increased sleep 
quantity over all nights evaluated, although this did not reach statistical significance. 
Melatonin did not appear to have a sedative effect, demonstrating no change in the 
subjective sedation scores over the evaluation period. It may be that the benetits of 
melatonin are not related to a direct soporific, but a chronohypnotic effect which 
deserves further investigation in a randomised controlled trial. 
114 
Melatonin, sleep and circadian rhythms in critical care patients Chapter 4 Formulation of an oral melatonin solution 
4 FORMULATION OF AN ORAL 
MELATONIN SOLUTION 
115 
Melatonin, sleep and circadian rhythms in critical care patients Chapter 4 Formulation of an oral melatonin solution 
Introduction 
A key issue identified when planning began for a randomised placebo-controlled 
study to investigate the efficacy of melatonin on sleep in intensive care patients, 
concerned the melatonin formulation to use. It was necessary to consider not only 
where to obtain a pharmaceutical grade product, but also the specific details of how 
the oral medication would be administered to critical care patients. Over half of all 
oral doses administered to critically ill patients in Sheffield high dependency and 
intensive care units are given through enteral feeding tubes. Patients with 
tracheostomies receive all their oral drugs by this route until either removal of the 
tracheostomy or deflation of the cuff and oral feeding has commenced with minimal 
gastro-intestinal aspirates. Therefore, it was not possible to use a proprietary 
modified release oral melatonin preparation such as done by other investigators [313] 
as this would require the tablet to be crushed by the nursing staff prior to naso-gastric 
or jejunal administration. This would result in, at best, an immediate release of the 
melatonin dose, or more likely a variable mixed immediate and delayed release 
pattern. This was undesirable in that it would add to the variability in plasma 
concentrations of melatonin. 
Melatonin is an unlicensed medicine in the UK and, as such, authorisation from the 
Medicines Control Agency (MCA) was required to undertake a clinical trial with a 
named, pharmaceutical grade melatonin product. A request was made to use 
Melatonin 5 mg capsules (Penn Pharmaceuticals, Gwent, Wales) in the Notification 
by a practitioner under the provisions of the medicines (exemptions form licenses) 
special cases and miscellaneous provisions order J 972 (Sf J 972 No J 200), 
commonly referred to as a DDX. The DDX also required a brief overview of the 
planned study methods, setting and patients. Penn Pharmaceuticals, as the supplier, 
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were also required to complete an undertaking to the MCA certifying that they held a 
product licence for the melatonin capsules. Subsequently the DDX was granted for 
the study using the 5 mg capsules. As a pharmacist, the author was unable to be 
named as the lead investigator on the DDX application. Therefore, one of the 
medical consultants (Dr S P Hutchinson) assumed this responsibility. 
In order to maintain the blinding of the nursing staff to the study, the melatonin and 
placebo presentations needed to be indistinguishable. Owing to the hygroscopic 
nature of melatonin it was necessary to find an inert placebo with similar 
characteristics when mixed with water. Initially, it was considered that the nursing 
staff would be able to mix the melatonin! placebo powder with water for injection 
prior to administration. However, even with the assistance of the pharmacy 
manufacturing unit personnel, it was not possible to identify or formulate a placebo 
powder with sufficiently similar physiochemical characteristics to the powder 
content of the melatonin capsules. As an alternative to a powder formulation, it was 
decided to develop a liquid presentation. Although such liquids are available 
commercially under the classification of 'health foods', they were unsuitable because 
they do not have to meet pharmaceutical standards of active content and stability 
[360,362,363]. Consequently, it was necessary to formulate an oral melatonin 
solution for use in the study using pharmaceutical grade melatonin. 
A "pharmaceutical grade" melatonin powder was sourced from BUF A (Uitgeest, 
Netherlands), and a new DDX was applied for with confirmation that the melatonin 
powder would be formulated into a pharmaceutical quality oral solution. 
The oral solution was formulated to meet the immediate needs of the study. The 
majority of doses would be administered via naso-gastric or jejunal tubes and 
therefore the colouring, flavouring and texture of the oral liquid, were regarded of 
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limited importance. The aim was to formulate a simple aqueous solution that was 
stable, and contained a preservative to prevent microbiological contamination. 
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Materials and Methods 
The oral melatonin solution was developed within the Extemporaneous Dispensing 
Unit of the Royal Hallamshire Hospital Pharmacy Department. Physiochemical 
stability testing was undertaken within the Quality Control Unit, also within the 
Pharmacy Department. 
Materials 
Since melatonin is hygroscopic it was necessary to add a small volume of ethanol to 
the formulation to ensure complete dissolution of the active ingredient in the final 
solution. The quantity of ethanol was minimised to ensure that any soporific effect 
was due to the melatonin and not the alcohol [214]. Sodium benzoate was used as the 
preservative, requiring pH adjustment to less than 5 to ensure optimal anti-
microbiological activity [364]. A pH of about 4.5 would also increase the stability of 
the melatonin [365, 366]. Citric acid was used as the acidifing agent. The final 
solution was stored in amber bottles and refrigerated to reduce photodegradation of 
melatonin [365] and to increase microbiological stability. 
Melatonin and glycerin BP were purchased from BUFA (Uitgeest, Netherlands), 
sodium benzoate and citric acid monohydrate from Courtin & Warner (London, UK), 
purified water BP from Baxter (Thetford, UK) and ethanol 90% BP from BDH 
(Poole, UK). 
For HPLC analysis, purified water BP was purchased from Baxter (Thetford, UK) 
and ethanol 90% BP, potassium dihydrogen orthophosphate AR and methanol HPLC 
grade from BDH (Poole, UK). All HPLC assays were carried out using a 
Merck/Hitachi system with L5000 LC controller, a 655A-12 pump, a Jasco MD-91O 
diode array detector and a Jasco 851-AS autosampler. The reverse phase HPLC 
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column (HiQ sil, C 18, 15cm, 5 micron and 4.6 mm internal diameter) was purchased 
from KY A Tech (Tokyo, Japan). 
Methods 
After several modifications, the formulation described in Table 4-1 was considered 
to be suitable. 
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Batch no. Ingredients Quantity Measured Checked by 
by 
02H20FN Melatonin 0.05 g CH HB 
101 FI6 Glycerin BP 10mi CH HB 
102FI6 Ethanol 90% 5 ml CH HB 
109D08 Sodium Benzoate 0.1 g CH HB 
102FI9 Citric Acid Qs CH HB 
101FI2 Purified Water To 100 ml CH HB 
Sheet written by : HB Checked by : HB 
-
Source of formula: NI A 
Method: Label: Label ref - NI A 
Make a 2% citric acid solution (approx. 30ml). No. labels printed 1 __ 1 
Weigh melatonin in 500ml beaker, add ethanol and Printed by ~I 
dissolve (leave for 10 minutes). Dissolve sodium Checked by 1 __ 1 
benzoate in 20 ml water before adding to beaker. Add 
glycerin and more water until nearly to volume then add 
citric acid solution until pH 4.5 (approximately 4 ml). 
Make to volume and pack. 
Expiry: To Be Confirmed 
Store in a refrigerator. Shake well 
before use. 
Calculations : Containers and closures: 
I x IOOml amber glass medical 
1 x R3/22 black polycone cap or 
clic loc cap 
1 x viskring 
Cautions: Finished product approved 
By: 
Date: 
Table 4-1 Royal Hallamshire Hospital Pharmacy Production 
worksheet for a 0.5 mg/ml oral melatonin solution 
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pH testing 
Single measurements of the pH of the solution were made with a Corning 250 ion-
analyser and a Mettler-Toledo general-purpose combination electrode at preparation 
and then at 7, 14, 70 and 450 days after preparation. 
Chemical stability 
The stability of the melatonin the solution was assessed at preparation and then at 7, 
14, 70 and 450 days by HPLC. 
The mobile phase was 0.05M potassium dihydrogen orthophosphate, pH 4.5 -
methanol 57:43 mixture delivered at a flow rate of 1 mllmin. Detection was by UV 
absorbance at 225nm. The components of the mobile phase were degassed 
ultrasonically under vacuum and filtered (0.45 microns) before mixing in the 
proportioning valve. Samples were diluted volumetrically in duplicate to give a 
concentration of approximately 0.002% w/v melatonin. Three aliquots of each 
dilution were injected onto the column three times. A fresh standard of melatonin 
was prepared on each day of analysis and triplicate injections made as for the sample 
dilutions. 
A solution of 0.01 % w/v melatonin in 0.1 M hydrochloric acid was autoclaved at 
121°C for 15 min to produce acid decomposition products. 
Statistical analysis 
The relationship between melatonin concentration and HPLC peak area was assessed 
by linear regression. The precision of the HPLC assay was expressed as relative 
standard deviation. Statistical analysis was done using SPSS 11.0 (SPSS Inc, 
Chicago, Illinois, USA). 
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Results 
pH Stability 
The pH of the solution was stable within the range 4.1 - 4.4 over 450 days (Table 4-
2). 
Time (days) pH pH 
4°C 25°C 
0 4.34 4.36 
7 4.34 4.32 
14 4.37 4.34 
70 4.34 4.33 
450 4.19 4.30 
Table 4-2 pH of 0.5 mg/ml oral melatonin solution over time 
Chemical stability 
The chromatogram shown in Figure 4-1 indicates baseline resolution of melatonin 
from products of acidic decomposition. At no time up to 450 days of storage were 
any decomposition peaks observed (Figure 4-2). 
Plots of melatonin concentration (0.0008 to 0.004% w/v) against peak area were 
linear with a regression coefficient of 0.99997 and with a 95% CI of the Y-axis 
intercept including zero. 
The relative standard deviation of the method was 0.43%. Duplicate measures of 
melatonin content of the solution stored at 4 and 25°C ranged from 98.6 - 101.5% 
over the period of the stability study (Table 4-3). 
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Time (days) % of Original % of Original 
4°C 25°C 
0 100 100 
7 98.6 99.1 
14 100.6 99.6 
70 101.5 101.3 
450 99.9 99.1 
Table 4-3 Stability of melatonin in the 0.5 mg/ml solutions 
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Figure 4-1 Chromatogram showing the separation of melatonin 
from acid decomposition products after autoclaving at 121-124°C 
for 15 min in O.lM hydrochloric acid 
Melatonin (Peak 4); Acid decomposition products (Peaks 1,2,3,5). 
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Figure 4-2 Chromatogram of the 0.05% w/v melatonin solution after 
storage at 25°C for 450 days 
Melatonin (Peak 2); Benzoic acid (Peak I). 
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Discussion 
The assessments of the stability of the final melatonin solution formulation indicated 
that a shelf life of up to one year when stored refrigerated or at room temperature 
was appropriate. For the purposes of the planned clinical trial, the Pharmacy 
Extemporaneous Dispensing Unit prepared the solution (melatonin or placebo) on 
the day of patient enrolment into the study, giving the product a 7 day expiry under 
refrigerated conditions. 
Storage was in amber bottles to reduce the possibility of photodegradation of 
melatonin [365]. Although Daya [366] reported that melatonin degrades in aqueous 
solution after 3 days irrespective of pH, this observation was not confirmed by the 
present study. 
The results of the stability study were in agreement with the findings of Cavallo 
[367] who reported stability at 4°C in aqueous solution up to 6 months. 
A supply of "pharmaceutical grade", chemically synthesised melatonin was used to 
ensure confidence that the product was free from contaminants that have been found 
in some melatonin health food products. Analogues of impurities similar to those in 
L-tryptophan, and associated with the development of eosinophilia-myalgia 
syndrome, have been identified in such products [360, 368]. As there is no 
monograph on melatonin in the British Pharmacopoeia (BP), by definition there is no 
official pharmaceutical grade of melatonin. The US Pharmacopeia (USP) includes a 
reference standard for melatonin, but currently there is no monograph to compare 
against. Nevertheless, the term "pharmaceutical grade" has been applied to the 
BUF A product as it meets the criteria for 99% purity and contains no binders, fillers, 
dyes or unknown substances. 
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In the initial attempts at formulation, there was some difficulty in getting the 
preservative, sodium benzoate, into solution. A concentration of 1 % w/v was used, 
which was excessive for the antimicrobial activity required. Therefore, the 
concentration of sodium benzoate used in subsequent formulations was reduced to 
O.l%w/v. 
Ethanol has sedating effects that are often used by insomniacs to aid sleep onset at 
bedtime. The final melatonin solution contained O.9g ethanol per 20ml dose of 
melatonin. This compares to the 14-16g of ethanol in a small glass (I 25ml) of white 
wine, and the 35g used in a typical study of the effects of ethanol on sleep [214]. The 
sedating effects of ethanol are also affected by the baseline alertness or sleepiness of 
the individual [369]. leu patients with demonstrated sleep fragmentation (if not 
deprivation) may, therefore, be expected to demonstrate increased sensitivity to the 
sedating effects of ethanol. This relationship is further complicated by an 
individual's previous tolerance to alcohol as well as their more recent exposure to 
GABAminergic drugs. In a dose ranging study of the sedating effects of ethanol, the 
starting dose of ethanol used was approximately 23g [370]. The dose of ethanol 
provided by administration of melatonin in the oral solution formulation would 
appear insignificant with respect to evaluating the sedative effects of melatonin. In 
any event, the placebo solution contained the same amount of ethanol as the active. 
The optimum use of melatonin as a chronohypnotic agent relies on the administration 
of an appropriate dose at an appropriate time. Ideally, there should be a peak effect 
soon after administration followed by exposure comparable to "normal nocturnal 
plasma levels", which then return to daytime levels by the morning. Given the 
relatively short plasma elimination half-life in healthy individuals, this could be best 
achieved with an oral dosage form with a two phase release profile. An initial 
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immediate release of melatonin should be followed by a modified release to provide 
the continuous nocturnal plasma concentrations. Such solid dosage forms have been 
manufactured, [359] and, in the case ofPosidorm (Alliance Pharmaceuticals), are 
undergoing Phase III studies in preparation for clinical use. An oral product 
providing only a sustained release of melatonin would require that the lag time to 
reach a physiological nocturnal plasma melatonin concentration be allowed for in 
dosing. However, any solid formulation is impractical in patients undergoing feeding 
by a naso-gastric tube, and a liquid formulation for oral administration is necessary. 
Parenteral administration would not be acceptable in patients recovering from critical 
illness because of the need to limit multiple vascular access. Transdermal delivery of 
melatonin would be attractive if a dependable delivery system could be formulated to 
provide the desirable surge-sustained dosing described. An obvious advantage of 
such transdermal administration is of course that it can be used independent of a 
functioning gastric-intestinal tract, a common limitation in this patient group. Like 
any transdermal delivery system variation in blood supply to the skin as a 
consequence of sepsis, vasoconstrictors and pyrexia may adversely affect the release 
characteristics of the drug with the potential to adversely affect the entrainment 
signal achieved. As with all transdermal delivery systems they have the ability to be 
found in the patient's bed after becoming dislodged at an unknown point in the 
preceding day; something that even the best designed product cannot circumvent. 
Nevertheless, trans dermal delivery systems for melatonin continue to be developed 
using novel vehicles such as elastic liposomes, [371] in an attempt to overcome the 
relatively short half life of melatonin. Sublingual delivery of melatonin would also 
bypass the "first pass effect" and improve bioavailability, irrespective of gastric-
intestinal function. Lower doses would be required but modified release would be 
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difficult to achieve. The labelling of some of the available melatonin health food 
products advocate sublingual dosing without appropriate dose modification (e.g. 
BioTonin, EuroHealth Inc. Perkasie, Pennsylvania, USA). Sublingual dosing of 
melatonin has also been used in the clinical environment to provide sedative pre-
medication prior to surgical procedures [372-374]. However, sublingual dosing may 
be haphazard in critical care patients with xerostomia as a consequence of factors 
such as dehydration, endotracheal tube in situ or the anticholinergic effects of drugs. 
Intranasal administration of melatonin as a liquid spray formulation again allows 
bypass of the liver to produce plasma concentrations comparable to IV doses [375]. 
A preliminary report suggests that work is ongoing with intranasal melatonin 
administration in leu patients [376]. This is an attractive approach for clinical 
application in leu patients, although development of an effective dosing strategy 
with this immediate release route is necessary. 
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Conclusions 
This stability study found that melatonin could be formulated in an oral solution that 
remained stable for up to a year. The availability of a pharmaceutical grade oral 
solution of melatonin met the regulatory requirements of the MeA and ensured 
dosing confidence in the planned randomised controlled trial. 
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Methodological Development 
Study Design 
Initially it was intended to carry out a cross over study thereby allowing better 
control of individual patient factors. However, this design necessitated the enrolment 
of patients for a long period (7-1 0 days), and there was a risk of carryover of the 
effects of melatonin into the placebo phase if the washout period was insufficient. 
Therefore, it was decided to adopt a parallel group design, despite the associated 
requirement for a greater number of patients. 
Patient Selection 
Non-sedated critical care patients were selected for recruitment who could be studied 
continuously over a period of 5 nights and who had a tracheostomy to assist weaning 
from mechanical ventilation. Such patients generally require a prolonged period of 
respiratory support as a consequence of cardiovascular or respiratory co-morbidities 
and! or a severe acute lung injury and, therefore, are likely to require an extended 
ICU admission with vulnerability to acute sleep disturbances. It was necessary to 
exclude patients with sleep disturbances prior to admission, with co-morbidities 
predictive of sleep disturbances and low levels of consciousness. 
Study Endpoints 
The planned primary endpoint was patient nocturnal sleep efficiency index (SEI) 
over nights 3 to 5 (total nocturnal sleep quantity expressed as a ratio of time available 
for nocturnal sleep). Analyses would be limited to nights 3 to 5, since the potential 
chronohypnotic benefits of melatonin are not immediate and may take three days to 
be realised [279, 377]. All five nights would be considered in a secondary analysis. 
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Polysomnography, [36] actigraphy [312] and the bispectral index (BIS) [378] have 
all been used as objective studies of sleep in previous critical care studies. Initially, it 
was proposed to use actigraphy as a continuous objective measure of sleep quantity, 
i.e. it would provide data on sleep quantity during the diurnal and nocturnal sleep 
periods. The latter was important as critical care patients' sleep traverses the day-
night period and as much as half of total sleep time can occur during the day [23]. 
While the primary interest was in using interventions such as medication to 
consolidate the quantity and quality of nocturnal sleep, daytime sleep, particularly 
later in the afternoon can have adverse effects on nocturnal sleep efficiency. 
Although this technique had been used previously to study the effects of melatonin in 
ICU patients, [313] it was thought that it would not provide all the information 
required. It was, therefore, planned to also use the BIS as another objective measure 
of sleep. It was decided to use the Richards Campbell Sleep Questionnaire to 
quantify patient assessment of sleep, as this tool has been validated in a critical care 
population versus polysomnography [29]. Nurse assessment of nocturnal sleep 
quantity would also be used. The frequency of nurse assessment of sleep in other 
critical care studies has ranged from 5 minutes, [27] to 8 times [87] per day. It was 
initially planned to adopt 15 minute intervals [28]. However, nursing staff felt that 
this may impinge on direct patient care. Therefore, it was agreed to limit nurse 
observation of sleep to hourly epochs during the night, according to the clinical 
practice at the time. 
The sleep measurement techniques were, therefore, finalised as BIS (Aspect Medical 
Systems, USA), actigraphy (Actiwatch Plus, Cambridge Neurotechnology, UK); 
nurse assessment (direct nurse observation using hourly epochs) and patient 
assessment (Richards Campbell Sleep Questionnaire, RCSQ). Although the RCSQ 
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provides a five component rating of nocturnal sleep, a total score can be calculated 
from the mean of total scores in the 5 domains. This total score has been used as a 
measure of sleep efficiency index and has been validated against polysomnography 
[29]. 
Although the possibility of using polysomnography as measure of sleep quality was 
explored, this was not possible on grounds of both availability and cost. However, it 
was decided to evaluate the relationship between the BIS and EMG scores of the 
Bispectral index and polysomnography in a study with normal subjects. 
Thus, the primary endpoint was planned to be nocturnal sleep efficiency as measured 
by actigraphy. Secondary endpoints would include nocturnal sleep efficiency 
measured by BIS, nurse assessment and patient assessment. Furthermore, diurnal 
sleep quantity as measured by actigraphy would also be investigated as a secondary 
analysis. 
Delirium screening was also planned as part of the study for two reasons. Firstly, 
delirium symptoms include sleep disturbances and, as such, knowledge of delirium 
status at baseline has implications for between group comparisons. Secondly, a 
significant disadvantage of traditional hypnotic agents is the potential for delirium, 
and information regarding the incidence of delirium in patients commencing 
melatonin versus placebo would be beneficial. Diagnosis of delirium is difficult in 
intensive care patients primarily because of their limited ability to communicate. A 
number of delirium screening techniques have been developed for use in this patient 
popUlation. It was decided to use the Confusion Assessment Method for the Intensive 
Care Unit (CAM-ICU) as it is both validated, [379] and accompanied by a 
substantial training package. Between group differences in delirium incidence, as 
measured by the CAM-ICU, was planned as a secondary endpoint. 
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Study Size 
Based on data from two studies in critical care patients by Shilo et al [312. 313] (SO 
= 0.11), it was estimated that a minimum of 12 patients would be needed to detect a 
difference in SEI of 0.20 by actigraphy (0.=0.05; power=0.8). Using nurse 
observation the results from the preliminary melatonin evaluation provided a larger 
variation (SD = 0.26), indicating that a minimum of 56 patients would be required 
(Chapter 3). Data from several polysomnography studies reported SO values of 0.1 -
0.24 [29,36, 193,380]. Therefore, it was decided to use a SO of 0.20 which resulted 
in a desired sample size of 34 patients for the randomised controlled trial. 
A review of the MetaVision clinical information system (iMDSoft, Tel Aviv, Israel) 
audit data over the period 2000-2002, identified 108 patients admitted to the Royal 
Hallamshire Hospital ICU with a tracheostomy requiring an ICU stay of at least 10 
days. Thus a single site study seemed feasible with regard to patient recruitment and 
would serve to support the Ethics Committee application. 
Melatonin Dose 
The development of an oral solution of melatonin is described in Chapter 4. A 5 mg 
dose administered at 2200 h was used in the preliminary evaluation (Chapter 3), 
although subsequently other patients had received doses up to 10 mg. The latter dose 
was reported to entrain the circadian rhythm of melatonin secretion by Sack [287]. 
Therefore, it was decided to use a 10 mg dose administered at 2100 h hours to 
coincide with the normal phase response curve of melatonin [266]. 
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Measurement of plasma melatonin 
An assay was required to measure both endogenous plasma levels of melatonin and 
concentrations after oral administration. Radioimmunoassay (RIA) kits are 
commercially available that can be used to measure concentrations of the order of 10 
pg/ ml, [259,348, 381] while gas chromatography-mass spectrometry (GC-MS) has 
been used down to 1 pg/ ml [382] and high performance liquid chromatography-mass 
spectroscopy (HPLC-MS) has a lower detection limit of2 ng! ml [383]. Because of 
the low sensitivity of published HPLC-MS methods and a lack of access to GC-MS, 
it was decided to use a RIA (lmmuno Biological Laboratories, Hamburg, Germany), 
despite its inherent lower precision. A particular concern with RIA is lack of 
specificity due to cross-reaction of the antibodies with drug metabolites. Plasma 
concentrations of 6-hydroxymelatonin are much higher (35 fold) than those of the 
parent compound [255]. However, preliminary studies with a source of this 
metabolite (BUF A, Uitgeest, Netherlands) indicated only 0.004% cross-reactivity 
with the kit that was used (Immuno Biological Laboratories, Hamburg, Germany). 
The suppliers of the kit claim cross-reactivities of 0.8, 0.7 and 0.08% with N-
acetyl serotonin, 5-methoxytryptophol and 5-methoxytryptamine, respectively. The 
latter are not important metabolites of exogenous melatonin, but are present 
endogenously in plasma as a result of indoleamine biosynthesis and metabolism 
[384]. 6-hydroxymelatonin is metabolised to 6-sulphamethoxymelatonin [385]. 
Although it was not possible to source an authentic sample of this compound to 
check cross-reactivity, Hartter et al [386] reported no cross reaction with any 
melatonin metabolites with the RIA kit that they used. 
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Melatonin RIA procedure 
The RIA was undertaken according to the manufacturers' instructions (Melatonin 
direct RIA (Plasma), Immuno Biological Laboratories, Hamburg, Germany). Quality 
control samples were included and confirmed to be within the acceptable ranges. 
Plasma samples were defrosted immediately prior to testing and centrifuged before 
assaying in duplicate. Samples suspected to contain concentrations higher than the 
linear range of the assay (30 - 200 pgl ml) were diluted with buffered bovine 
albumin solution prior to testing. The limit of detection was 3.5 pg/ ml. The intra-
assay precision (% CV) of the assay at plasma concentrations of approximately 10 
and 150 pgl ml was l3.6 and 6.8%, respectively. The inter-assay coefficient of 
variation was 25%. 
Pharmacokinetic analysis 
A formal evaluation of the kinetics of melatonin was carried out on data from the 
first 9 patients on active treatment recruited to the study. Baseline levels (2100 h) of 
plasma melatonin in each subject receiving active treatment were subtracted from the 
data obtained after oral administration of melatonin. Values of the area under the 
corrected plasma concentration-time curves (AUe) were determined using the linear 
and log linear trapezoidal rules implemented in PKSolution 2.0 (Summit Research 
Services, Montrose, USA). Extrapolation of these values to infinity was done from 
the ratio of the last measured concentration divided by the terminal elimination rate 
constant (k) determined by the linear regression from the final data points (7 to 24 
hours after melatonin administration). Mean Residence Time (MRT) was calculated 
using trapezoid area calculations extrapolated to infinity. Hence, oral clearance was 
calculated from dose/ AUC(O-infinity) and reported together with Cmax (maximum 
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plasma concentration), tmax (time to Cmax) and overall elimination life (from In2 x 
MRT). 
Circadian rhythm analysis 
Plasma melatonin levels provide a robust marker of an individual's circadian rhythm 
[311]. It was planned to measure plasma melatonin and cortisol levels to provide 
both information on the patients' rhythm, and to describe the timing and 
concentration relationships between the hormones. Plasma samples in the first 9 
placebo patients would also be assayed for melatonin levels to provide circadian 
rhythm data. Plasma melatonin AUC(o-24) was calculated in placebo patients using the 
trapezoidal rule to allow comparison of melatonin secretion over a 24 hour period 
with data from healthy elderly volunteers [387]. 
A chemiluminescent enzyme immunoassay was chosen to measure plasma cortisol 
levels. Rhythm analyses of plasma hormone levels would use single cosinor analysis 
(Time Series Analysis Seriel Cosinor 6.3, Expert Soft Technologie, France). 
In addition to providing sleep quantity data, actigraphy would also provide 
information on the patients' rest-activity rhythm [26]. Cosinor analysis is not suitable 
to describe the rest activity data, since it lacks sensitivity when analysing data that is 
irregular and! or has a non-sinusoidal appearance [388]. Instead, non-parametric 
parameters analysis was used [388]. 
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Cortisol assay procedure 
Plasma samples were defrosted and centrifuged before cortisol assay in duplicate 
using a competitive chemiluminescent enzyme immunoassay (Immulite 1000, 
Diagnostic Process Corporation, Los Angeles, USA). The intra and inter-assay 
precisions (%CV) were 8.8 and 10%, respectively. Cross reactivity of cortisol with 
prednisolone was reported to be 62%. 
Neuromuscular strength assessment 
There were substantial concerns regarding the potential for significant neuromuscular 
weakness in patients recovering from a critical illness. Intensive care acquired 
abnormalities of the neuromuscular system are associated with sepsis, the use of 
drugs such as steroids [389] and neuromuscular blockers and severity of illness 
[390]. The pathology may affect nerves, muscles or both, although myopathy is 
probably he most common or predominant problem. Studies using 
electrophysiological testing suggest an incidence in the region of 50% in patients 
ventilated for 7 days or more [391]. Such patients would be anticipated to have 
reduced movement, which could be misinterpreted by the actigraphy algorithm as a 
sleep period, with consequent overestimation of sleep time. Diagnosis requires the 
use of nerve conduction studies or electromyography. However, it was not practical 
or feasible to undertake such monitoring in this study. Instead, it was decided to use 
grip strength testing and compare results to normal values from age and sex matched 
controls, [392] to provide a measure of neuromuscular weakness. 
Environmental control 
Environmental disturbances are a risk factor for sleep disturbances in critical care 
patients [35]. Therefore, it was necessary to control for potential differences in 
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nocturnal disturbances between groups. Ideally, continuous noise and light 
monitoring would have been undertaken during the study periods. After meetings 
with estates management concerning the equipment required and costs, this was 
regarded as unfeasible. Light levels at the head of each bed, when all non-emergency 
lighting was switched off, were measured prior to the start of the study (Luxmeter 
PU150, Eagle International, Wembley, UK). This would enable comment regarding 
illuminance level and any potential for suppression of dim light melatonin onset 
(DLMO), a circadian rhythm marker. 
Meetings with nursing staff and environmental posters were used to raise awareness 
of the potential consequences for nocturnal sleep disturbances. Nursing staff were 
also encouraged to switch off all main lights at 2200 h and to minimise non-clinical 
light interruptions. The aim was to reduce noise and patient disruption during the 
night. A record of important environmental disturbances was developed to allow 
between group comparison of disturbances as well as the opportunity for subjective 
ranking of noise levels each night by nursing staff. The provision of ear plugs and 
eye masks was also deemed a useful patient option to minimise noise and light 
disturbances. 
Peer support 
To facilitate the implementation of the study, support was obtained from the Critical 
Care Directorate Clinical Management Team. A series of meetings were held with 
nursing staff to explain the trial rationale, the theoretical benefits of melatonin and its 
possible mechanism of action, the logistics of the study and how the nursing staff 
could assist with patient enrolment and data collection (demographics, delirium 
screening, patient sleep assessment) and blood sampling. Posters containing 
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information about melatonin in relation to critical care patients were also placed on 
notice boards. 
Funding 
Two internal hospital grants and one external project grant were applied for. The 
latter, from the Anaesthesia Research Society was short listed but not granted. 
Funding (£15,000) was secured from the Sheffield Teaching Hospitals Department of 
Pharmacy and Medicines Management and Small Grants Schemes. 
Ethics Committee Approval 
The study protocol was submitted to the South Sheffield Research Ethics Committee 
(SSREC) in June 2002. As with other intensive care studies submitted at that time, 
the SSREC expressed reservations about the general intrusiveness of the study in a 
vulnerable group of patients, and requested a resubmission after modification. Issues 
were raised regarding the planned consenting options. In patients unable to provide 
consent, it was recommended to obtain retrospective consent from the patient in 
addition to the prospective consent from relatives. The SSREC also felt that a study 
over 5 nights was excessive and that delirium screening should not be undertaken 
daily. They also sought clarification on patient inclusion (restriction to patients with 
tracheostomies only), more details on exclusion criteria, time to study entry 
following discontinuation of sedation regimes and further supporting evidence for 
the choice of melatonin dose. 
Thus ethics committee approval had several implications for the planned study. 
Firstly, that the study would be conducted over 4 nights and, therefore, the primary 
sleep endpoint would now be sleep quantity over nights 3 and 4. Secondly, that 
delirium screening would only provide data to allow baseline group comparison, and 
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not incident delirium monitoring. Finally, the risk of including a patient in the study 
and subsequently an inability to use the data without retrospective consent was 
substantial. Therefore, it was decided to seek patients capable of providing informed 
consent, even though this would have an impact on patient recruitment. 
A revised protocol was submitted in October 2002, which also included the addition 
of documentation of daily APACHE II (Acute Physiology and Chronic Health 
Evaluation) scores and current drug therapy. This was agreed in December 2002 and 
the study commenced in April 2003. 
After commencing the study a COREC (Central Office for Research Ethics 
Committees) amendment application was submitted to change the primary sleep 
measurement technique to the BIS. This followed concerns about the validity of 
actigraphy sleep measurement in the presence of extreme neuromuscular weakness. 
A measure of grip strength was also included in the protocol. 
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Final St"udy Protocol 
Schema 
Indusion/ Exdusion Criteria 
Imooned Consent 
Randomisation 
CAM-ICU 
Ear plugs & eye masks 
1st Dose Melatonin! Placebo 
BIS Monitoring 
Acti ra Commences 
Environment report 
RCSQ 
Ear plugs & eye masks 
2rd Dose Melatonin! Placebo 
SIS Moniloring 
Environment report 
RCSQ 
Ear plugs & eye masks 
3rd Dose Melatonin! Placebo 
BIS Montoring 
Environment report 
RCSQ 
Ear plugs & eye masks 
4th Dose Melatonin! Placebo 
BI S Monitoring 
Environment report 
RCSQ 
CAM-ICU 
SIS Monitoring 
Actigraphy Discontinued 
Day 
Time 
, .... ~, ":!,w, , ..... t.:".* _, 
6 16 24 32 40 
Plasma 
Samples 
o.y1 
48 56 64 
12 16 20 24 26 
Hrii r r 
Figure 5-1 Final study protocol 
72 80 68 96 104 11 2 
48 36 
r 
40 
r r r 
CAM-ICU: Confusion Assessment Method for the Intensive Care Unit; BIS: Bispectrallndex; RCSQ: 
Richards Campbell Sleep Questionnaire 
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Study objectives 
Primary end point 
Difference in BIS SEI between treatment groups on nights 3 and 4. 
Secondary end points 
Difference in BIS Aue between treatment groups on nights 3 and 4. 
Difference in BIS SEI between treatment groups on all nights. 
Differences in nocturnal SEI as measured by actigraphy, nurse and patient 
assessment. 
Agreement in SEI between BIS and other measures of sleep quantity; actigraphy; 
nurse and patient assessment. 
Differences in rest-activity parameters between treatment groups. 
The kinetics of melatonin in critical care patients 
Plasma melatonin rhythms in critical care patients 
The relationship between plasma melatonin and cortisol rhythms in critical care 
patients. 
Patient eligibility criteria 
Patients admitted to an adult general intensive care unit (leU) with acute respiratory 
failure requiring mechanical ventilation and tracheostomy to assist weaning. 
Exclusion criteria were: expected leu length of stay <5 days; pre-admission 
treatment of sleep disturbances; contraindications to enteral feeding; previous history 
of convulsions; psychiatric or neurological disease; alcohol consumption ~ 50 units 
per week or drug use; sleep apnoea; severe heart failure (NYHA IIIIIV); low levels 
of consciousness, defined as values < 4 on the Sedation Agitation Scale (SAS) [393]. 
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Patient randomisation 
Patients were included who met the inclusion! exclusion criteria and who were 
deemed capable by the ICU consultant to provide informed consent. Patients were 
allocated to either active treatment or placebo by the Pharmacy, using randomisation 
in blocks of four. 
Treatment schedule 
Melatonin (10 mg) oral solution or matching placebo was administered enterally at 
2100 h for four consecutive nights (Chapter 4). No other hypnotics were allowed 
during the study. Haloperidol was allowed in very agitated patients (SAS ~ 6). Ear 
plugs and eye masks were made available for use at the patients' discretion. 
Environmental disturbances were documented on the locally derived scale composed 
of light interruptions and clinical activities (Appendix 3). Nursing staff subjectively 
ranked the noise level each night (Appendix 3). 
Drug records were compiled daily for drugs known to adversely affect sleep (Table 
2-3) or melatonin kinetics (Table 2-4). 
Delirium was screened for at baseline upon study entry and after completion of the 
study using the CAM-ICU. Dynamometric measurements of patient grip strength 
(Jamar hydraulic hand dynamometer, Asimov Engineering Co. California, USA) 
were undertaken on study completion. 
Sleep measurement 
Nocturnal sleep was evaluated using the Bispectral Index (BIS; BIS XP, Quattro 
sensor) commenced prior to administration of melatonin! placebo, BIS data was 
recorded in 5-second intervals and downloaded into a personal computer. Two 
outcome measures were calculated from the BIS data; sleep efficiency index (SEI) 
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and area under the curve (AUC). SEI was defined as the ratio of patient's total sleep 
time over time available for "nocturnal" sleep (9 hours, from 2200 to 0700 h, 
corresponding to nursing staff shift patterns). Sleep was defined as BIS < 80 [32]. 
AUC was calculated using the trapezoidal rule. For each night, SEI and AUC values 
were set to missing if recordings were not made for more than 2 hours. 
Actigraphy was recorded continuously over the whole study period from the non-
dominant hand in 30 second epochs. Delirium positive patients determined using the 
CAM-ICU [379] were excluded from RCSQ evaluation. Nurse assessment of 
nocturnal sleep was by direct observation using hourly epochs according to the 
critical care units routine sleep monitoring. 
Results of the four techniques for nocturnal sleep were expressed as a common 
measure, the SEI, in order for comparison. 
Plasma samples 
Twelve blood samples were collected from each patient at appropriately spaced 
intervals after the first oral dose. Sample times post 2100 h administration were 0, 
0.5 h, 1 h, 1.5 h, 2 h, 3 h, 5 h, 7 h, 11 h, 15 h, 21 hand 24 h. All blood samples were 
taken from the arterial line, immediately centrifuged, providing two plasma samples 
to be labelled and stored at -20°C until assay. 
Statistical analysis 
Sleep and Circadian Rhythm analysis 
Differences between treatment groups in mean values of BIS SEI and AVe, 
averaged over nights 3 and 4, were analysed using the t test with equal variances 
(95% confidence intervals). The secondary analysis including all four nights used a 
multilevel model, namely Prais regression, which accounts for the within-patient 
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correlation between measurements on successive nights. Mean and standard 
deviation or median and interquartile range to were used for descriptive statistics. 
The Pearson Correlation and Spearman Rank Order Correlation were used for tests 
of association as appropriate. Simple linear regression was used to test the 
relationship between administration of drugs with CYPIA2 activity and measures of 
melatonin exposure. Mean and standard deviation or median and interquartile range 
were used as appropriate for descriptive statistics. 
Differences between treatment groups in non-parametric rhythm parameters were 
analysed by t test with equal variances. Cosinor analysis was used to describe the 
rhythms of plasma hormone levels. 
Dynamometric testing of grip strength was based on the mean of three recordings 
and results were expressed as percentage of normal values for age and sex matched 
controls [392]. 
Agreement 
Agreement between techniques was evaluated using the limits of agreement method 
[394]. This approach compares two techniques at a time and consists of; 1) drawing a 
simple scatter plot of the results of the two techniques for each patient with the line 
of equality (y=x). If the techniques have perfect agreement, then all points should fall 
along this line; 2) drawing a graph of the differences between the results of the two 
techniques plotted against the average measurement value (Bland-Altman plot). 
From this plot it is possible to not only evaluate the magnitude of the differences and, 
thus, decide on its clinical acceptability, but also to see whether the magnitude of the 
differences varies with the magnitude of the measurements (e.g. increase in the 
differences with increase in the average values); 3) from the mean and standard 
deviation (SD) of these differences, calculating the 95% limits of agreement, i.e. the 
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range within which 95% of the differences should lie (mean - 1.96 * SD; mean + 
1.96 * SO). 
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6MELATONIN THERAPY TO 
IMPROVE NOCTURNAL SLEEP IN 
CRITICALLY ILL PATIENTS 
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Introduction 
The sleep disturbances commonly experienced by critically ill patients are 
characterised by sleep fragmentation, with loss of monophasic nocturnal sleep 
combined and frequent diurnal naps. This sleep pattern is a circadian rhythm sleep 
disorder sub-type, classified as an Irregular Sleep-Wake Pattern, [18] most often seen 
in patients with neurological conditions such as dementia or brain injury [395, 396]. 
Compared to that in healthy individuals, the sleep that does occur in critical care 
patients has less of the deeper, more restorative sleep phases such as SWS and REM 
sleep [36]. Although the consequences of such prolonged sleep fragmentation are 
unknown, they may be comparable to the significant morbidity associated with 
prolonged sleep deprivation [23]. For example, such sleep loss may reduce 
inspiratory muscle endurance in mechanically ventilated patients, [110] hence 
prolonging weaning from mechanical ventilation and increasing associated risks, 
such as healthcare associated infections. Sleep disturbances may also predispose to 
delirium, either as a direct predisposing factor, [397] or as a consequence of attempts 
to correct sleep disorders with sedative medication [398]. Furthermore, patients 
themselves perceive sleep disturbances to be one of the most stressful components of 
their intensive care stay [33]. Therefore, interventions that reduce sleep disturbances 
in critical care patients are warranted. Conventional hypnotic agents are often of 
limited efficacy in treating sleep disorders in critical care patients, and may 
paradoxically worsen sleep quality, [398] or have adverse cognitive effects [196]. 
Nocturnal secretion of melatonin synchronises the sleep-wake and dark-light cycles, 
[276] and disruption to the normal timing and amplitude of the circadian rhythm of 
melatonin secretion is associated with reduced sleep efficiency [399,400]. Compared 
to healthy individuals, critical care patients undergoing mechanical ventilation have 
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reduced plasma melatonin levels and lack of circadian rhythm [312,401-403]. The 
pattern of critical care patients sleep disorders and the disruption in melatonin 
secretion suggest that specific circadian sleep disorder therapies may be beneficial. 
Exogenous melatonin has been demonstrated to be safe and effective in the treatment 
of other circadian rhythm sleep disorders [265,404]. The current study aimed to 
examine further the effect of exogenous melatonin on nocturnal sleep in patients 
weaning from mechanical ventilation. 
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Methods 
A detailed description of the study design, patient inclusion! exclusion criteria, 
patient recruitment, randomisation, medication administration, sleep monitoring, data 
collection and data analysis is given in Chapter 5. In summary, the study was a 
randomised double-blind placebo controlled trial in patients admitted to an adult 
general ICU with acute respiratory failure requiring mechanical ventilation and a 
tracheostomy to assist weaning. Melatonin 10 mg or matching placebo were 
administered enterally at 2100 h for four consecutive nights. 
Nocturnal sleep was evaluated primarily using BIS, with actigraphy, nurse and 
patient assessment as secondary measures. Analyses were limited to nights 3 and 4, 
since the potential chronohypnotic benefits of melatonin are not immediate and may 
take three days to be realised [279, 377, 405]. All four nights were considered in a 
secondary analysis. 
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Results 
Figure 6-1 summarises patient inclusion in the study. Due to slow recruitment, it was 
only possible to recruit 24 patients. There were 4 patients (3 in the placebo and 1 in 
the melatonin group) with missing BIS data for nights 3 and 4, the reasons being; 
discharged/re-sedated (4 nights), patient removed sensor (2 nights); signal quality 
index low (1 night); patient refused (1 night). 
Table 6-1 shows patients' baseline characteristics in the two treatment groups. An 
imbalance of known risk factors for sleep disturbances was present due to small 
sample size, potentially leading to more sleep disturbance in the melatonin group. 
The risk factors for sleep disturbances included older age, [406] delirium [19] and 
ventilation with pressure support ventilation (because of the possibility of 
desynchrony) [105]. No differences between the melatonin and control group were 
observed with regard to either patient use of ear plugs or eye masks (9% and 2% of 
nights, respectively), or nocturnal environmental disturbances score. Mean (SO) 
baseline illuminance at the head of each bed when all lights were turned offwas 9.6 
(2.6) lux. 
There was no disparity between the groups in their exposure to potentially sleep 
disruptive medication. In patients that received morphine and midazolam, sufficient 
time elapsed between discontinuation of sedation and study enrolment to limit 
distortion of results due to accumulation of these agents. None of the patients 
received haloperidol on nights 3 or 4. Nocturnal sleep time did not seem to correlate 
with severity of illness, as measured by the daily APACHE II score, although a wide 
confidence interval does not allow for definitive conclusions (r= 0.10; -0.36 to 0.52; 
p = 0.68). 
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Results of the effect of melatonin on primary and secondary sleep measurements are 
shown (Table 6-2). Nocturnal sleep time was two and a half hours in the placebo 
group and it was one hour longer in the melatonin group, although the difference was 
not statistically significant (Table 6-2). BIS Ave showed a statistically significant 
7% decrease in the melatonin group, with a lower Ave indicating "better" sleep 
(AVe difference = -54.23; -104.47 to -3.98; p = 0.04). In order to account for the 
imbalance in baseline characteristics, the analyses were adjusted using linear 
regression. The small sample size limited the number of covariates that could be 
adjusted for, [407] and therefore a single variable was created that provided an 
indication of the overall baseline risk of sleep disturbances. High risk was defined as 
the presence of any two of the following: age ~ 70 years; delirium positive; 
ventilation with BIPAP or ePAP/ASB. The results of the adjusted analysis did not 
vary substantially, apart from an expected loss in precision of the estimates; SEI 
difference: 0.12 (-0.04 to 0.28;p = 0.12); AVe difference: -48.76 (-103.06 to 5.54;p 
= 0.07). 
Any evidence of a treatment effect nearly disappeared when considering all four 
nights; SEI difference: 0.05 (-0.07 to 0.17); AVe difference: -26.62 (-70.51 to 
17.28). 
Results from the additional sleep measurement methods did not support those 
obtained with BIS, and indeed they were all inconclusive (Table 6-2). 
As regards possible side effects of melatonin, one patient in the melatonin group 
reported a headache on a single night, which responded to acetaminophen 
administration. 
154 
Melatonin. sleep and 'Ircadlan rh~1hms an cntical can: patients Chapter 6 [frKI or melltonin on ItOtturna' sleep 
Patients meeting inclusion! exclusion criteria & deemed 
competent to provide informed consent. n = 36 
Excluded. Refused to 
participate. n = 11 
I Randomised. n = 25 I 
+ + 
Allocated to melatonin. n = 13 I Allocated to placebo. n = 12 J 
Lost to follow up. VWhdrew I Lost to follow up. n = 0 J 
consent prior to data 
collection commencing. n = 1 
Analysed. n = 12 I Analysed. n = 12 I 
Figure 6-1 Patients recruitment analysis 
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Placebo Melatonin 
{n=12) {n=12} 
Male 7 (58.3) 4 (33.3) {n (%)) 
Reason for rcu admission 
{n (%)) 
Severe sepsis 8 (66.7) 1 0 (83.3) 
Postoperative respiratory failure 2 (16.7) I (8.3) 
Pneumonia 2 (16.7) I (8.3) 
Age 58.7 (12.5) 69.9 (12.0) {mean (SD)] 
APACHE II on study entry 16.8 (3.4) 17.3 (3.8) [mean (SD)] 
, ABW (kg) 
69.0 (57.4; 77.5) 65.0 (63.5; 70.0) [median (IQR)] 
IBW (kg) 60.0 (6.9) 57.2 (6.5) {mean (SD)] 
BMI 24.6 (4.7) 25.0 (3.1) (mean (SD)] 
Patients' usual sleep quantity (hours)' 6.5 (1.57) 6.2 (2.07) [mean (SD)] 
ICU length of stay prior to study (days) 16.5 (13.0; 20.5) 16.5 (11.0; 19.0) {median (IQR)) 
Time of ventilation prior to study (days) 20.0 (14.3) 13.6 (6.5) [mean (SD)] 
Sedation (morphine/midazolam) prior to study 2 (16.7) 2 (16.7) {n (%)) 
Time since sedation stopped prior to study 
(days) 6.6 (2.9) 7.5 (4.7) 
{mean (SD)] 
Delirium during study period 1 (8.3) 4 (33.3) {n (%)) 
Ventilation mode on Nights 3 and 4 
[n (%)] 
BIPAPI CPAP-ASB 7 (70.0) 7 (58.3) 
External CPAPI High Flow Oxygen 3 (30.0) 5 (41.7) 
Table 6-1 Baseline patient characteristics 
ABW - Actual body weight; IBW - Ideal body weight; BMI - Body mass index 
I Usual sleep time at home, reported by the patient. 
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Sleep BIS SEI (95%CI) 
measurement Melatonin p-value of 
method Placebo group Difference tbe group difference 
Primary Analysis 
0.12 
0.26 0.39 
BIS (-0.02 to 0.09 (0.17 to 0.36) (0.27 to 0.51) 
0.27) 
Secondary Analysis 
-0.02 
0.75 0.73 
Actigraphy (-0.24 to 0.84 
(0.67 to 0.83) (0.53 to 0.93) 
0.20) 
-0.06 
0.51 0.45 
Nurse Assessment (-0.29 to 0.58 (0.35 to 0.68) (0.26 to 0.64) 
0.17) 
Patient -0.09 
0.50 0.41 
Assessment (-0.28 to 0.32 
(RCSQ) (0.43 to 0.58) (0.24 to 0.59) 0.09) 
Table 6-2 Effect of melatonin on nocturnal sleep efficiency on nights 
3 & 4, determined using different outcome measures 
BIS: Bispectrallndex; RCSQ: Richards Campbell Sleep Questionnaire; SEI: Sleep efficiency index 
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Discussion 
The results of the study are in agreement with previous reports [378,408] that show 
nocturnal sleep in patients weaning from mechanical ventilation is highly 
compromised, with an average of only two and a half hours in the placebo group. 
Melatonin therapy was associated with a one-hour increase in nocturnal sleep 
compared with placebo, corresponding to an increase of 47%, although the SEI 
difference did not reach statistical significance. There was a statistically significant 
reduction of 7% in BIS Ave with melatonin administration, suggesting sleep 
improvement. The use of AVe has some advantages compared to SEI. Apart from 
providing greater statistical power, BIS Ave measures both sleep quantity and 
quality, [378] which might be more informative than sleep quantity data alone. 
However, the clinical significance and interpretation of a reduced AVe remains 
unclear [409]. 
Two other small trials investigated the effect of melatonin on nocturnal sleep in 
critically ill patients, [313,403], but comparison is limited due to the use of different 
sleep measurement methods. In fact, although polysomnography is the gold standard 
for quantifying and qualifying sleep, the challenges of the critical care environment 
have led to the utilisation of a number of alterative methods. The potential for 
significant differences in sleep measurement results reported using the various sleep 
measurement techniques was the reason for the use of four different techniques in the 
current study with the additional aim of measuring agreement between them. The 
implications of sleep measurement technique selection for research and clinical 
applications in critical care patients are discussed in detail in Chapter 8. Shilo el al 
[313] examined the effects of melatonin on sleep in eight respiratory patients in a 
cross-over trial, and showed positive sleep quantity results as measured by 
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actigraphy. Baseline sleep was reported to increase from approximately three to six 
hours with melatonin administration, although results of the comparison between 
melatonin and placebo were not reported. A second study used nurse observation to 
evaluate 32 tracheostomised patients and showed negative results [403]. Placebo 
patients slept for about four hours, but only for 15 minutes more in the melatonin 
group. Alexander e/ ai, [410] gave a preliminary report of an unpublished study of 
melatonin administration in critical care patients. Twenty three patients recovering 
from critical illness were randomised to receive 6 mg melatonin (n=ll) or placebo 
for 10 nights [410]. Sleep was measured by actigraphy, nurse assessment (15 minute 
epochs) and patient assessment using a 10 point visual analogue scale (V AS) [410]. 
Conventional night sedation was allowed throughout the study according to a local 
ICU guideline. There were no differences between the groups in nocturnal sleep 
quantity, daytime sleep quantity or number of nocturnal sleep bouts [410]. Although 
melatonin was reported to have a "sedative-sparing affect", differences in mean 
requirement for night sedation per night was not statistically significant (0.27 versus 
0.6, p = 0.13). The primary sleep measure used was actigraphy, and no details 
regarding other measures of sleep quantity were provided [410]. The combined use 
of a conventional hypnotic with melatonin is representative of clinical practice in 
some UK ICUs [227]. This combined use is based on the premise that melatonin may 
facilitate the conditions for sleep, but that some patients require a further stimulus for 
sleep to commence. The latter is an attempt to create a "pseudo sleep homeostasis" or 
drive for sleep, in combination with the circadian drive created by the administration 
of nocturnal melatonin. However, there is no evidence that this combined approach 
increases efficacy, and indeed it may only increase adverse effects. A study in 
healthy volunteers reported no increase in daytime sleep quantity after combined 
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administration of melatonin 5 mg and zolpidem 20 mg, when compared to 
administration of the individual agents [405]. Individual melatonin administration 
maintained memory and cognitive perfonnance, which was impaired when combined 
with zolpidem [405]. 
Actigraphy has important limitations when used as a measure of sleep in critically ill 
patients, being influenced by abnonnalities of the neuromuscular system which are 
common in these patients [389]. As regards nurse observation, intensive observation 
of sleep (5 minute intervals) is probably necessary to allow differentiation between 
interventions in critical care studies [411] and even then it suffers from being a 
SUbjective measure which may overestimate sleep quantity [27]. Patient assessment 
has been used in critical care sleep studies of other interventions, but its applicability 
is limited by patient acute cognitive and perceptual problems [412]. BIS was chosen 
as the primary outcome measure in the current study since it is an objective measure 
of sleep that is not adversely affected by the presence of neuromuscular weakness. 
However, the BIS, as with other EEG based techniques, can be adversely affected by 
conditions such as traumatic brain injury, [413] dementia [414] or delirium [415] 
which result in electroencephalographic (EEG) slowing [413]. Although BIS XP 
technology was used, a degree of susceptibility to increased BIS values as, a 
consequence of electro myographic (EMG) artefact remains [416]. The results from 
the secondary outcome measures, actigraphy, nurse observation and patient 
assessment, were all inconclusive. Differences between the BIS SEI results in the 
current study and those of the secondary measures may be explained in part by 
residual neuromuscular weakness in patients recovering from sepsis (actigraphy); the 
use of hourly epochs (nurse assessment) and limitations of patients' ability to 
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complete the RCSQ (patient assessment). All of these factors may contribute to 
overestimation of sleep quantity and SEI. 
The effects of melatonin on sleep have also been studied in non-critical care 
hospitalised patients. A randomised placebo controlled study of nocturnal melatonin 
in 33 hospitalised medical patients reported improvements in nocturnal sleep 
parameters after administration of oral melatonin [417]. Melatonin was administered 
in a flexible dose regime, with a mean daily dose of approximately 5 mg 
administered to each patient over the 16 day study period. Patients who had received 
melatonin reported reduced sleep latency and increased night time sleep duration 
compared to patients who had received placebo [417]. Patient assessment was based 
on a simple 3 point V AS, which only allowed patients to indicate whether they 
subjectively rated their own sleep parameters at the end of the study as no different. 
better or worse than baseline. A small double-blind cross over study (n = 7), [418] 
compared the effects of melatonin and amitriptyline on sleep quality in patients with 
sleep disorders after traumatic brain injury. Patients assessed their own sleep based 
on sleep latency, sleep quantity, sleep quality and daytime alertness. Compared to 
baseline data, no significant improvements in any sleep variable were reported for 
either melatonin or amitriptyline. Given the small sample size, this is not unexpected 
and the authors went on the calculate effect sizes compared to baseline. which 
suggested small to medium beneficial effect sizes on the sleep variables for both 
drugs [418]. 
Rajaratnam et al [419] conducted a study of melatonin on sleep in 8 healthy 
individuals using an extended sleep opportunity model. Although undertaken in 
healthy individuals, the extended sleep opportunity protocol resembled some of the 
sleep conditions patients recovering from critical illness are exposed to [419]. 
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Participants were confined to their beds for 9 days, with no interaction or recreational 
facilities provided; hence extended sleep periods were available. Volunteers were 
randomised to receive melatonin (1.5 mg immediate-sustained release) or placebo at 
1600 h daily for 8 days, before repeating the study in the other treatment allocation 
after a 14 day washout period. Sleep was monitored in private research rooms using 
polysomnography for 16 hours each day. The results of the study showed that 
melatonin advanced the timing of sleep without affecting TST [419]. Comparison of 
results from the post treatment night and sleep parameters during melatonin 
administration allowed separation of the hypnotic and circadian phase-shifting 
effects of melatonin. Melatonin was reported to have direct sleep-promoting effects 
[419]. Melatonin both phase-advanced, and directly facilitated sleep for 
approximately 3 hours after administration [419]. Melatonin increased TST over the 
first 8 hours post dose, but when the full 16 hours were analysed, there was no 
change in TST. Therefore, melatonin changed the timing of sleep, i.e. it facilitated, 
rather than induced sleep, which contrasts with conventional hypnotic agents. Also, 
melatonin administration did not reduce the quantity of SWS or REM sleep [419]. 
When melatonin (5 mg) is administered during the nocturnal period in healthy 
patients with a normal melatonin circadian rhythm, it has no effects on sleep [264]. 
However, when administered during the day, when endogenous plasma melatonin 
levels are low, it has a soporific effect similar to temazepam 20 mg [264]. In critical 
care patients with a disrupted circadian rhythm of melatonin, appropriate melatonin 
dosing would be anticipated to re-enforce the timing and consolidate nocturnal sleep, 
without adversely affecting sleep quality. Furthermore, the absence of significant 
sleep inertia (morning hangover) and detrimental cognitive effects the next day after 
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drug administration. [264.284.405] are further advantages of melatonin over 
conventional hypnotic agents in critical care patients [196]. 
Melatonin appears to have a favourable adverse effect profile: headaches. dizziness, 
nausea and drowsiness are the most common adverse events reported with short term 
administration [275]. Melatonin treatment appeared to be well tolerated by the 
patients in the current study. with only one patient reporting a single episode of 
headache. 
The sleep results of the current study are clinically significant as they suggest that 
administration of melatonin may form part of interventions to improve sleep in 
critical care patients. Sleep is regulated by two processes; circadian and homeostatic 
(sleep drive). Re-enforcing the circadian rhythm, for example, by the administration 
of exogenous melatonin may improve the circadian process, but sleep drive is still 
required. Therefore, correcting the circadian rhythm disorder alone will not result in 
maximum sleep quality without also encouraging sleep homeostasis. Furthermore. 
sleep disturbances in critical care patients are multi-factorial and, therefore, a single 
intervention, such a melatonin administration, cannot be expected to result in 
complete resolution of symptoms. Sleep hygiene, is a term used to describe an 
approach to ensuring lifestyle and environmental conditions are conducive to sleep. 
Sleep hygiene is used as a basis for the treatment of most sleep disorders and, in 
summary, is focused on maintaining a suitable environment for sleep to occur, re-
enforcing circadian rhythms and avoiding sleep disturbing medications. In treating 
sleep disturbances in critical care patients, administration of melatonin may assist 
with re-enforcing the circadian rhythm, but other improvements in the environment 
and appropriate drug review must also be made. Unfortunately, this is frequently not 
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the case, and it is often regarded as easier to administer another drug than to embrace 
the significant practical changes that are required. 
There are a number of obvious limitations to the current study that should be 
reviewed when considering the methodology of future studies. 
The current study was smaller than planned, with only 71 % of the target sample size 
being reached, mainly due to problems in obtaining consent in the most acutely ill 
patients. Statistical power was further decreased by the presence of missing data. 
Both these problems should be taken into account when designing a study, 
particularly in deciding on inclusion criteria and the complexity of the study 
protocol. The small sample size also meant that there were imbalances in baseline 
characteristics between the groups, although the attempt to adjust for important sleep 
related factors (age, delirium and ventilator status) did not materially alter the results. 
Furthermore, the inclusion of ventilator status as a risk factor for sleep disturbances 
assumes that patient-ventilator de synchrony occurred [105]. Mode of mechanical 
ventilation has not been demonstrated to be an important factor affecting sleep in 
critical care patients when ventilatory settings are optimised [84]. 
The use of alternative sleep measurement techniques to polysomnography also 
limited the scope of the current results. Sleep stage data were not available and, 
therefore, it was not possible to comment on the effect of melatonin of SWS or REM 
sleep phases. The ultimate aim of sleep interventions in critical care patients is to 
attempt to consolidate nocturnal sleep and increase both SWS and REM sleep 
phases. At low doses melatonin has a sleep promoting effect without a significant 
adverse affect on normal sleep architecture, [419, 420] a potential advantage over 
conventional hypnotic agents. Indeed it could be suggested that the improvements in 
sleep quantity observed may have been achieved with a conventional hypnotic agent 
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e.g. zopiclone. The significant potential for adverse cognitive effects ofthese agents, 
particularly in older patients, [196] still makes melatonin (or melatonin agonists such 
as ramelteon) worth continued investigation. 
Ideally polysomnography should be used as a continuous measure of sleep in further 
studies. However, this would present significant logistical and technical challenges, 
and is associated with specific difficulties, including patient tolerability and sleep 
stage interpretation in patients experiencing complex electrophysiological changes 
[378]. 
A useful measure of daytime sleep was not available because the actigraphy data 
appeared to significantly overestimate nocturnal and diurnal sleep quantity, (see 
Chapter 8) and the BIS recording was restricted to the nocturnal period due to patient 
tolerability. Therefore, it is also not possible to comment on the effect of melatonin 
on daytime sleep. While the primary aim of a sleep intervention is to optimise 
nocturnal sleep quality and quantity, the potential impact diurnal sleep periods have 
on nocturnal sleep efficiency should not be forgotten. Approximately half of total 
sleep time of critical care patients may occur during the diurnal period, with 
significant inter and intra-patient variability as to whether sleep deprivation is present 
over 24 hours [23]. 
A 10 mg oral melatonin dose was used in the current study. Although a similar 
melatonin dose has been used in other studies, [287] it may have been excessive and 
complicated the entraining effect of melatonin on the sleep rhythm (see Chapter 7 for 
discussion). 
The environmental score only provided a guide to nocturnal patient disturbances. 
Noise, light and patient disturbances have been shown to account for approximately 
30% of nocturnal arousals and awakenings [35]. Although the ambient nocturnal 
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illuminations were at an appropriate level to allow normal melatonin secretion, [421] 
an accurate measure of light interruptions was not used. The absence of continuous 
light and noise measurements and lack of quantification of patient disturbances by 
staff are, therefore, further potential limitations. Ear plugs can improve sleep quality 
in healthy volunteers exposed to simulated intensive care noise [89]. However, in the 
current study, patient willingness to use eye masks and/or ear plugs was very low, 
which limits their routine clinical application. 
Finally, future studies should consider extending the sleep intervention to a 
coordinated bright light and exogenous melatonin therapy. The sleep-wake process 
relies on a combination of homeostatic and circadian factors for its optimum 
function, [266] and the full activity of melatonin on the sleep-wake cycle in humans 
requires the coordination of other time cues such as light [265]. 
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Conclusions 
Melatonin administration appeared to increase the sleep quantity of critical care 
patients weaning from mechanical ventilation. Although suggesting a possible future 
role of melatonin in the routine care of critically ill patients, the findings of the 
current study need to be confirmed by a larger, possibly multicentre, randomised 
controlled trial, ideally using polysomnography as a continuous measure of sleep 
quantity and quality. 
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